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iabetes is a chronic illness that re-
quires continuing medical care and
ongoing patient self-management
education and support to prevent acute
complications and to reduce the risk of
long-term complications. Diabetes care is
complex and requires that many issues,
beyondglycemiccontrol,beaddressed.A
large body of evidence exists that sup-
ports a range of interventions to improve
diabetes outcomes.
These standards of care are intended
to provide clinicians, patients, research-
ers, payors, and other interested individ-
uals with the components of diabetes
care, general treatment goals, and tools to
evaluate the quality of care. While indi-
vidual preferences, comorbidities, and
other patient factors may require modiﬁ-
cation of goals, targets that are desirable
for most patients with diabetes are pro-
vided. These standards are not intended
to preclude clinical judgment or more ex-
tensiveevaluationandmanagementofthe
patient by other specialists as needed. For
moredetailedinformationaboutmanage-
ment of diabetes, refer to references 1–3.
The recommendations included are
screening, diagnostic, and therapeutic ac-
tions that are known or believed to favor-
ably affect health outcomes of patients
withdiabetes.Agradingsystem(Table1),
developed by the American Diabetes As-
sociation (ADA) and modeled after exist-
ing methods, was used to clarify and
codify the evidence that forms the basis
for the recommendations. The level of ev-
idence that supports each recommenda-
tion is listed after each recommendation
using the letters A, B, C, or E.
These standards of care are revised
annually by the ADA multidisciplinary
Professional Practice Committee, and
new evidence is incorporated. Members
of the Professional Practice Committee
andtheirdisclosedconﬂictsofinterestare
listed in the Introduction. Subsequently,
as with all position statements, the stan-
dards of care are reviewed and approved
by the Executive Committee of ADA’s
Board of Directors.
I. CLASSIFICATION AND
DIAGNOSIS
A. Classiﬁcation
The classiﬁcation of diabetes includes
four clinical classes:
● type 1 diabetes (results from -cell de-
struction, usually leading to absolute
insulin deﬁciency)
● type 2 diabetes (results from a progres-
sive insulin secretory defect on the
background of insulin resistance)
● other speciﬁc types of diabetes due to
other causes, e.g., genetic defects in
-cell function, genetic defects in insu-
lin action, diseases of the exocrine pan-
creas(suchascysticﬁbrosis),anddrug-
or chemical-induced diabetes (such as
in the treatment of AIDS or after organ
transplantation)
● gestational diabetes mellitus (GDM)
(diabetes diagnosed during pregnancy)
Some patients cannot be clearly classiﬁed
as having type 1 or type 2 diabetes. Clin-
ical presentation and disease progression
vary considerably in both types of diabe-
tes. Occasionally, patients who otherwise
havetype2diabetesmaypresentwithke-
toacidosis. Similarly, patients with type 1
diabetes may have a late onset and slow
(but relentless) progression despite hav-
ing features of autoimmune disease. Such
difﬁcultiesindiagnosismayoccurinchil-
dren, adolescents, and adults. The true
diagnosismaybecomemoreobviousover
time.
B. Diagnosis of diabetes
Recommendations
For decades, the diagnosis of diabetes has
been based on plasma glucose (PG) crite-
ria, either fasting PG (FPG) or 2-h 75-g
oralglucosetolerancetest(OGTT)values.
In 1997, the ﬁrst Expert Committee on
the Diagnosis and Classiﬁcation of Diabe-
tes Mellitus revised the diagnostic criteria
using the observed association between
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thy as the key factor with which to iden-
tify threshold FPG and 2-h PG levels. The
committee examined data from three
cross-sectionalepidemiologicstudiesthat
assessedretinopathywithfundusphotog-
raphy or direct ophthalmoscopy and
measured glycemia as FPG, 2-h PG, and
HbA1c (A1C). The studies demonstrated
glycemiclevelsbelowwhichtherewaslit-
tle prevalent retinopathy and above
which the prevalence of retinopathy in-
creased in an apparently linear fashion.
The deciles of FPG, 2-h PG, and A1C at
which retinopathy began to increase were
the same for each measure within each
population. The analyses helped to in-
form a then-new diagnostic cut point of
126 mg/dl (7.0 mmol/l) for FPG and
conﬁrmed the long-standing diagnostic
2-h PG value of 200 mg/dl (11.1
mmol/l) (4).
ADA has not previously recom-
mended the use of A1C for diagnosing
diabetes, in part due to lack of standard-
ization of the assay. However, A1C assays
arenowhighlystandardized,andtheirre-
sults can be uniformly applied both tem-
porally and across populations. In a
recentreport(5),afteranextensivereview
of both established and emerging epide-
miological evidence, an international ex-
pert committee recommended the use of
the A1C test to diagnose diabetes with a
thresholdof6.5%,andADAafﬁrmsthis
decision (6). The diagnostic test should
be performed using a method certiﬁed by
the National Glycohemoglobin Standard-
ization Program (NGSP) and standard-
ized or traceable to the Diabetes Control
and Complications Trial (DCCT) refer-
ence assay. Point-of-care A1C assays are
notsufﬁcientlyaccurateatthistimetouse
for diagnostic purposes.
Epidemiologic datasets show a rela-
tionship between A1C and the risk of ret-
inopathy similar to that which has been
shownforcorrespondingFPGand2-hPG
thresholds. The A1C has several advan-
tagestotheFPG,includinggreaterconve-
nience, since fasting is not required;
evidence to suggest greater preanalytical
stability; and less day-to-day perturba-
tions during periods of stress and illness.
These advantages must be balanced by
greater cost, limited availability of A1C
testing in certain regions of the develop-
ingworld,andincompletecorrelationbe-
tween A1C and average glucose in certain
individuals. In addition, the A1C can be
misleading in patients with certain forms
of anemia and hemoglobinopathies. For
patients with a hemoglobinopathy but
normal red cell turnover, such as sickle
cell trait, an A1C assay without interfer-
ence from abnormal hemoglobins should
beused(anupdatedlistofA1Cassaysand
whether abnormal hemoglobins impact
them is available at www.ngsp.org/prog/
index3.html). For conditions with abnor-
mal red cell turnover, such as pregnancy or
anemias from hemolysis and iron deﬁ-
ciency, the diagnosis of diabetes must use
glucose criteria exclusively.
The established glucose criteria for
the diagnosis of diabetes (FPG and 2-h
PG)remainvalid.Patientswithseverehy-
perglycemia such as those who present
with severe classic hyperglycemic symp-
tomsorhyperglycemiccrisiscancontinue
to be diagnosed when a random (or ca-
sual) PG of 200 mg/dl (11.1 mmol/l) is
found. It is likely that in such cases the
health care professional would also con-
duct an A1C test as part of the initial as-
sessment of the severity of the diabetes
and that it would be above the diagnostic
cut point. However, in rapidly evolving
diabetes such as the development of type
1 in some children, the A1C may not be
signiﬁcantly elevated despite frank
diabetes.
Just as there is 100% concordance
between the FPG and 2-h PG tests, there
is not perfect concordance between A1C
and either glucose-based test. Analyses of
National Health and Nutrition Examina-
tionSurvey(NHANES)dataindicatethat,
assuminguniversalscreeningoftheundi-
agnosed, the A1C cut point of 6.5%
identiﬁesone-thirdfewercasesofundiag-
nosed diabetes than a fasting glucose cut
point of 126 mg/dl (7.0 mmol/l) (E.
Gregg, personal communication). How-
ever, in practice, a large portion of the
diabetic population remains unaware of
their condition. Thus, the lower sensitiv-
ityofA1Catthedesignatedcutpointmay
well be offset by the test’s greater practi-
cality, and wider application of a more
convenient test (A1C) may actually in-
crease the number of diagnoses made.
As with most diagnostic tests, a test
result diagnostic of diabetes should be re-
peated to rule out laboratory error, unless
the diagnosis is clear on clinical grounds,
suchasapatientwithclassicsymptomsof
hyperglycemia or hyperglycemic crisis. It
ispreferablethatthesametestberepeated
for conﬁrmation, since there will be a
greater likelihood of concurrence in this
case. For example, if the A1C is 7.0% and
a repeat result is 6.8%, the diagnosis of
diabetes is conﬁrmed. However, there are
scenarios in which results of two different
tests (e.g., FPG and A1C) are available for
the same patient. In this situation, if the
two different tests are both above the di-
Table 1 —ADA evidence grading system for clinical practice recommendations
Level of
evidence Description
A Clear evidence from well-conducted, generalizable, randomized controlled trials that
are adequately powered, including:
● Evidence from a well-conducted multicenter trial
● Evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling nonexperimental evidence, i.e., all or none rule developed by Center
for Evidence Based Medicine at Oxford
Supportive evidence from well-conducted randomized controlled trials that are
adequately powered, including:
● Evidence from a well-conducted trial at one or more institutions
● Evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies:
● Evidence from a well-conducted prospective cohort study or registry
● Evidence from a well-conducted meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies
● Evidence from randomized clinical trials with one or more major or three or
more minor methodological ﬂaws that could invalidate the results
● Evidence from observational studies with high potential for bias (such as case
series with comparison to historical controls)
● Evidence from case series or case reports
Conﬂicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
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betes is conﬁrmed.
On the other hand, if two different
testsareavailableinanindividualandthe
results are discordant, the test whose re-
sult is above the diagnostic cut point
should be repeated, and the diagnosis is
made on the basis of the conﬁrmed test.
That is, if a patient meets the diabetes cri-
terionoftheA1C(tworesults6.5%)but
nottheFPG(126mg/dlor7.0mmol/l),
or vice versa, that person should be con-
sidered to have diabetes. Admittedly, in
most circumstance the “nondiabetic” test
is likely to be in a range very close to the
threshold that deﬁnes diabetes.
Since there is preanalytic and analytic
variabilityofallthetests,itisalsopossible
that when a test whose result was above
the diagnostic threshold is repeated, the
second value will be below the diagnostic
cut point. This is least likely for A1C,
somewhat more likely for FPG, and most
likely for the 2-h PG. Barring a laboratory
error, such patients are likely to have test
results near the margins of the threshold
for a diagnosis. The healthcare profes-
sional might opt to follow the patient
closely and repeat the testing in 3–6
months.
The current diagnostic criteria for di-
abetes are summarized in Table 2.
C. Categories of increased risk for
diabetes
In1997and2003,TheExpertCommittee
on the Diagnosis and Classiﬁcation of Di-
abetes Mellitus (4,7) recognized an inter-
mediate group of individuals whose
glucose levels, although not meeting cri-
teria for diabetes, are nevertheless too
high to be considered normal. This group
was deﬁned as having impaired fasting
glucose (IFG) (FPG levels of 100 mg/dl
[5.6 mmol/l] to 125 mg/dl [6.9 mmol/l])
or impaired glucose tolerance (IGT) (2-h
OGTT values of 140 mg/dl [7.8 mmol/l]
to 199 mg/dl [11.0 mmol/l]).
IndividualswithIFGand/orIGThave
been referred to as having pre-diabetes,
indicating the relatively high risk for the
future development of diabetes. IFG and
IGT should not be viewed as clinical en-
tities in their own right but rather risk
factors for diabetes as well as cardiovas-
cular disease (CVD). IFG and IGT are
associated with obesity (especially
abdominal or visceral obesity), dyslipide-
mia with high triglycerides and/or low
HDL cholesterol, and hypertension.
Structured lifestyle intervention, aimed at
increasing physical activity and produc-
ing 5–10% loss of body weight, and cer-
tain pharmacological agents have been
demonstrated to prevent or delay the de-
velopment of diabetes in people with IGT
(see Table 7). It should be noted that the
2003 ADA Expert Committee report re-
duced the lower FPG cut point to deﬁne
IFG from 110 mg/dl (6.1 mmol/l) to 100
mg/dl (5.6 mmol/l), in part to make the
prevalence of IFG more similar to that of
IGT. However, the World Health Organi-
zation (WHO) and many other diabetes
organizations did not adopt this change.
As the A1C becomes increasingly
used to diagnose diabetes in individuals
with risk factors, it will also identify those
at high risk for developing diabetes in the
future. As was the case with the glucose
measures, deﬁning a lower limit of an in-
termediate category of A1C is somewhat
arbitrary, since risk of diabetes with any
measureorsurrogateofglycemiaisacon-
tinuum extending well into the normal
ranges.Tomaximizeequityandefﬁciency
of preventive interventions, such an A1C
cutpoint,shouldbalancethecostsoffalse
negatives(failingtoidentifythosewhoare
going to develop diabetes) against the
costs of false positives (falsely identifying
andthenspendinginterventionresources
on those who were not going to develop
diabetes anyway).
Linear regression analyses of nation-
ally representative U.S. data (NHANES
2005–2006) indicate that among the
nondiabetic adult population, an FPG of
110 mg/dl corresponds to an A1C of
5.6%, while an FPG of 100 mg/dl corre-
sponds to an A1C of 5.4%. Receiver op-
erating curve analyses of these data
indicate that an A1C value of 5.7%, com-
pared with other cut points, has the best
combination of sensitivity (39%) and
speciﬁcity (91%) to identify cases of IFG
(FPG 100 mg/dl [5.6 mmol/l]) (R.T.
Ackerman, Personal Communication).
Other analyses suggest that an A1C of
5.7% is associated with diabetes risk sim-
ilar to that of the high-risk participants in
the Diabetes Prevention Program (DPP)
(R.T. Ackerman, personal communica-
tion). Hence, it is reasonable to consider
an A1C range of 5.7–6.4% as identifying
individuals with high risk for future dia-
betes and to whom the term pre-diabetes
may be applied (6).
As is the case for individuals found to
have IFG and IGT, individuals with an
A1C of 5.7–6.4% should be informed of
their increased risk for diabetes as well
as CVD and counseled about effective
strategiestolowertheirrisks(seeIV.PRE-
VENTION/DELAYOFTYPE2DIABETES).
As with glucose measurements, the contin-
uum of risk is curvilinear, so that as A1C
rises, the risk of diabetes rises dispropor-
tionately. Accordingly, interventions
should be most intensive and follow-up
should be particularly vigilant for those
with an A1C 6.0%, who should be con-
sidered to be at very high risk. However,
justasanindividualwithafastingglucoseof
98 mg/dl (5.4 mmol/l) may not be at negli-
gible risk for diabetes, individuals with an
A1C 5.7% may still be at risk, depending
on the level of A1C and presence of other
risk factors, such as obesity and family
history.
Table 2—Criteria for the diagnosis of diabetes
1. A1C 6.5%. The test should be performed in a laboratory using a method
that is NGSP certiﬁed and standardized to the DCCT assay.*
OR
2. FPG 126 mg/dl (7.0 mmol/l). Fasting is deﬁned as no caloric intake for at
least 8 h.*
OR
3. Two-hour plasma glucose 200 mg/dl (11.1 mmol/l) during an OGTT.
The test should be performed as described by the World Health
Organization, using a glucose load containing the equivalent of 75 g
anhydrous glucose dissolved in water.*
OR
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic
crisis, a random plasma glucose 200 mg/dl (11.1 mmol/l).
*In the absence of unequivocal hyperglycemia, criteria 1–3 should be conﬁrmed by repeat testing.
Table 3—Categories of increased risk for
diabetes*
FPG 100–125 mg/dl (5.6–6.9 mmol/l)
IFG
2-h PG on the 75-g OGTT 140–199 mg/dl
(7.8–11.0 mmol/l) IGT
A1C 5.7–6.4%
*For all three tests, risk is continuous, extending
below the lower limit of the range and becoming
disproportionately greater at higher ends of the
range.
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II. TESTING FOR DIABETES
IN ASYMPTOMATIC
PATIENTS
Recommendations
● Testing to detect type 2 diabetes and
assessriskforfuturediabetesinasymp-
tomaticpeopleshouldbeconsideredin
adultsofanyagewhoareoverweightor
obese (BMI 25 kg/m
2) and who have
one or more additional risk factors for
diabetes (Table 4). In those without
these risk factors, testing should begin
at age 45 years. (B)
● Iftestsarenormal,repeattestingshould
be carried out at least at 3-year inter-
vals. (E)
● To test for diabetes or to assess risk of
future diabetes, either A1C, FPG , or
2-h 75-g OGTT are appropriate. (B)
● In those identiﬁed with increased risk
for future diabetes, identify and, if ap-
propriate, treat other CVD risk factors.
(B)
For many illnesses there is a major dis-
tinction between screening and diagnos-
tictesting.However,fordiabetesthesame
tests would be used for “screening” as for
diagnosis. Type 2 diabetes has a long
asymptomatic phase and signiﬁcant clin-
ical risk markers. Diabetes may be identi-
ﬁedanywherealongaspectrumofclinical
scenarios ranging from a seemingly low-
risk individual who happens to have glu-
cose testing, to a higher-risk individual
who the provider tests because of high
suspicion of diabetes, to the symptomatic
patient. The discussion herein is primar-
ily framed as testing for diabetes in indi-
viduals without symptoms. Testing for
diabetes will also detect individuals at in-
creased future risk for diabetes, herein re-
ferred to as pre-diabetic.
A. Testing for type 2 diabetes and
risk of future diabetes in adults
Type 2 diabetes is frequently not diag-
nosed until complications appear, and
approximately one-fourth of all people
with diabetes in the U.S. may be undiag-
nosed. Although the effectiveness of early
identiﬁcationofpre-diabetesanddiabetes
through mass testing of asymptomatic in-
dividualshasnotbeenprovendeﬁnitively
(and rigorous trials to provide such proof
are unlikely to occur), pre-diabetes and
diabetes meet established criteria for con-
ditions in which early detection is appro-
priate. Both conditions are common, are
increasing in prevalence, and impose sig-
niﬁcant public health burdens. There is a
longpresymptomaticphasebeforethedi-
agnosisoftype2diabetesisusuallymade.
Relatively simple tests are available to de-
tect preclinical disease (9). Additionally,
the duration of glycemic burden is a
strong predictor of adverse outcomes,
and effective interventions exist to pre-
vent progression of pre-diabetes to diabe-
tes (see IV. PREVENTION/DELAY OF
TYPE 2 DIABETES) and to reduce risk of
complications of diabetes (see VI. PRE-
VENTION AND MANAGEMENT OF DI-
ABETES COMPLICATIONS).
Recommendations for testing for dia-
betes in asymptomatic undiagnosed
adultsarelistedinTable4.Testingshould
be considered in adults of any age with
BMI25kg/m
2andoneormoreriskfac-
tors for diabetes. Because age is a major
risk factor for diabetes, testing of those
withoutotherriskfactorsshouldbeginno
later than at age 45 years.
Either A1C, FPG, or 2-h OGTT is ap-
propriate for testing. The 2-h OGTT identi-
ﬁes people with either IFG or IGT and thus
more people at increased risk for the devel-
opment of diabetes and CVD. It should be
noted that the two tests do not necessarily
detect the same individuals (10). The efﬁ-
cacy of interventions for primary preven-
tion of type 2 diabetes (11–17) has
primarily been demonstrated among indi-
viduals with IGT, but not for individuals
with IFG (who do not also have IGT) or
those with speciﬁc A1C levels.
The appropriate interval between
tests is not known (18). The rationale for
the 3-year interval is that false negatives
will be repeated before substantial time
elapses, and there is little likelihood that
an individual will develop signiﬁcant
complications of diabetes within 3 years
of a negative test result.
Becauseoftheneedforfollow-upand
discussion of abnormal results, testing
should be carried out within the health
care setting. Community screening out-
side a health care setting is not recom-
mended because people with positive
tests may not seek, or have access to, ap-
propriate follow-up testing and care.
Conversely,theremaybefailuretoensure
appropriate repeat testing for individuals
who test negative. Community screening
may also be poorly targeted, i.e., it may
fail to reach the groups most at risk and
inappropriately test those at low risk (the
worried well) or even those already diag-
nosed (19,20).
B. Testing for type 2 diabetes in
children
The incidence of type 2 diabetes in ado-
lescents has increased dramatically in the
last decade, especially in minority popu-
lations (21), although the disease remains
rare in the general pediatric population
(22). Consistent with recommendations
for adults, children and youth at in-
creased risk for the presence or the devel-
opment of type 2 diabetes should be
tested within the health care setting (23).
The recommendations of the ADA con-
sensus statement on type 2 diabetes in
Table 4—Criteria for testing for diabetes in asymptomatic adult individuals
1. Testing should be considered in all adults who are overweight (BMI 25 kg/m
2*) and
have additional risk factors:
● physical inactivity
● ﬁrst-degree relative with diabetes
● members of a high-risk ethnic population (e.g., African American, Latino, Native
American, Asian American, Paciﬁc Islander)
● women who delivered a baby weighing 9 lb or were diagnosed with GDM
● hypertension (140/90 mmHg or on therapy for hypertension)
● HDL cholesterol level 35 mg/dl (0.90 mmol/l) and/or a triglyceride level 250
mg/dl (2.82 mmol/l)
● women with polycystic ovary syndrome
● A1C 5.7%, IGT, or IFG on previous testing
● other clinical conditions associated with insulin resistance (e.g., severe obesity,
acanthosis nigricans)
● history of CVD
2. In the absence of the above criteria, testing diabetes should begin at age 45 years
3. If results are normal, testing should be repeated at least at 3-year intervals, with
consideration of more frequent testing depending on initial results and risk
status.
*At-risk BMI may be lower in some ethnic groups.
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tions, are summarized in Table 5.
C. Screening for type 1 diabetes
Generally, people with type 1 diabetes
present with acute symptoms of diabetes
and markedly elevated blood glucose lev-
els, and most cases are diagnosed soon
after the onset of hyperglycemia. How-
ever, evidence from type 1 diabetes pre-
vention studies suggests that measurement
of islet autoantibodies identiﬁes individ-
uals who are at risk for developing type 1
diabetes.Suchtestingmaybeappropriate
in high-risk individuals, such as those
with prior transient hyperglycemia or
those who have relatives with type 1 dia-
betes, in the context of clinical research
studies (see, for example, http://www2.
diabetestrialnet.org). Widespread clini-
cal testing of asymptomatic low-risk
individuals cannot currently be recom-
mended, as it would identify very few in-
dividuals in the general population who
are at risk. Individuals who screen posi-
tive should be counseled about their risk
of developing diabetes. Clinical studies
are being conducted to test various meth-
ods of preventing type 1 diabetes or re-
versingearlytype1diabetesinthosewith
evidence of autoimmunity.
III. DETECTION AND
DIAGNOSIS OF GDM
Recommendations
● Screen for GDM using risk factor anal-
ysis and, if appropriate, an OGTT. (C)
● Women with GDM should be screened
for diabetes 6–12 weeks postpartum
and should be followed up with subse-
quent screening for the development of
diabetes or pre-diabetes. (E)
Formanyyears,GDMhasbeendeﬁnedas
anydegreeofglucoseintolerancewithon-
set or ﬁrst recognition during pregnancy
(4). Although most cases resolve with de-
livery, the deﬁnition applied whether the
condition persisted after pregnancy and
didnotexcludethepossibilitythatunrec-
ognizedglucoseintolerancemayhavean-
tedated or begun concomitantly with the
pregnancy. This deﬁnition facilitated a
uniform strategy for detection and classi-
ﬁcation of GDM, but its limitations were
recognized for many years. As the ongo-
ing epidemic of obesity and diabetes has
led to more type 2 diabetes in women of
childbearing age, the number of pregnant
women with undiagnosed type 2 diabetes
has increased (24). After deliberations in
2008–2009, the International Associa-
tion of Diabetes and Pregnancy Study
Groups (IADPSG), an international con-
sensus group with representatives from
multiple obstetrical and diabetes organi-
zations, including ADA, recommended
that high-risk women found to have dia-
betes at their initial prenatal visit using
standard criteria (Table 2) receive a diag-
nosis of overt, not gestational, diabetes.
Approximately 7% of all pregnancies
(ranging from 1 to 14% depending on the
population studied and the diagnostic
tests used) are complicated by GDM, re-
sulting in more than 200,000 cases
annually.
Because of the risks of GDM to the
mother and neonate, screening and diag-
nosis are warranted. Current screening
and diagnostic strategies, based on the
2004 ADA position statement on GDM
(25), are outlined in Table 6.
ResultsoftheHyperglycemiaandAd-
versePregnancyOutcomes(HAPO)study
(26), a large-scale (25,000 pregnant
women) multinational epidemiologic
study, demonstrated that risk of adverse
maternal, fetal, and neonatal outcomes
continuously increased as a function of
maternal glycemia at 24–28 weeks, even
within ranges previously considered nor-
mal for pregnancy. For most complica-
tions there was no threshold for risk.
Theseresultshaveledtocarefulreconsid-
erationofthediagnosticcriteriaforGDM.
The IADPSG recommended that all
women not known to have prior diabetes
undergo a 75-g OGTT at 24–28 weeks of
gestation. The group developed diagnos-
tic cut points for the fasting, 1-h, and 2-h
PG measurements that conveyed an odds
ratio for adverse outcomes of at least 1.75
compared with women with the mean
glucose levels in the HAPO study.
At the time of this update to the Stan-
dards of Medical Care in Diabetes, ADA is
planningtoworkwithU.S.obstetricalor-
ganizations to consider adoption of the
IADPSG diagnostic criteria and to discuss
theimplicationsofthischange.Whilethis
change will signiﬁcantly increase the
prevalenceofGDM,thereismountingev-
idence that treating even mild GDM re-
duces morbidity for both mother and
baby (27).
Because women with a history of
GDMhaveagreatlyincreasedsubsequent
risk for diabetes (28), they should be
screened for diabetes 6–12 weeks post-
partum, using nonpregnant OGTT crite-
ria, and should be followed up with
subsequent screening for the develop-
ment of diabetes or pre-diabetes, as out-
lined in II. TESTING FOR DIABETES IN
ASYMPTOMATIC PATIENTS. Informa-
tion on the National Diabetes Education
Program (NDEP) campaign to prevent
type 2 diabetes in women with GDM can
be found at http://ndep.nih.gov/media/
NeverTooEarly_Tipsheet.pdf.
IV. PREVENTION/DELAY
OF TYPE 2 DIABETES
Recommendations
● Patients with IGT (A), IFG (E), or an
A1C of 5.7–6.4% (E) should be re-
ferred to an effective ongoing support
program for weight loss of 5–10% of
bodyweightandanincreaseinphysical
activity of at least 150 min/week of
moderate activity such as walking.
● Follow-upcounselingappearstobeim-
portant for success. (B)
● Based on potential cost savings of dia-
betes prevention, such counseling
should be covered by third-party pay-
ors. (E)
● In addition to lifestyle counseling, met-
forminmaybeconsideredinthosewho
are at very high risk for developing di-
abetes (combined IFG and IGT plus
Table 5—Testing for type 2 diabetes in asymptomatic children
Criteria: Overweight (BMI 85th percentile for age and sex, weight for height
85th percentile, or weight 120% of ideal for height)
Plus any two of
the following
risk factors:
● Family history of type 2 diabetes in ﬁrst- or second-degree relative
● Race/ethnicity (Native American, African American, Latino, Asian
American, Paciﬁc Islander)
● Signs of insulin resistance or conditions associated with insulin
resistance (acanthosis nigricans, hypertension, dyslipidemia,
polycystic ovary syndrome, or small for gestational age
birthweight)
● Maternal history of diabetes or GDM during the child’s gestation
Age of
initiation:
Age 10 years or at onset of puberty, if puberty occurs at a younger
age
Frequency: Every 3 years
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hypertension, low HDL cholesterol, el-
evatedtriglycerides,orfamilyhistoryof
diabetes in a ﬁrst-degree relative) and
who are obese and under 60 years of
age. (E)
● Monitoring for the development of di-
abetes in those with pre-diabetes
should be performed every year. (E)
Randomized controlled trials have shown
that individuals at high risk for develop-
ing diabetes (those with IFG, IGT, or
both) can be given interventions that sig-
niﬁcantly decrease the rate of onset of di-
abetes (11–17). These interventions
include intensive lifestyle modiﬁcation
programsthathavebeenshowntobevery
effective (58% reduction after 3 years)
and use of the pharmacologic agents met-
formin, -glucosidase inhibitors, orlistat,
andthiazolidinediones,eachofwhichhas
been shown to decrease incident diabetes
to various degrees. A summary of major
diabetes prevention trials is shown in Ta-
ble 7.
Two studies of lifestyle intervention
have shown persistent reduction in the
role of conversion to type 2 diabetes with
3 years (29) to 14 years (30) of postinter-
vention follow-up.
Based on the results of clinical trials
and the known risks of progression of
pre-diabetestodiabetes,anADAConsen-
sus Development Panel (36) concluded
that people with IGT and/or IFG should
be counseled on lifestyle changes with
goals similar to those of the DPP (5–10%
weight loss and moderate physical activ-
ity of 30 min/day). Regarding the more
difﬁcult issue of drug therapy for diabetes
prevention, the consensus panel felt that
metformin should be the only drug con-
sideredforuseindiabetesprevention.For
otherdrugs,theissuesofcost,sideeffects,
and lack of persistence of effect in some
studies led the panel to not recommend
use for diabetes prevention. Metformin
use was recommended only for very-
high-risk individuals (those with com-
bined IGT and IFG who are obese and
have at least one other risk factor for dia-
betes) who are under 60 years of age. In
addition, the panel highlighted the evi-
dence that in the DPP, metformin was
most effective compared with lifestyle in
individuals with BMI 35 kg/m
2 and
those under age 60 years.
V. DIABETES CARE
A. Initial evaluation
A complete medical evaluation should be
performed to classify the diabetes, detect
the presence of diabetes complications,
review previous treatment and glycemic
controlinpatientswithestablisheddiabe-
tes, assist in formulating a management
plan, and provide a basis for continuing
care. Laboratory tests appropriate to the
evaluation of each patient’s medical con-
dition should be performed. A focus on
the components of comprehensive care
(Table8)willassistthehealthcareteamto
ensure optimal management of the pa-
tient with diabetes.
B. Management
People with diabetes should receive med-
ical care from a physician-coordinated
team. Such teams may include, but are
notlimitedto,physicians,nursepractitio-
ners, physician’s assistants, nurses, dieti-
tians, pharmacists, and mental health
professionals with expertise and a special
interest in diabetes. It is essential in this
collaborative and integrated team ap-
proach that individuals with diabetes as-
sume an active role in their care.
The management plan should be for-
mulated as a collaborative therapeutic al-
liance among the patient and family, the
physician, and other members of the
health care team. A variety of strategies
andtechniquesshouldbeusedtoprovide
adequate education and development of
problem-solving skills in the various as-
pects of diabetes management. Imple-
mentation of the management plan
requires that each aspect is understood
and agreed to by the patient and the care
providers and that the goals and treat-
ment plan are reasonable. Any plan
should recognize diabetes self-manage-
menteducation(DSME)andon-goingdi-
abetes support as an integral component
Table 6—Screening for and diagnosis of GDM
Carry out diabetes risk assessment at the ﬁrst prenatal visit.
Women at very high risk should be screened for diabetes as soon as possible after the
conﬁrmation of pregnancy. Criteria for very high risk are:
● Severe obesity
● Prior history of GDM or delivery of large-for-gestational-age infant
● Presence of glycosuria
● Diagnosis of PCOS
● Strong family history of type 2 diabetes
Screening/diagnosis at this stage of pregnancy should use standard diagnostic testing (Table
2).
All women of greater than low risk of GDM, including those above not found to have diabetes
early in pregnancy, should undergo GDM testing at 24–28 weeks of gestation. Low-
risk status, which does not require GDM screening, is deﬁned as women with ALL of
the following characteristics:
● Age 25 years
● Weight normal before pregnancy
● Member of an ethnic group with a low prevalence of diabetes
● No known diabetes in ﬁrst-degree relatives
● No history of abnormal glucose tolerance
● No history of poor obstetrical outcome
Two approaches may be followed for GDM screening at 24–28 weeks:
1. Two-step approach:
A. Perform initial screening by measuring plasma or serum glucose 1 h after a 50-g load
of 140 mg/dl identiﬁes 80% of women with GDM, while the sensitivity is further
increased to 90% by a threshold of 130 mg/dl.
B. Perform a diagnostic 100-g OGTT on a separate day in women who exceed the chosen
threshold on 50-g screening.
2. One-step approach (may be preferred in clinics with high prevalence of GDM): Perform
a diagnostic 100-g OGTT in all women to be tested at 24–28 weeks.
The 100-g OGTT should be performed in the morning after an overnight fast of at least 8
h.
To make a diagnosis of GDM, at least two of the following plasma glucose values must be
found:
● Fasting 95 mg/dl
● 1-h 180 mg/dl
● 2-h 155 mg/dl
● 3-h 140 mg/dl
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ation should be given to the patient’s age,
school or work schedule and conditions,
physical activity, eating patterns, social
situation and cultural factors, and pres-
ence of complications of diabetes or other
medical conditions.
C. Glycemic control
1. Assessment of glycemic control
Two primary techniques are available for
healthprovidersandpatientstoassessthe
effectiveness of the management plan on
glycemic control: patient self-monitoring
of blood glucose (SMBG) or interstitial
glucose and A1C.
a. Glucose monitoring
Recommendations
● SMBG should be carried out three or
moretimesdailyforpatientsusingmul-
tiple insulin injections or insulin pump
therapy. (A)
● For patients using less frequent insulin
injections, noninsulin therapies, or
medical nutrition therapy (MNT)
alone,SMBGmaybeusefulasaguideto
the success of therapy. (E)
● To achieve postprandial glucose tar-
gets,postprandialSMBGmaybeappro-
priate. (E)
● When prescribing SMBG, ensure that
patients receive initial instruction in,
and routine follow-up evaluation of,
SMBG technique and using data to ad-
just therapy. (E)
● Continuousglucosemonitoring(CGM)
in conjunction with intensive insulin
regimens can be a useful tool to lower
A1C in selected adults (age 25 years)
with type 1 diabetes (A).
● Although the evidence for A1C lower-
ing is less strong in children, teens, and
youngeradults,CGMmaybehelpfulin
these groups. Success correlates with
adherence to ongoing use of the device.
(C)
● CGM may be a supplemental tool to
SMBG in those with hypoglycemia un-
awareness and/or frequent hypoglyce-
mic episodes. (E)
The ADA consensus and position state-
mentsonSMBGprovideacomprehensive
review of the subject (37,38). Major clin-
ical trials of insulin-treated patients that
demonstrated the beneﬁts of intensive
glycemic control on diabetes complica-
tions have included SMBG as part of
multifactorial interventions, suggesting
that SMBG is a component of effective
therapy. SMBG allows patients to eval-
uate their individual response to ther-
apy and assess whether glycemic targets
arebeingachieved.ResultsofSMBGcan
be useful in preventing hypoglycemia
and adjusting medications (particularly
prandial insulin doses), MNT, and
physical activity.
Table 7—Therapies proven effective in diabetes prevention trials
Study (ref.) n Population
Mean
age
(years)
Duration
(years)
Intervention
(daily dose)
Incidence in
control
subjects
(%/year)
Relative risk
reduction (%)
(95% CI)
3-Year
number
needed to
treat*
Lifestyle
Finnish DPS (12) 522 IGT, BMI 25 kg/m
2 55 3.2 I-D&E 6 58 (30–70) 8.5
DPP (11) 2,161† IGT, BMI 24 kg/m
2,
FPG 5.3 mmol/l
51 3 I-D&E 10.4 58 (48–66) 6.9
Da Qing (13) 259† IGT (randomized
groups)
45 6 G-D&E 14.5 38 (14–56) 7.9
Toranomon Study (31) 458 IGT (men), BMI 	 24
kg/m
2
55 4 I-D&E 2.4 67 (P  0.043)‡ 20.6
Indian DPP (17) 269† IGT 46 2.5 I-D&E 23 29 (21–37) 6.4
Medications
DPP (11) 2,155† IGT, BMI 24 kg/m
2,
FPG 5.3 mmol/l
51 2.8 Metformin
(1,700
mg)
10.4 31 (17–43) 13.9
Indian DPP (17) 269† IGT 46 2.5 Metformin
(500 mg)
23 26 (19–35) 6.9
STOP NIDDM (15) 1,419 IGT, FPG 5.6
mmol/l
54 3.2 Acarbose
(300 mg)
12.4 25 (10–37) 9.6
XENDOS (32) 3,277 BMI 30 kg/m
2 43 4 Orlistat (360
mg)
2.4 37 (14–54) 45.5
DREAM (16) 5,269 IGT or IFG 55 3.0 Rosiglitazone
(8 mg)
9.1 60 (54–65) 6.9
Voglibose Ph-3 (33) 1,780 IGT 56 3.0 (1-year Rx) Vogliobose
(0.2 mg)
12.0 40 (18–57) 21 (1-year
Rx)
ACT-NOW (34) 602 IGT or IFG 52 2.6 Pioglitizone
(45 mg)
6.8 81 (61–91) 6.3
Modiﬁed and reprinted with permission (35). Percentage points: *Number needed to treat to prevent 1 case of diabetes, standardized for a 3-year period to improve
comparisons across studies. †Number of participants in the indicated comparisons, not necessarily in entire study. ‡Calculated from information in the article.
ACT-NOW, ACTos Now Study for the Prevention of Diabetes; DPP, Diabetes Prevention Program; DPS, Diabetes Prevention Study; DREAM, Diabetes Reduction
Assessment with Ramipril and Rosiglitazone Medication; STOP NIDDM, Study to Prevent Non-Insulin Dependent Diabetes; XENDOS, Xenical in the prevention of
Diabetes in Obese Subjects. I, individual; G, group; D&E, diet and exercise.
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shouldbedictatedbytheparticularneeds
and goals of the patient. SMBG is espe-
cially important for patients treated with
insulin in order to monitor for and pre-
ventasymptomatichypoglycemiaandhy-
perglycemia. For most patients with type
1 diabetes and pregnant women taking
insulin, SMBG is recommended three or
more times daily. For these populations,
signiﬁcantlymorefrequenttestingmaybe
required to reach A1C targets safely with-
outhypoglycemia.Theoptimalfrequency
andtimingofSMBGforpatientswithtype
2 diabetes on noninsulin therapy is un-
clear. A meta-analysis of SMBG in non–
insulin-treated patients with type 2
diabetes concluded that some regimen of
SMBG was associated with a reduction in
A1Cof0.4%.However,manyofthestud-
ies in this analysis also included patient
education with diet and exercise counsel-
ingand,insomecases,pharmacologicin-
tervention,makingitdifﬁculttoassessthe
contribution of SMBG alone to improved
control (39). Several recent trials have
called into question the clinical utility
andcost-effectivenessofroutineSMBGin
non–insulin-treated patients (40–42).
Because the accuracy of SMBG is in-
strument and user dependent (43), it is
important to evaluate each patient’s mon-
itoring technique, both initially and at
regular intervals thereafter. In addition,
optimal use of SMBG requires proper in-
terpretation of the data. Patients should
be taught how to use the data to adjust
food intake, exercise, or pharmacological
therapytoachievespeciﬁcglycemicgoals,
and these skills should be reevaluated
periodically.
CGMthroughthemeasurementofin-
terstitial glucose (which correlates well
with PG) is available. These sensors re-
quire calibration with SMBG, and the lat-
ter are still recommended for making
acute treatment decisions. CGM devices
also have alarms for hypo- and hypergly-
cemic excursions. Small studies in se-
lected patients with type 1 diabetes have
suggested that CGM use reduces the time
spent in hypo- and hyperglycemic ranges
andmaymodestlyimproveglycemiccon-
trol. A larger 26-week randomized trial of
322 type 1 diabetic patients showed that
adults age 25 years and older using inten-
sive insulin therapy and CGM experi-
enced a 0.5% reduction in A1C (from
7.6 to 7.1%) compared with usual in-
tensive insulin therapy with SMBG (44).
Sensor use in children, teens, and adults
toage24yearsdidnotresultinsigniﬁcant
A1C lowering, and there was no signiﬁ-
cant difference in hypoglycemia in any
group.Importantly,thegreatestpredictor
of A1C lowering in this study for all age-
groups was frequency of sensor use,
which was lower in younger age-groups.
Inasmallerrandomizedcontrolledtrialof
129 adults and children with baseline
A1C 7.0%, outcomes combining A1C
and hypoglycemia favored the group us-
ing CGM, suggesting that CGM is also
beneﬁcial for individuals with type 1 dia-
beteswhohavealreadyachievedexcellent
control with A1C 7.0% (45). Although
CGMisanevolvingtechnology,emerging
data suggest that it may offer beneﬁt in
appropriately selected patients who are
motivated to wear it most of the time.
CGM may be particularly useful in those
with hypoglycemia unawareness and/or
frequent episodes of hypoglycemia, and
studies in this area are ongoing.
b. A1C
Recommendations
● Perform the A1C test at least two times
ayearinpatientswhoaremeetingtreat-
ment goals (and who have stable glyce-
mic control). (E)
Table 8—Components of the comprehensive diabetes evaluation
Medical history
● Age and characteristics of onset of diabetes (e.g., DKA, asymptomatic laboratory ﬁnding)
● Eating patterns, physical activity habits, nutritional status, and weight history; growth
and development in children and adolescents
● Diabetes education history
● Review of previous treatment regimens and response to therapy (A1C records)
Current treatment of diabetes, including medications, meal plan, physical activity patterns,
and results of glucose monitoring and patient’s use of data
● DKA frequency, severity, and cause
● Hypoglycemic episodes
● Hypoglycemia awareness
● Any severe hypoglycemia: frequency and cause
● History of diabetes-related complications
● Microvascular: retinopathy, nephropathy, neuropathy (sensory, including history of
foot lesions; autonomic, including sexual dysfunction and gastroparesis)
● Macrovascular: CHD, cerebrovascular disease, PAD
● Other: psychosocial problems*, dental disease*
Physical examination
● Height, weight, BMI
● Blood pressure determination, including orthostatic measurements when indicated
● Fundoscopic examination*
● Thyroid palpation
● Skin examination (for acanthosis nigricans and insulin injection sites)
● Comprehensive foot examination:
● Inspection
● Palpation of dorsalis pedis and posterior tibial pulses
● Presence/absence of patellar and Achilles reﬂexes
● Determination of proprioception, vibration, and monoﬁlament sensation
Laboratory evaluation
● A1C, if results not available within past 2–3 months
● If not performed/available within past year:
● Fasting lipid proﬁle, including total, LDL- and HDL cholesterol and triglycerides
● Liver function tests
● Test for urine albumin excretion with spot urine albumin/creatinine ratio
● Serum creatinine and calculated GFR
● TSH in type 1 diabetes, dyslipidemia, or women over age 50 years
Referrals
● Annual dilated eye exam
● Family planning for women of reproductive age
● Registered dietitian for MNT
● DSME
● Dental examination
● Mental health professional, if needed
* See appropriate referrals for these categories.
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tients whose therapy has changed or
whoarenotmeetingglycemicgoals.(E)
● Use of point-of-care testing for A1C al-
lows for timely decisions on therapy
changes, when needed. (E)
Because A1C is thought to reﬂect average
glycemia over several months (43) and
has strong predictive value for diabetes
complications (11,46), A1C testing
should be performed routinely in all pa-
tients with diabetes, at initial assessment
and then as part of continuing care. Mea-
surement approximately every 3 months
determines whether a patient’s glycemic
targets have been reached and main-
tained.Foranyindividualpatient,thefre-
quency of A1C testing should be
dependent on the clinical situation, the
treatment regimen used, and the judg-
ment of the clinician. Some patients with
stable glycemia well within target may do
well with testing only twice per year,
while unstable or highly intensively man-
aged patients (e.g., pregnant type 1 dia-
betic women) may be tested more
frequently than every 3 months. The
availability of the A1C result at the time
thatthepatientisseen(point-of-caretest-
ing) has been reported to result in in-
creased intensiﬁcation of therapy and
improvement in glycemic control
(47,48).
The A1C test is subject to certain lim-
itations. Conditions that affect erythro-
cyte turnover (hemolysis, blood loss) and
hemoglobin variants must be considered,
particularlywhentheA1Cresultdoesnot
correlate with the patient’s clinical situa-
tion (43). In addition, A1C does not pro-
vide a measure of glycemic variability or
hypoglycemia. For patients prone to gly-
cemic variability (especially type 1 dia-
betic patients, or type 2 diabetic patients
with severe insulin deﬁciency), glycemic
control is best judged by the combination
of results of SMBG testing and the A1C.
The A1C may also serve as a check on the
accuracy of the patient’s meter (or the pa-
tient’sreportedSMBGresults)andthead-
equacy of the SMBG testing schedule.
Table 9 contains the correlation be-
tween A1C levels and mean PG levels
basedondatafromtheinternationalA1C-
Derived Average Glucose (ADAG) trial
using frequent SMBG and CGM in 507
adults (83% Caucasian) with type 1, type
2, and no diabetes (49). ADA and the
American Association of Clinical Chem-
ists have determined that the correlation
(r 	 0.92) is strong enough to justify re-
porting both an A1C result and an esti-
mated average glucose (eAG) result when
a clinician orders the A1C test. In previ-
ous versions of the Standards of Medical
Care in Diabetes, the table describing the
correlation between A1C and mean glu-
cose was derived from relatively sparse
data (one seven-point proﬁle over 1 day
per A1C reading) in the primarily Cauca-
siantype1participantsintheDCCT(50).
Clinicians should note that the numbers
in the table are now different, as they are
based on2,800 readings per A1C in the
ADAG trial.
In the ADAG trial, there were no sig-
niﬁcant differences among racial and eth-
nicgroupsintheregressionlinesbetween
A1C and mean glucose, although there
was a trend toward a difference between
Africans/African Americans participants
and Caucasians that might have been sig-
niﬁcant had more Africans/African Amer-
icans been studied. A recent study
comparing A1C to CGM data in 48 type 1
diabetic children found a highly statisti-
cally signiﬁcant correlation between A1C
and mean blood glucose, although the
correlation (r 	 0.7) was signiﬁcantly
lower than in the ADAG trial (51).
Whether there are signiﬁcant differences
in how A1C relates to average glucose in
children or in African American patients
is an area for further study. For the time
being,thequestionhasnotledtodifferent
recommendations about testing A1C or
different interpretations of the clinical
meaning of given levels of A1C in those
populations.
For patients in whom A1C/eAG and
measured blood glucose appear discrep-
ant, clinicians should consider the possi-
bilities of hemoglobinopathy or altered
red cell turnover and the options of more
frequent and/or different timing of SMBG
oruseofCGM.Othermeasuresofchronic
glycemia such as fructosamine are avail-
able, but their linkage to average glucose
and their prognostic signiﬁcance are not
as clear as is the case for A1C.
2. Glycemic goals in adults
● Lowering A1C to below or around 7%
has been shown to reduce microvascu-
lar and neuropathic complications of
type 1 and type 2 diabetes. Therefore,
for microvascular disease prevention,
the A1C goal for nonpregnant adults in
general is 7%. (A)
● In type 1 and type 2 diabetes, random-
izedcontrolledtrialsofintensiveversus
standard glycemic control have not
shown a signiﬁcant reduction in CVD
outcomes during the randomized por-
tion of the trials. Long-term follow-up
of the DCCT and UK Prospective Dia-
betes Study (UKPDS) cohorts suggests
that treatment to A1C targets below or
around 7% in the years soon after the
diagnosis of diabetes is associated with
long-term reduction in risk of macro-
vascular disease. Until more evidence
becomes available, the general goal of
7% appears reasonable for many
adults for macrovascular risk reduc-
tion. (B)
● Subgroupanalysesofclinicaltrialssuch
astheDCCTandUKPDS,andevidence
forreducedproteinuriaintheActionin
DiabetesandVascularDisease:Preterax
and Diamicron Modiﬁed Release Con-
trolled Evaluation (ADVANCE) trial
suggest a small but incremental beneﬁt
in microvascular outcomes with A1C
values closer to normal. Therefore, for
selected individual patients, providers
might reasonably suggest even lower
A1C goals than the general goal of
7%, if this can be achieved without
signiﬁcant hypoglycemia or other ad-
verseeffectsoftreatment.Suchpatients
might include those with short dura-
tion of diabetes, long life expectancy,
and no signiﬁcant CVD. (B)
● Conversely, less-stringent A1C goals
than the general goal of 7% may be
appropriate for patients with a history
of severe hypoglycemia, limited life ex-
pectancy, advanced microvascular or
macrovascular complications, and ex-
tensive comorbid conditions and those
with longstanding diabetes in whom
the general goal is difﬁcult to attain de-
Table 9—Correlation of A1C with average
glucose
A1C (%)
Mean plasma glucose
mg/dl mmol/l
6 126 7.0
7 154 8.6
8 183 10.2
9 212 11.8
10 240 13.4
11 269 14.9
12 298 16.5
These estimates are based on ADAG data of 2,700
glucosemeasurementsover3monthsperA1Cmea-
surement in 507 adults with type 1, type 2, and no
diabetes. The correlation between A1C and average
glucose was 0.92 (49). A calculator for converting
A1C results into estimated average glucose (eAG),
in either mg/dl or mmol/l, is available at
http://professional.diabetes.org/eAG.
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tion, appropriate glucose monitoring,
and effective doses of multiple glucose-
lowering agents including insulin. (C)
Glycemic control is fundamental to the
management of diabetes. The DCCT, a
prospective, randomized, controlled trial
of intensive versus standard glycemic
controlinpatientswithrelativelyrecently
diagnosed type 1 diabetes, showed deﬁn-
itively that improved glycemic control is
associated with signiﬁcantly decreased
rates of microvascular (retinopathy and
nephropathy) as well as neuropathic
complications (53). Follow-up of the
DCCT cohorts in the Epidemiology of Di-
abetes Interventions and Complications
(EDIC) study has shown persistence of
this effect in previously intensively
treated subjects, even though their glyce-
mic control has been equivalent to that of
previous standard arm subjects during
follow-up (54,55).
In type 2 diabetes, the Kumamoto
study (56) and the UKPDS (57,58) dem-
onstrated signiﬁcant reductions in micro-
vascular and neuropathic complications
with intensive therapy. Similar to the
DCCT-EDIC ﬁndings, long-term fol-
low-up of the UKPDS cohort has recently
demonstrated a “legacy effect” of early in-
tensive glycemic control on long-term
rates of microvascular complications,
even with loss of glycemic separation be-
tween the intensive and standard cohorts
after the end of the randomized con-
trolled trial (59). The more recent Veter-
ans Affairs Diabetes Trial (VADT) in type
2 diabetes also showed signiﬁcant reduc-
tions in albuminuria with intensive
(achieved median A1C 6.9%) compared
with standard glycemic control but no
difference in retinopathy and neuropathy
(60,61).
In each of these large randomized
prospective clinical trials, treatment regi-
mens that reduced average A1C to 7%
(1% above the upper limits of normal)
were associated with fewer markers of
long-term microvascular complications;
however, intensive control was found to
increase the risk of severe hypoglycemia
and led to weight gain (46,60,62).
Epidemiological analyses of the
DCCTandUKPDS(46,53)demonstratea
curvilinearrelationshipbetweenA1Cand
microvascular complications. Such anal-
yses suggest that, on a population level,
the greatest number of complications will
be averted by taking patients from very
poorcontroltofairorgoodcontrol.These
analysesalsosuggestthatfurtherlowering
of A1C from 7 to 6% is associated with
further reduction in the risk of microvas-
cular complications, albeit the absolute
risk reductions become much smaller.
The ADVANCE study of intensive versus
standard glycemic control in type 2 dia-
betes found a statistically signiﬁcant re-
duction in albuminuria with an A1C
target of 6.5% (achieved median A1C
6.3%) compared with standard therapy
achieving a median A1C of 7.0% (63).
Given the substantially increased risk of
hypoglycemia (particularly in those with
type1diabetes,butalsointherecenttype
2 diabetes trials described below), the
concerning mortality ﬁndings in the Ac-
tiontoControlCardiovascularRiskinDi-
abetes (ACCORD) trial described below
and the relatively much greater effort re-
quired to achieve near-normoglycemia,
the risks of lower targets may outweigh
the potential beneﬁts on microvascular
complications on a population level.
However,selectedindividualpatients,es-
pecially those with little comorbidity and
long life expectancy (who may reap the
beneﬁts of further lowering glycemia be-
low 7%) may, at patient and provider
judgment, adopt glycemic targets as close
tonormalaspossibleaslongassigniﬁcant
hypoglycemia does not become a barrier.
Whereas many epidemiologic studies
and meta-analyses (64,65) have clearly
shown a direct relationship between A1C
andCVD,thepotentialofintensiveglyce-
mic control to reduce CVD has been less
clearly deﬁned. In the DCCT, there was a
trend toward lower risk of CVD events
with intensive control (risk reduction
41%, 95% CI 10–68%), but the number
of events was small. However, 9-year
post-DCCT follow-up of the cohort has
shown that participants previously ran-
domized to the intensive arm had a 42%
reduction (P 	 0.02) in CVD outcomes
and a 57% reduction (P 	 0.02) in the
risk of nonfatal myocardial infarction
(MI), stroke, or CVD death compared
with participants previously in the stan-
dard arm (66). The beneﬁt of intensive
glycemic control in this type 1 diabetic
cohort has recently been shown to persist
for up to 30 years (67).
The UKPDS trial of type 2 diabetes
observeda16%reductionincardiovascu-
larcomplications(combinedfatalornon-
fatal MI and sudden death) in the
intensive glycemic control arm, although
this difference was not statistically signif-
icant (P 	 0.052), and there was no sug-
gestionofbeneﬁtonotherCVDoutcomes
such as stroke. In an epidemiologic anal-
ysis of the study cohort, a continuous as-
sociationwasobservedsuchthatforevery
percentage point lower median on-study
A1C (e.g., 8–7%), there was a statistically
signiﬁcant 18% reduction in CVD events,
again with no glycemic threshold. A re-
cent report of 10 years of follow-up of the
UKPDS cohort described, for the partici-
pants originally randomized to intensive
glycemic control compared with those
randomized to conventional glycemic
control,long-termreductionsinMI(15%
with sulfonylurea or insulin as initial
pharmacotherapy, 33% with metformin
as initial pharmacotherapy, both statisti-
cally signiﬁcant) and in all-cause mortal-
ity (13 and 27%, respectively, both
statistically signiﬁcant) (59).
Because of ongoing uncertainty re-
garding whether intensive glycemic con-
trol can reduce the increased risk of CVD
eventsinpeoplewithtype2diabetes,sev-
eral large long-term trials were launched
in the past decade to compare the effects
of intensive versus standard glycemic
control on CVD outcomes in relatively
high-risk participants with established
type 2 diabetes. In 2008, results of three
large trials (ACCORD, ADVANCE, and
VADT)suggestednosigniﬁcantreduction
inCVDoutcomeswithintensiveglycemic
control in these populations. Details of
thesethreestudiesareshowninTable10,
and their results and implications are re-
viewed more extensively in a recent ADA
position statement (52).
The ACCORD study randomized
10,251 participants with either history of
a CVD event or signiﬁcant CVD risk to a
strategyofintensiveglycemiccontrol(tar-
get A1C 6.0%) or standard glycemic
control(A1Ctarget7.0–7.9%).Investiga-
tors used multiple glycemic medications
in both arms. From a baseline median
A1C of 8.1%, the intensive arm reached a
medianA1Cof6.4%within12monthsof
randomization, while the standard group
reached a median A1C of 7.5%. Other
risk factors were treated aggressively and
equally in both groups. The intensive gly-
cemic control group had more use of in-
sulin in combination with multiple oral
agents, signiﬁcantly more weight gain,
and more episodes of severe hypoglyce-
mia than the standard group.
In early 2008, the glycemic control
arm of ACCORD was halted on the rec-
ommendation of the study’s data safety
monitoring board due to the ﬁnding of an
increasedrateofmortalityintheintensive
arm compared with the standard arm
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95% CI 1.01–1.46), with a similar in-
crease in cardiovascular deaths. The pri-
mary outcome of ACCORD (MI, stroke,
or cardiovascular death) was lower in the
intensive glycemic control group due to a
reduction in nonfatal MI, although this
ﬁnding was not statistically signiﬁcant
when the study was terminated (68). Of
note,prespeciﬁedsubsetanalysesshowed
that participants with no previous CVD
event and those who had a baseline A1C
8% had a statistically signiﬁcant reduc-
tion in the primary CVD outcome, al-
though overall mortality was not reduced
in these groups.
The cause of excess deaths in the in-
tensive group of the ACCORD has been
difﬁcult to pinpoint (and is discussed in
some detail in a 2009 ADA position state-
ment [52]). However, exploratory analy-
ses of the mortality ﬁndings of ACCORD
(evaluating variables including weight
gain, use of any speciﬁc drug or drug
combination,andhypoglycemia)werere-
portedly unable to identify a clear expla-
nation for the excess mortality in the
intensive arm. At the 69th Scientiﬁc Ses-
sions of the American Diabetes Associa-
tion, the ACCORD investigators
presentedadditionalanalysesshowingno
increase in mortality in participants who
achievedA1Clevels7%orinthosewho
lowered their A1C quickly after trial en-
rollment. In fact, the converse was ob-
served: those at highest risk for mortality
were participants in the intensive arm
with the highest A1C levels.
The ADVANCE study randomized
participants to a strategy of intensive gly-
cemic control (with primary therapy be-
ing the sulfonylurea gliclizide and
additional medications as needed to
achieveatargetA1Cof6.5%)ortostan-
dard therapy (in which any medication
but gliclizide could be used and the gly-
cemic target was according to “local
guidelines”). ADVANCE participants
Table 10—Comparison of the three trials of intensive glycemic control and CVD outcomes
ACCORD ADVANCE VADT
Participant characteristics
n 10,251 11,140 1,791
Mean age (years) 62 66 60
Duration of diabetes (years) 10 8 11.5
History of CVD (%) 35 32 40
Median baseline A1C (%) 8.1 7.2 9.4
On insulin at baseline (%) 35 1.5 52
Protocol characteristics
A1C goals (%) (I vs. S)* 6.0 vs. 7.0–7.9 6.5 vs. “based on local guidelines” 6.0 (action if 6.5) vs.
planned separation of 1.5
Protocol for glycemic control
(I vs. S)* Multiple drugs in both
arms
Multiple drugs added to gliclizide vs.
multiple drugs with no gliclizide
Multiple drugs in both arms
Management of other risk
factors Embedded blood pressure
and lipid trials
Embedded blood pressure trial Protocol for intensive
treatment in both arms
On-study characteristics
Achieved median A1C (%)
(I vs. S) 6.4 vs. 7.5 6.3 vs. 7.0 6.9 vs. 8.5
On insulin at study end (%)
(I vs. S)* 77 vs. 55* 40 vs. 24 89 vs. 0.74
Weight changes (kg)
Intensive glycemic control arm 
3.5 0.1 
7.8
Standard glycemic control arm 
0.4 1.0 
3.4
Severe hypoglycemia
(participants with one or more
episodes during study) (%)
Intensive glycemic control arm 16.2 2.7 21.2
Standard glycemic control arm 5.1 1.5 9.9
Outcomes
Deﬁnition of primary outcome Nonfatal MI, nonfatal
stroke, CVD death
Microvascular plus macrovascular
(nonfatal MI, nonfatal stroke, CVD
death) outcomes
Nonfatal MI, nonfatal stroke,
CVD death,
hospitalization for heart
failure, revascularization
HR for primary outcome
(95% CI) 0.90 (0.78–1.04) 0.9 (0.82–0.98);
macrovascular 0.94 (0.84–1.06)
0.88 (0.74–1.05)
HR for mortality ﬁndings
(95% CI) 1.22 (1.01–1.46) 0.93 (0.83–1.06) 1.07 (0.81–1.42)
*Insulin rates for ACCORD are for any use during the study. I, intensive glycemic control; S, standard glycemic control. Abridged from ref. 52.
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CORD and VADT and had similar high
CVD risk. However, they had an average
duration of diabetes that was 2 years
shorter, lower baseline A1C (median
7.2%), and almost no use of insulin at
enrollment. The median A1C levels
achieved in the intensive and standard
arms were 6.3 and 7.0%, respectively,
and maximal separation between the
arms took several years to achieve. Use of
other drugs that favorably impact CVD
risk (aspirin, statins, and angiotensin en-
zyme inhibitors) was lower in ADVANCE
than in ACCORD or VADT.
The primary outcome of ADVANCE
was a combination of microvascular
events (nephropathy and retinopathy)
and major adverse cardiovascular events
(MI, stroke, and cardiovascular death).
Intensive glycemic control signiﬁcantly
reduced the primary end point, although
this was due to a signiﬁcant reduction in
the microvascular outcome, primarily de-
velopment of macroalbuminuria, with no
signiﬁcant reduction in the macrovascu-
lar outcome. There was no difference in
overall or cardiovascular mortality be-
tween the intensive compared with the
standard glycemic control arms (63).
VADT randomized participants with
type2diabetesuncontrolledoninsulinor
maximal dose oral agents (median entry
A1C 9.4%) to a strategy of intensive gly-
cemic control (goal A1C 6.0%) or stan-
dard glycemic control, with a planned
A1C separation of at least 1.5%. Medica-
tion treatment algorithms were used to
achieve the speciﬁed glycemic goals, with
agoalofusingsimilarmedicationsinboth
groups. Median A1C levels of 6.9 and
8.4% were achieved in the intensive and
standard arms, respectively, within the
1st year of the study. Other CVD risk fac-
tors were treated aggressively and equally
in both groups.
The primary outcome of VADT was a
compositeofCVDevents.Thecumulative
primary outcome was nonsigniﬁcantly
lower in the intensive arm. There were
more CVD deaths in the intensive arm
than in the standard arm, but the differ-
ence was not statistically signiﬁcant (60).
Post hoc subgroup analyses suggested
that duration of diabetes interacted with
randomization such that participants
with duration of diabetes less than about
12 years appeared to have a CVD beneﬁt
of intensive glycemic control while those
with longer duration of disease prior to
study entry had a neutral or even adverse
effectofintensiveglycemiccontrol.Other
exploratory analyses suggested that se-
vere hypoglycemia within the past 90
dayswasastrongpredictoroftheprimary
outcome and of CVD mortality (69).
All three of these trials were carried
outinparticipantswithestablisheddiabe-
tes(meanduration8–11years)andeither
known CVD or multiple risk factors sug-
gesting the presence of established ath-
erosclerosis. Subset analyses of the three
trials suggested a signiﬁcant beneﬁt of in-
tensive glycemic control on CVD in par-
ticipants with shorter duration of
diabetes, lower A1C at entry, and/or ab-
sence of known CVD. The DCCT-EDIC
study and the long-term follow-up of the
UKPDScohortbothsuggestthatintensive
glycemic control initiated soon after diag-
nosis of diabetes in patients with a lower
level of CVD risk may impart long-term
protection from CVD events. As is the
case with microvascular complications, it
may be that glycemic control plays a
greater role before macrovascular disease
is well developed and minimal or no role
when it is advanced. Consistent with this
concept, data from an ancillary study of
VADT demonstrated that intensive glyce-
mic control was quite effective in reduc-
ing CVD events in individuals with less
atherosclerosis at baseline (assessed by
coronary calcium) but not in people with
more extensive baseline atherosclerosis
(70).
The beneﬁts of intensive glycemic
control on microvascular and neuro-
pathic complications are well established
for both type 1 and type 2 diabetes. AD-
VANCEandVADThaveaddedtothatev-
idence base by demonstrating a
signiﬁcant reduction in the risk of new or
worsening albuminuria with intensive
glycemic control. The lack of signiﬁcant
reduction in CVD events with intensive
glycemic control in ACCORD, AD-
VANCE, and VADT should not lead clini-
cians to abandon the general target of an
A1C 7.0% and thereby discount the
beneﬁtofgoodcontrolonseriousandde-
bilitating microvascular complications.
The evidence for a cardiovascular
beneﬁt of intensive glycemic control pri-
marily rests on long-term follow-up of
study cohorts treated early in the course
of type 1 and type 2 diabetes as well as
subset analyses of ACCORD, ADVANCE,
and VADT. A recent group-level meta-
analysis of the three trials suggests that
glucose lowering has a modest (9%) but
statistically signiﬁcant reduction in major
CVD outcomes, primarily nonfatal MI,
with no signiﬁcant increase in mortality.
A prespeciﬁed subgroup analysis sug-
gested that major CVD outcome reduc-
tion occurred in patients without known
CVD at baseline (HR 0.84 [95% CI 0.74–
0.94]) (71). Conversely, the mortality
ﬁndings in ACCORD and subgroup anal-
yses of VADT suggest that the potential
risks of very intensive glycemic control
may outweigh its beneﬁts in some pa-
tients, such as those with very long dura-
tion of diabetes, known history of severe
hypoglycemia, advanced atherosclerosis,
and advanced age/frailty. Certainly, pro-
vidersshouldbevigilantinpreventingse-
vere hypoglycemia in patients with
advanced disease and should not aggres-
sively attempt to achieve near-normal
A1C levels in patients in whom such a
target cannot be reasonably easily and
safely achieved.
Recommended glycemic goals for
nonpregnant adults are shown in Table
11. The recommendations are based on
those for A1C values, with listed blood
glucose levels that appear to correlate
withachievementofanA1Cof7%.The
issue of pre- versus postprandial SMBG
targets is complex (72). Elevated post-
challenge (2-h OGTT) glucose values
have been associated with increased car-
diovascular risk independent of FPG in
some epidemiological studies. In diabetic
subjects, some surrogate measures of vas-
cular pathology, such as endothelial dys-
function, are negatively affected by
postprandial hyperglycemia (73). It is
clear that postprandial hyperglycemia,
like preprandial hyperglycemia, contrib-
utes to elevated A1C levels, with its rela-
tive contribution being higher at A1C
levelsthatarecloserto7%.However,out-
come studies have clearly shown A1C to
be the primary predictor of complica-
tions, and landmark glycemic control tri-
als such as the DCCT and UKPDS relied
overwhelmingly on preprandial SMBG.
Additionally, a randomized controlled
trial in patients with known CVD found
no CVD beneﬁt of insulin regimens tar-
geting postprandial glucose compared
with those targeting preprandial glucose
(74). For individuals who have premeal
glucose values within target but A1C val-
uesabovetarget,areasonablerecommen-
dationforpostprandialtestingandtargets
is monitoring postprandial plasma glu-
cose(PPG)1–2hafterthestartofthemeal
andtreatmentaimedatreducingPPGval-
ues to 180 mg/dl to help lower A1C.
As noted above, less stringent treat-
ment goals may be appropriate for adults
withlimitedlifeexpectanciesoradvanced
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dren are provided in VII.A.1.a. Glycemic
control. Severe or frequent hypoglycemia
is an absolute indication for the modiﬁca-
tion of treatment regimens, including set-
ting higher glycemic goals.
Regarding goals for glycemic control
for women with GDM, recommendations
from the Fifth International Workshop-
Conference on Gestational Diabetes (75)
are to target maternal capillary glucose
concentrations of:
● Preprandial 95 mg/dl (5.3 mmol/l)
and either
● 1-h postmeal 140 mg/dl (7.8
mmol/l)
or
● 2-h postmeal 120 mg/dl (6.7
mmol/l)
For women with preexisting type 1 or
type 2 diabetes who become pregnant, a
recent consensus statement (76) recom-
mends the following as optimal glycemic
goals, if they can be achieved without ex-
cessive hypoglycemia:
● premeal, bedtime, and overnight glu-
cose 60–99 mg/dl (3.3–5.4 mmol/l)
● peak postprandial glucose 100–129
mg/dl (5.4–7.1 mmol/l)
● A1C 6.0%
3. Approach to treatment
a. Therapy for type 1 diabetes. The
DCCT clearly showed that intensive insu-
lin therapy (three or more injections per
day of insulin or continuous subcutane-
ous insulin infusion [CSII] or insulin
pump therapy) was a key part of im-
proved glycemia and better outcomes
(53,66). At the time of the study, therapy
was carried out with short- and interme-
diate-acting human insulins. Despite bet-
ter microvascular outcomes, intensive
insulintherapywasassociatedwithahigh
rate in severe hypoglycemia (62 episodes
per 100 patient-years of therapy). Since
the time of the DCCT, a number of rapid-
acting and long-acting insulin analogs
have been developed. These analogs are
associated with less hypoglycemia with
equal A1C lowering in type 1 diabetes
(77,78).
Recommended therapy for type 1 di-
abetes therefore consists of the following
components: 1) use of multiple dose in-
sulininjections(3–4injectionsperdayof
basal and prandial insulin) or CSII ther-
apy; 2) matching of prandial insulin to
carbohydrate intake, premeal blood glu-
cose, and anticipated activity; and 3) for
manypatients(especiallyifhypoglycemia
is a problem), use of insulin analogs.
There are excellent reviews available that
guide the initiation and management of
insulin therapy to achieve desired glyce-
mic goals (3,77,79).
Because of the increased frequency of
other autoimmune diseases in type 1 dia-
betes, screening for thyroid dysfunction,
vitamin B12 deﬁciency, or celiac disease
should be considered based on signs and
symptoms. Periodic screening in the ab-
sence of symptoms has been recom-
mended, but the effectiveness and
optimal frequency are unclear.
b.Therapyfortype2diabetes. TheADA
and the European Association for the
Study of Diabetes (EASD) published a
consensus statement on the approach to
managementofhyperglycemiainindivid-
uals with type 2 diabetes (80) and a sub-
sequent update (81). Highlights of this
approach include: intervention at the
time of diagnosis with metformin in com-
bination with lifestyle changes (MNT and
exercise) and continuing timely augmen-
tation of therapy with additional agents
(including early initiation of insulin ther-
apy) as a means of achieving and main-
taining recommended levels of glycemic
control(i.e.,A1C7%formostpatients).
The overall objective is to achieve and
maintain glycemic control and to change
interventions when therapeutic goals are
not being met.
The algorithm took into account the
evidence for A1C lowering of the individ-
ual interventions, their additive effects,
andtheirexpense.Theprecisedrugsused
and their exact sequence may not be as
important as achieving and maintaining
glycemic targets safely. Medications not
included in the consensus algorithm, ow-
ing to less glucose-lowering effectiveness,
limited clinical data, and/or relative ex-
pense,stillmaybeappropriatechoicesfor
individual patients to achieve glycemic
goals. Initiation of insulin at the time of
diagnosisisrecommendedforindividuals
presenting with weight loss or other se-
vere hyperglycemic symptoms or signs.
D. Medical nutrition therapy
General recommendations
● Individuals who have pre-diabetes or
diabetes should receive individualized
MNT as needed to achieve treatment
goals, preferably provided by a regis-
tereddietitianfamiliarwiththecompo-
nents of diabetes MNT. (A)
● Because it can result in cost savings and
improved outcomes (B), MNT should
be covered by insurance and other pay-
ors (E).
Energy balance, overweight, and
obesity
● In overweight and obese insulin-
resistant individuals, modest weight
loss has been shown to reduce insulin
resistance. Thus, weight loss is recom-
mended for all overweight or obese in-
dividuals who have or are at risk for
diabetes. (A)
● For weight loss, either low-carbohy-
drate or low-fat calorie-restricted diets
Table 11 —Summary of glycemic recommendations for non-pregnant adults with diabetes
A1C 7.0%*
Preprandial capillary plasma glucose 70–130 mg/dl (3.9–7.2 mmol/l)
Peak postprandial capillary plasma glucose† 180 mg/dl (10.0 mmol/l)
Key concepts in setting glycemic goals:
● A1C is the primary target for glycemic control
● Goals should be individualized based on:
● duration of diabetes
● age/life expectancy
● comorbid conditions
● known CVD or advanced microvascular
complications
● hypoglycemia unawareness
● individual patient considerations
● More or less stringent glycemic goals may be
appropriate for individual patients
Postprandial glucose may be targeted if A1C goals are not
met despite reaching preprandial glucose goals
*Referenced to a nondiabetic range of 4.0–6.0% using a DCCT-based assay. †Postprandial glucose mea-
surements should be made 1–2 h after the beginning of the meal, generally peak levels in patients with
diabetes.
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to 1 year). (A)
● Forpatientsonlow-carbohydratediets,
monitor lipid proﬁles, renal function,
and protein intake (in those with ne-
phropathy) and adjust hypoglycemic
therapy as needed. (E)
● Physical activity and behavior modiﬁ-
cation are important components of
weight loss programs and are most
helpful in maintenance of weight loss.
(B)
Primary prevention of diabetes
● Among individuals at high risk for de-
veloping type 2 diabetes, structured
programs emphasizing lifestyle
changes that include moderate weight
loss (7% body weight) and regular
physical activity (150 min/week) with
dietary strategies including reduced
calories and reduced intake of dietary
fat can reduce the risk for developing
diabetes and are therefore recom-
mended. (A)
● Individuals at high risk for type 2 dia-
betes should be encouraged to achieve
the U.S. Department of Agriculture
(USDA) recommendation for dietary ﬁ-
ber (14 g ﬁber/1,000 kcal) and foods
containing whole grains (one-half of
grain intake). (B)
Dietary fat intake in diabetes
management
● Saturated fat intake should be 7% of
total calories. (A)
● Reducing intake of trans fat lowers LDL
cholesterol and increases HDL choles-
terol (A); therefore intake of trans fat
should be minimized (E).
Carbohydrate intake in diabetes
management
● Monitoring carbohydrate intake,
whether by carbohydrate counting, ex-
changes, or experience-based estima-
tion,remainsakeystrategyinachieving
glycemic control. (A)
● Forindividualswithdiabetes,useofthe
glycemic index and glycemic load may
provide a modest additional beneﬁt for
glycemic control over that observed
when total carbohydrate is considered
alone. (B)
Other nutrition recommendations
● Sugar alcohols and nonnutritive sweet-
eners are safe when consumed within
the acceptable daily intake levels estab-
lished by the Food and Drug Adminis-
tration (FDA). (A)
● If adults with diabetes choose to use
alcohol, daily intake should be limited
to a moderate amount (one drink per
day or less for adult women and two
drinks per day or less for adult men).
(E)
● Routine supplementation with antioxi-
dants, such as vitamins E and C and
carotene, is not advised because of lack
of evidence of efﬁcacy and concern re-
lated to long-term safety. (A)
● Beneﬁt from chromium supplementa-
tion in people with diabetes or obesity
has not been conclusively demon-
strated and therefore cannot be recom-
mended. (C)
● Individualized meal planning should
include optimization of food choices to
meet recommended dietary allowances
(RDAs)/dietary reference intakes
(DRIs) for all micronutrients. (E)
MNTisanintegralcomponentofdiabetes
prevention, management, and self-
management education. In addition to its
role in preventing and controlling diabe-
tes, ADA recognizes the importance of
nutrition as an essential component of an
overall healthy lifestyle. A full review of
the evidence regarding nutrition in pre-
venting and controlling diabetes and its
complications and additional nutrition-
relatedrecommendationscanbefoundin
the ADA position statement, Nutrition
Recommendations and Interventions for
Diabetes, published in 2006 and updated
for 2008 (82). Achieving nutrition-
related goals requires a coordinated team
effortthatincludestheactiveinvolvement
of the person with pre-diabetes or diabe-
tes.Becauseofthecomplexityofnutrition
issues,itisrecommendedthataregistered
dietitian who is knowledgeable and
skilledinimplementingnutritiontherapy
into diabetes management and education
be the team member who provides MNT.
Clinical trials/outcome studies of
MNT have reported decreases in A1C at
3–6 months ranging from 0.25 to 2.9%
with higher reductions seen in type 2 di-
abetes of shorter duration. Multiple stud-
ies have demonstrated sustained
improvements in A1C at 12 months and
longer when a registered dietitian pro-
vided follow-up visits ranging from
monthly to three sessions per year (83–
90). Meta-analyses of studies in nondia-
betic,free-livingsubjectsreportthatMNT
reduces LDL cholesterol by 15–25 mg/dl
(91) or by up to 16% (92), while clinical
trials support a role for lifestyle modiﬁca-
tion in treating hypertension (92,93).
Because of the effects of obesity on
insulin resistance, weight loss is an im-
portant therapeutic objective for over-
weight or obese individuals with pre-
diabetes or diabetes (94). Short-term
studies have demonstrated that moderate
weight loss (5% of body weight) in sub-
jects with type 2 diabetes is associated
with decreased insulin resistance, im-
provedmeasuresofglycemiaandlipemia,
and reduced blood pressure (95); longer-
term studies (52 weeks) showed mixed
effects on A1C in adults with type 2 dia-
betes (96–99), and results were con-
founded by pharmacologic weight loss
therapy. A systematic review of 80 weight
loss studies of 1 year duration demon-
strated that moderate weight loss
achieved through diet alone, diet and ex-
ercise, and meal replacements can be
achieved and maintained over the long
term (4.8–8% weight loss at 12 months
[100]). The multifactorial intensive life-
style intervention used in the DPP, which
included reduced intake of fat and calo-
ries, led to weight loss averaging 7% at 6
months and maintenance of 5% weight
loss at 3 years, associated with a 58% re-
duction in incidence of type 2 diabetes
(11). Look AHEAD (Action for Health in
Diabetes) is a large clinical trial designed
to determine whether long-term weight
loss will improve glycemia and prevent
cardiovascular events in subjects with
type 2 diabetes. One-year results of the
intensive lifestyle intervention in this trial
show an average of 8.6% weight loss, sig-
niﬁcant reduction of A1C, and reduction
in several CVD risk factors (101). When
completed, the Look AHEAD study
should provide insight into the effects of
long-term weight loss on important clin-
ical outcomes.
The optimal macronutrient distribu-
tion of weight loss diets has not been es-
tablished. Although low-fat diets have
traditionally been promoted for weight
loss, several randomized controlled trials
found that subjects on low-carbohydrate
diets (130 g/day of carbohydrate) lost
moreweightat6monthsthansubjectson
low-fat diets (102,103); however, at 1
year, the difference in weight loss be-
tween the low-carbohydrate and low-fat
diets was not signiﬁcant and weight loss
was modest with both diets. Another
study of overweight women randomized
to one of four diets showed signiﬁcantly
more weight loss at 12 months with the
Atkins low-carbohydrate diet than with
higher-carbohydrate diets (104).
Changes in serum triglyceride and HDL
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low-carbohydrate diets. In one study,
those subjects with type 2 diabetes dem-
onstratedagreaterdecreaseinA1Cwitha
low-carbohydrate diet than with a low-fat
diet(103).Arecentmeta-analysisshowed
that at 6 months, low-carbohydrate diets
were associated with greater improve-
mentsintriglycerideandHDLcholesterol
concentrations than low-fat diets; how-
ever, LDL cholesterol was signiﬁcantly
higher with the low-carbohydrate diets
(105). In a 2-year dietary intervention
study, Mediterranean and low-carbohy-
drate diets were found to be effective and
safe alternatives to a low-fat diet for
weight reduction in moderately obese
participants (99).
The RDA for digestible carbohydrate
is 130 g/day and is based on providing
adequate glucose as the required fuel for
the central nervous system without reli-
anceonglucoseproductionfromingested
protein or fat. Although brain fuel needs
can be met on lower-carbohydrate diets,
long-term metabolic effects of very-low-
carbohydrate diets are unclear, and such
diets eliminate many foods that are im-
portant sources of energy, ﬁber, vitamins,
andmineralsthatareimportantindietary
palatability (106).
Although numerous studies have at-
tempted to identify the optimal mix of
macronutrients for meal plans of people
with diabetes, it is unlikely that one such
combination of macronutrients exists.
The best mix of carbohydrate, protein,
and fat appears to vary depending on
individual circumstances. For those
individualsseekingguidanceastomacro-
nutrient distribution in healthy adults,
DRIs may be helpful (106). It must be
clearly recognized that regardless of the
macronutrient mix, the total caloric in-
take must be appropriate to the weight
managementgoal.Further,individualiza-
tion of the macronutrient composition
willdependonthemetabolicstatusofthe
patient (e.g., lipid proﬁle and renal func-
tion) and/or food preferences. Plant-
based diets (vegan or vegetarian) that are
well planned and nutritionally adequate
have also been shown to improve meta-
bolic control (107,108).
The primary goal with respect to di-
etary fat in individuals with diabetes is to
limit saturated fatty acids, trans fatty ac-
ids, and cholesterol intake so as to reduce
risk for CVD. Saturated and trans fatty ac-
ids are the principal dietary determinants
of plasma LDL cholesterol. There is a lack
of evidence on the effects of speciﬁc fatty
acids on people with diabetes; therefore,
the recommended goals are consistent
with those for individuals with CVD
(92,109).
The FDA has approved ﬁve nonnutri-
tivesweetenersforuseintheU.S.:acesul-
fame potassium, aspartame, neotame,
saccharin, and sucralose. Before being al-
lowed on the market, all underwent rig-
orous scrutiny and were shown to be safe
when consumed by the public, including
people with diabetes and women during
pregnancy. Reduced calorie sweeteners
approved by the FDA include sugar alco-
hols (polyols) such as erythritol, isomalt,
lactitol, maltitol, mannitol, sorbitol, xyli-
tol,tagatose,andhydrogenatedstarchhy-
drolysates. The use of sugar alcohols
appears to be safe; however, they may
causediarrhea,especiallyinchildren.Ste-
via (Rebaudioside A) has been designated
by the FDA as being generally recognized
as safe (GRAS).
Reimbursement for MNT
MNT, when delivered by a registered dieti-
tian according to nutrition practice guide-
lines, is reimbursed as part of the Medicare
program as overseen by the Centers for
Medicare and Medicaid Services (www.
cms.hhs.gov/ medicalnutritiontherapy).
E. Bariatric surgery
Recommendations
● Bariatric surgery should be considered
for adults with BMI 35 kg/m
2 and
type 2 diabetes, especially if the diabe-
tes or associated comorbidities are dif-
ﬁcult to control with lifestyle and
pharmacologic therapy. (B)
● Patients with type 2 diabetes who have
undergone bariatric surgery need life-
long lifestyle support and medical moni-
toring. (E)
● Although small trials have shown glyce-
micbeneﬁtofbariatricsurgeryinpatients
with type 2 diabetes and BMI of 30–35
kg/m
2, there is currently insufﬁcient evi-
dencetogenerallyrecommendsurgeryin
patientswithBMI35kg/m
2outsideofa
research protocol. (E)
● The long-term beneﬁts, cost-effectiveness,
andrisksofbariatricsurgeryinindivid-
uals with type 2 diabetes should be
studied in well-designed, randomized
controlled trials with optimal medical
and lifestyle therapy as the comparator.
(E)
Gastric reduction surgery, either gastric
banding or procedures that involve by-
passing or transposing sections of the
small intestine, when part of a compre-
hensive team approach, can be an effec-
tive weight loss treatment for severe
obesity, and national guidelines support
its consideration for people with type 2
diabetes who have BMI 35 kg/m
2. Bari-
atric surgery has been shown to lead to
near or complete normalization of glyce-
mia in 55–95% of patients with type 2
diabetes, depending on the surgical pro-
cedure. A meta-analysis of studies of bari-
atric surgery reported that 78% of
individualswithtype2diabeteshadcom-
plete “resolution” of diabetes (normaliza-
tionofbloodglucoselevelsintheabsence
of medications) and that the resolution
rates were sustained in studies that had
follow-up exceeding 2 years (110). Reso-
lution rates are lower with procedures
that only constrict the stomach and
higher with those that bypass portions of
thesmallintestine.Additionally,thereisa
suggestion that intestinal bypass proce-
dures may have glycemic effects that are
independent of their effects on weight.
A recent randomized controlled trial
compared adjustable gastric banding to
the “best available” medical and lifestyle
therapy in subjects with type 2 diabetes
diagnosed 2 years before randomiza-
tionandwithBMI30–40kg/m
2(111).In
this trial, 73% of surgically treated pa-
tientsachieved“remission”oftheirdiabe-
tes, compared with 13% of those treated
medically.Thelattergrouplostonly1.7%
ofbodyweight,suggestingthattheirther-
apy was not optimal. Overall the trial had
60 subjects, and only 13 had a BMI 35
kg/m
2, making it difﬁcult to generalize
these results to diabetic patients who are
less severely obese or with longer dura-
tion of diabetes.
Bariatric surgery is costly in the short
termandhassomerisks.Ratesofmorbidity
and mortality directly related to the surgery
have been reduced considerably in recent
years, with 30-day mortality rates now
0.28%,similartothoseoflaparoscopiccho-
lecystectomy (112). Longer-term concerns
include vitamin and mineral deﬁciencies,
osteoporosis, and rare but often severe hy-
poglycemia from insulin hypersecretion.
Cohort studies attempting to match sub-
jectssuggestthattheproceduremayreduce
longer-term mortality rates (113), and it is
reasonable to postulate that there may be
recoupingofcostsoverthelongterm.How-
ever,studiesofthemechanismsofglycemic
improvement,long-termbeneﬁtsandrisks,
andcost-effectivenessofbariatricsurgeryin
individualswithtype2diabeteswillrequire
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with optimal medical and lifestyle therapy
ofdiabetesandcardiovascularriskfactorsas
the comparators.
F. Diabetes self-management
education
Recommendations
● People with diabetes should receive
DSME according to national standards
when their diabetes is diagnosed and as
needed thereafter. (B)
● Effective self-management and quality
of life are the key outcomes of DSME
and should be measured and moni-
tored as part of care. (C)
● DSME should address psychosocial is-
sues, since emotional well-being is as-
sociated with positive diabetes
outcomes. (C)
● Because DSME can result in cost-
savings and improved outcomes (B),
DSME should be reimbursed by third-
party payors. (E)
DSME is an essential element of dia-
betes care (114–120), and national stan-
dards for DSME (121) are based on
evidence for its beneﬁts. Education helps
peoplewithdiabetesinitiateeffectiveself-
management and cope with diabetes
when they are ﬁrst diagnosed. Ongoing
DSME and support also help people with
diabetes maintain effective self-
management throughout a lifetime of di-
abetes as they face new challenges and as
treatment advances become available.
DSME helps patients optimize metabolic
control, prevent and manage complica-
tions, and maximize quality of life in a
cost-effective manner (122).
DSME is the on-going process of fa-
cilitating the knowledge, skill, and ability
necessary for diabetes self-care (121).
This process incorporates the needs,
goals, and life experiences of the person
with diabetes. The overall objectives of
DSME are to support informed decision-
making, self-care behaviors, problem-
solving, and active collaboration with the
health care team and to improve clinical
outcomes,healthstatus,andqualityoflife
in a cost-effective manner (121).
Current best practice of DSME is a
skills-based approach that focuses on
helping those with diabetes make in-
formed self-management choices. DSME
has changed from a didactic approach fo-
cusing on providing information, to a
more theoretically based empowerment
model that focuses on helping those with
diabetesmakeinformedself-management
decisions. Care of diabetes has shifted to
an approach that is more patient centered
and places the person with diabetes at the
center of the care model working in col-
laboration with health care professionals.
Patient-centered care is respectful of and
responsive to individual patient prefer-
ences, needs, and values and ensures that
patient values guide all decision making
(123).
1. Evidence for the beneﬁts of DSME
Multiple studies have found that DSME is
associated with improved diabetes
knowledge and self-care behavior (115);
improvedclinicaloutcomessuchaslower
A1C (116,117,119,120,124), lower self-
reported weight (115), improved quality
of life (118,125), and healthy coping
(126); and lower costs (127). Better out-
comes were reported for DSME interven-
tions that were longer and included
follow-up support (115,128–131), that
wereculturally(132)andageappropriate
(133,134) and tailored to individual
needs and preferences (114), and that ad-
dressed psychosocial issues (114,115,
119,135). Both individual and group ap-
proacheshavebeenfoundeffective(136–
138). There is growing evidence for the
role of community health workers and
peer (139) and lay leaders (140) in deliv-
ering DSME and support in addition to
the core team (141).
Diabetes education is associated with
increased use of primary and preventive
services and lower use of acute, inpatient
hospital services (127). Patients who par-
ticipate in diabetes education are more
likely to follow best practice treatment
recommendations, particularly among
the medicare population, and to have
lower Medicare and commercial claim
costs (142).
2. National Standards for DSME
The National Standards for DSME are de-
signed to deﬁne quality diabetes self-
management education and to assist
diabetes educators in a variety of settings
to provide evidence-based education
(121). The standards, most recently re-
vised in 2007, are reviewed and updated
every 5 years by a task force representing
key organizations involved in the ﬁeld of
diabetes education and care.
3. Reimbursement for DSME
DSME, when provided by a program that
meets ADA recognition standards, is re-
imbursedaspartoftheMedicareprogram
overseen by the Centers for Medicare and
Medicaid Services (www.cms.hhs.gov/
DiabetesSelfManagement).
G. Physical activity
Recommendations
● People with diabetes should be advised
to perform at least 150 min/week of
moderate-intensity aerobic physical ac-
tivity (50–70% of maximum heart
rate). (A)
● In the absence of contraindications,
people with type 2 diabetes should be
encouragedtoperformresistancetrain-
ing three times per week. (A)
ADA technical reviews on exercise in pa-
tients with diabetes, currently being up-
dated, have summarized the value of
exercise in the diabetes management plan
(143,144). Regular exercise has been
shown to improve blood glucose control,
reduce cardiovascular risk factors, con-
tribute to weight loss, and improve well
being. Furthermore, regular exercise may
prevent type 2 diabetes in high-risk indi-
viduals (11–13). Structured exercise in-
terventions of at least 8 weeks’ duration
have been shown to lower A1C by an av-
erage of 0.66% in people with type 2 di-
abetes, even with no signiﬁcant change in
BMI (145). Higher levels of exercise in-
tensity are associated with greater im-
provements in A1C and ﬁtness (146).
1. Frequency and type of exercise
The U.S. Department of Health and Hu-
man Services’ Physical Activity Guide-
lines for Americans (147) suggest that
adultsoverage18yearsperform150min/
week of moderate-intensity or 75 min/
week of vigorous aerobic physical activity
or an equivalent combination of the two.
In addition, the guidelines suggest that
adults also do muscle-strengthening ac-
tivities that involve all major muscle
groups two or more days per week. The
guidelines suggest that adults over age 65
years,orthosewithdisabilities,followthe
adultguidelinesifpossibleor(ifthisisnot
possible) be as physically active as they
are able. Studies included in the meta-
analysisofeffectsofexerciseinterventions
on glycemic control (145) had a mean
number of sessions per week of 3.4, with
a mean of 49 min/session. The DPP life-
style intervention, which included 150
min/week of moderate intensity exercise,
had a beneﬁcial effect on glycemia in
those with pre-diabetes. Therefore, it
seemsreasonabletorecommendthatpeo-
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activity guidelines for the general
population.
Progressive resistance exercise im-
proves insulin sensitivity in older men
withtype2diabetestothesameorevento
a greater extent as aerobic exercise (148).
Clinical trials have provided strong evi-
dence for the A1C-lowering value of re-
sistance training in older adults with type
2 diabetes (149,150) and for an additive
beneﬁt of combined aerobic and resis-
tanceexerciseinadultswithtype2diabe-
tes (151).
2. Evaluation of the diabetic patient
before recommending an exercise
program
Prior guidelines have suggested that be-
forerecommendingaprogramofphysical
activity, the provider should assess pa-
tients with multiple cardiovascular risk
factors for coronary artery disease (CAD).
As further discussed in VI.A.5. Coronary
heartdiseasescreeningandtreatment,the
area of screening asymptomatic diabetic
patients for CAD remains unclear, and a
recent ADA consensus statement on this
issue concluded that routine screening is
not recommended (152). Providers
should use clinical judgment in this area.
Certainly, high-risk patients should be
encouraged to start with short periods of
low-intensity exercise and to increase the
intensity and duration slowly.
Providers should assess patients for
conditions that might contraindicate cer-
tain types of exercise or predispose to in-
jury, such as uncontrolled hypertension,
severe autonomic neuropathy, severe pe-
ripheral neuropathy or history of foot le-
sions, and unstable proliferative
retinopathy. The patient’s age and previ-
ous physical activity level should be
considered.
3. Exercise in the presence of
nonoptimal glycemic control
a. Hyperglycemia. When people with
type 1 diabetes are deprived of insulin for
12–48 h and are ketotic, exercise can
worsen hyperglycemia and ketosis (153);
therefore, vigorous activity should be
avoided in the presence of ketosis. How-
ever, it is not necessary to postpone exer-
cise simply based on hyperglycemia,
provided the patient feels well and urine
and/or blood ketones are negative.
b. Hypoglycemia. In individuals taking
insulin and/or insulin secretagogues,
physical activity can cause hypoglycemia
if medication dose or carbohydrate con-
sumption is not altered. For individuals
on these therapies, added carbohydrate
should be ingested if pre-exercise glucose
levels are 100 mg/dl (5.6 mmol/l)
(154,155). Hypoglycemia is rare in dia-
betic individuals who are not treated with
insulin or insulin secretagogues, and no
preventive measures for hypoglycemia
are usually advised in these cases.
4. Exercise in the presence of speciﬁc
long-term complications of diabetes
a. Retinopathy. In the presence of pro-
liferative diabetic retinopathy (PDR) or
severe non-proliferative diabetic retinop-
athy (NPDR), vigorous aerobic or resis-
tance exercise may be contraindicated
because of the risk of triggering vitreous
hemorrhage or retinal detachment (156).
b. Peripheral neuropathy. Decreased
painsensationintheextremitiesresultsin
increased risk of skin breakdown and in-
fection and of Charcot joint destruction.
Prior recommendations have advised
non–weight-bearing exercise for patients
with severe peripheral neuropathy. Stud-
ies have shown that moderate-intensity
walking may not lead to increased risk of
foot ulcers or reulceration in those with
peripheral neuropathy (157). All individ-
uals with peripheral neuropathy should
wear proper footwear and examine their
feet daily for early detection of lesions.
Anyone with a foot injury or open sore
should be restricted to non–weight-
bearing activities.
c. Autonomic neuropathy. Autonomic
neuropathy can increase the risk of exer-
cise-induced injury or adverse events
through decreased cardiac responsive-
ness to exercise, postural hypotension,
impaired thermoregulation, impaired
night vision due to impaired papillary re-
action, and unpredictable carbohydrate
delivery from gastroparesis predisposing
to hypoglycemia (158). Autonomic neu-
ropathy is also strongly associated with
CVD in people with diabetes (159,160).
People with diabetic autonomic neuropa-
thy should undergo cardiac investigation
before beginning physical activity more
intense than that to which they are
accustomed.
d. Albuminuria and nephropathy. Phys-
ical activity can acutely increase urinary
protein excretion. However, there is no
evidence that vigorous exercise increases
the rate of progression of diabetic kidney
disease and likely no need for any speciﬁc
exercise restrictions for people with dia-
betic kidney disease (161).
H. Psychosocial assessment and care
Recommendations
● Assessment of psychological and social
situation should be included as an on-
going part of the medical management
of diabetes. (E)
● Psychosocial screening and follow-up
should include, but is not limited to,
attitudes about the illness, expectations
for medical management and out-
comes, affect/mood, general and diabe-
tes-related quality of life, resources
(ﬁnancial, social, and emotional), and
psychiatric history. (E)
● Screen for psychosocial problems such
as depression and diabetes-related dis-
tress, anxiety, eating disorders, and
cognitive impairment when self-
management is poor. (C)
Psychological and social problems can
impair the ability of the individual (162–
164) or the family to carry out diabetes
care tasks and therefore compromise
health status. There are opportunities for
the clinician to assess psychosocial status
in a timely and efﬁcient manner so that
referral for appropriate services can be
accomplished.
Key opportunities for screening of
psychosocial status occur at diagnosis,
during regularly scheduled management
visits, during hospitalizations, at discov-
ery of complications, or when problems
withglucosecontrol,qualityoflife,orad-
herence are identiﬁed. Patients are likely
to exhibit psychological vulnerability at
diagnosis and when their medical status
changes, i.e., the end of the honeymoon
period, when the need for intensiﬁed
treatment is evident, and when complica-
tions are discovered (164).
Issues known to impact self-
management and health outcomes in-
clude but are not limited to: attitudes
abouttheillness,expectationsformedical
management and outcomes, affect/mood,
general and diabetes-related quality of
life, diabetes-related distress (165), re-
sources (ﬁnancial, social, and emotional)
(166), and psychiatric history (167,168).
Screeningtoolsareavailableforanumber
of these areas (135). Indications for refer-
ral to a mental health specialist familiar
with diabetes management may include
gross noncompliance with medical regi-
men (by self or others) (168), depression
with the possibility of self-harm
(169,170), debilitating anxiety (alone or
with depression), indications of an eating
disorder, or cognitive functioning that
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erable to incorporate psychological as-
sessment and treatment into routine care
rather than waiting for identiﬁcation of a
speciﬁc problem or deterioration in psy-
chological status (135). Although the cli-
nician may not feel qualiﬁed to treat
psychological problems, using the pa-
tient-provider relationship as a founda-
tionforfurthertreatmentcanincreasethe
likelihood that the patient will accept re-
ferral for other services. It is important to
establishthatemotionalwell-beingispart
of diabetes management.
I. When treatment goals are not met
Foravarietyofreasons,somepeoplewith
diabetes and their health care providers
do not achieve the desired goals of treat-
ment (Table 11). Rethinking the treat-
ment regimen may require assessment of
barriersincludingincome,healthliteracy,
diabetes distress, depression, and com-
peting demands, including those related
to family responsibilities and dynamics.
Other strategies may include culturally
appropriate and enhanced DSME, co-
management with a diabetes team, refer-
ral to a medical social worker for
assistance with insurance coverage, or
change in pharmacological therapy. Initi-
ation of or increase in SMBG, utilization
of CGM, frequent contact with the pa-
tient,orreferraltoamentalhealthprofes-
sional or physician with special expertise
in diabetes may be useful. Providing pa-
tients with an algorithm for self-titration
of insulin doses based on SMBG results
may be helpful for type 2 patients who
take insulin (171).
J. Intercurrent illness
The stress of illness, trauma, and/or sur-
gery frequently aggravates glycemic con-
trol and may precipitate diabetic
ketoacidosis (DKA) or nonketotic hyper-
osmolar state, life-threatening conditions
that require immediate medical care to
prevent complications and death (172).
Any condition leading to deterioration in
glycemic control necessitates more fre-
quent monitoring of blood glucose and
(in ketosis-prone patients) urine or blood
ketones. Marked hyperglycemia requires
temporary adjustment of the treatment
program and, if accompanied by ketosis,
vomiting, or alteration in level of con-
sciousness, immediate interaction with
thediabetescareteam.Thepatienttreated
with noninsulin therapies or MNT alone
may temporarily require insulin. Ade-
quate ﬂuid and caloric intake must be as-
sured. Infection or dehydration are more
likely to necessitate hospitalization of the
person with diabetes than the person
without diabetes.
The hospitalized patient should be
treated by a physician with expertise in
the management of diabetes. For further
information on management of patients
with hyperglycemia in the hospital, see
VIII.A. Diabetes care in the hospital. For
further information on management of
DKA or nonketotic hyperosmolar state,
refer to the ADA consensus statement on
hyperglycemic crises (173).
K. Hypoglycemia
Recommendations
● Glucose (15–20 g) is the preferred
treatment for the conscious individual
with hypoglycemia, although any form
of carbohydrate that contains glucose
may be used. If SMBG 15 min after
treatment shows continued hypoglyce-
mia, the treatment should be repeated.
Once SMBG glucose returns to normal,
the individual should consume a meal
orsnacktopreventrecurrenceofhypo-
glycemia. (E)
● Glucagon should be prescribed for all
individuals at signiﬁcant risk of severe
hypoglycemia, and caregivers or family
membersoftheseindividualsshouldbe
instructed in its administration. Gluca-
gon administration is not limited to
health care professionals. (E)
● Individuals with hypoglycemia un-
awareness or one or more episodes of
severehypoglycemiashouldbeadvised
to raise their glycemic targets to strictly
avoid further hypoglycemia for at least
several weeks to partially reverse hypo-
glycemia unawareness and reduce risk
of future episodes. (B)
Hypoglycemia is the leading limiting fac-
tor in the glycemic management of type 1
and insulin-treated type 2 diabetes (174).
Treatmentofhypoglycemia(PG70mg/
dl) requires ingestion of glucose- or car-
bohydrate-containing foods. The acute
glycemic response correlates better with
the glucose content than with the carbo-
hydrate content of the food. Although
pure glucose is the preferred treatment,
any form of carbohydrate that contains
glucose will raise blood glucose. Added
fat may retard and then prolong the acute
glycemic response (175). Ongoing activ-
ityofinsulinorinsulinsecretagoguesmay
leadtorecurrenceofhypoglycemiaunless
further food is ingested after recovery.
Severehypoglycemia(wheretheindi-
vidual requires the assistance of another
person and cannot be treated with oral
carbohydrate due to confusion or uncon-
sciousness)shouldbetreatedusingemer-
gency glucagon kits, which require a
prescription. Those in close contact with
or who have custodial care of people with
hypoglycemia-prone diabetes (family
members, roommates, school personnel,
child care providers, correctional institu-
tion staff, or coworkers) should be in-
structed in use of such kits. An individual
does not need to be a health care profes-
sional to safely administer glucagon. Care
should be taken to ensure that unexpired
glucagon kits are available.
Prevention of hypoglycemia is a crit-
ical component of diabetes management.
Teaching people with diabetes to balance
insulin use, carbohydrate intake, and ex-
ercise is a necessary but not always sufﬁ-
cient strategy. In type 1 diabetes and
severely insulin-deﬁcient type 2 diabetes,
the syndrome of hypoglycemia unaware-
ness, or hypoglycemia-associated auto-
nomic failure, can severely compromise
stringent diabetes control and quality of
life.Thedeﬁcientcounter-regulatoryhor-
monereleaseandautonomicresponsesin
this syndrome are both risk factors for
and are caused by hypoglycemia. A corol-
lary to this “vicious cycle” is that several
weeks of avoidance of hypoglycemia has
been demonstrated to improve counter-
regulation and awareness to some extent
in many patients (174,176,177). Hence,
patients with one or more episodes of se-
vere hypoglycemia may beneﬁt from at
least short-term relaxation of glycemic
targets.
L. Immunization
Recommendations
● Annually provide an inﬂuenza vaccine
to all diabetic patients 6 months of
age. (C)
● Administer pneumococcal polysaccha-
ride vaccine to all diabetic patients 2
yearsofage.Aone-timerevaccinationis
recommended for individuals 64
years of age previously immunized
when they were 65 years of age if the
vaccine was administered 5 years
ago. Other indications for repeat vacci-
nation include nephrotic syndrome,
chronic renal disease, and other immu-
nocompromised states, such as after
transplantation. (C)
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preventable infectious diseases associated
with high mortality and morbidity in the
elderly and in people with chronic dis-
eases. Though there are limited studies
reporting the morbidity and mortality of
inﬂuenza and pneumococcal pneumonia
speciﬁcally in people with diabetes, ob-
servational studies of patients with a vari-
ety of chronic illnesses, including
diabetes, show that these conditions are
associatedwithanincreaseinhospitaliza-
tions for inﬂuenza and its complications.
People with diabetes may be at increased
risk of the bacteremic form of pneumo-
coccal infection and have been reported
to have a high risk of nosocomial bactere-
mia, which has a mortality rate as high as
50% (178).
Safe and effective vaccines are avail-
able that can greatly reduce the risk of
serious complications from these diseases
(179,180). In a case-control series, inﬂu-
enza vaccine was shown to reduce diabe-
tes-relatedhospitaladmissionbyasmuch
as79%duringﬂuepidemics(179).There
is sufﬁcient evidence to support that peo-
ple with diabetes have appropriate sero-
logic and clinical responses to these
vaccinations. The Centers for Disease
Control and Prevention’s Advisory Com-
mittee on Immunization Practices recom-
mends inﬂuenza and pneumococcal
vaccines for all individuals with diabetes
(http://www.cdc.gov/vaccines/recs/). For
a complete discussion on the prevention
of inﬂuenza and pneumococcal disease in
people with diabetes, consult the techni-
cal review and position statement on this
subject (178,181).
VI. PREVENTION AND
MANAGEMENT OF
DIABETES COMPLICATIONS
A. Cardiovascular disease
CVD is the major cause of morbidity and
mortality for individuals with diabetes and
the largest contributor to the direct and in-
direct costs of diabetes. The common con-
ditionscoexistingwithtype2diabetes(e.g.,
hypertension and dyslipidemia) are clear
riskfactorsforCVD,anddiabetesitselfcon-
fers independent risk. Numerous studies
have shown the efﬁcacy of controlling indi-
vidual cardiovascular risk factors in pre-
venting or slowing CVD in people with
diabetes.Largebeneﬁtsareseenwhenmul-
tiple risk factors are addressed globally
(182,183). Risk for coronary heart disease
and CVD in general can be estimated using
multivariable risk factor approaches, and
such a strategy may be desirable to under-
take in adult patients prior to instituting
preventive therapy.
1. Hypertension/blood pressure
control
Recommendations
Screening and diagnosis
● Blood pressure should be measured at
every routine diabetes visit. Patients
found to have systolic blood pressure
130 mmHg or diastolic blood pres-
sure 80 mmHg should have blood
pressure conﬁrmed on a separate day.
Repeat systolic blood pressure 130
mmHgordiastolicbloodpressure80
mmHg conﬁrms a diagnosis of hyper-
tension. (C)
Goals
● Patientswithdiabetesshouldbetreated
to a systolic blood pressure 130
mmHg. (C)
● Patientswithdiabetesshouldbetreated
to a diastolic blood pressure 80
mmHg. (B)
Treatment
● Patients with a systolic blood pressure
130–139 mmHg or a diastolic blood
pressure 80–89 mmHg may be given
lifestyle therapy alone for a maximum
of 3 months, and then if targets are not
achieved, patients should be treated
with the addition of pharmacological
agents. (E)
● Patients with more severe hypertension
(systolic blood pressure 140 mmHg
or diastolic blood pressure 90
mmHg) at diagnosis or follow-up
should receive pharmacologic therapy
in addition to lifestyle therapy. (A)
● Lifestyle therapy for hypertension con-
sists of weight loss if overweight,
DASH-style dietary pattern including
reducing sodium and increasing potas-
sium intake, moderation of alcohol in-
take, and increased physical activity.
(B)
● Pharmacologic therapy for patients
with diabetes and hypertension should
be paired with a regimen that includes
either an ACE inhibitor or an angioten-
sin II receptor blocker (ARB). If one
class is not tolerated, the other should
be substituted. If needed to achieve
blood pressure targets, a thiazide di-
ureticshouldbeaddedtothosewithan
estimated glomerular ﬁltration rate
(GFR) (see below) 30 ml   min/1.73
m
2andaloopdiureticforthosewithan
estimated GFR 30 ml   min/1.73 m
2.
(C)
● Multiple drug therapy (two or more
agents at maximal doses) is generally
required to achieve blood pressure tar-
gets. (B)
● IfACEinhibitors,ARBs,ordiureticsare
used,kidneyfunctionandserumpotas-
sium levels should be closely moni-
tored. (E)
● In pregnant patients with diabetes and
chronic hypertension, blood pressure
target goals of 110–129/65–79 mmHg
are suggested in the interest of long-
term maternal health and minimizing
impaired fetal growth. ACE inhibitors
and ARBs are contraindicated during
pregnancy. (E)
Hypertension is a common comorbidity
of diabetes that affects the majority of pa-
tients,withprevalencedependingontype
of diabetes, age, obesity, and ethnicity.
Hypertension is a major risk factor for
both CVD and microvascular complica-
tions. In type 1 diabetes, hypertension is
often the result of underlying nephropa-
thy, while in type 2 diabetes it usually
coexists with other cardiometabolic risk
factors.
a. Screening and diagnosis. Measure-
ment of blood pressure in the ofﬁce
should be done by a trained individual
and should follow the guidelines estab-
lished for nondiabetic individuals: mea-
surement in the seated position, with feet
on the ﬂoor and arm supported at heart
level, after 5 min of rest. Cuff size should
be appropriate for the upper arm circum-
ference. Elevated values should be con-
ﬁrmed on a separate day. Because of the
clearsynergisticrisksofhypertensionand
diabetes, the diagnostic cutoff for a diag-
nosis of hypertension is lower in people
with diabetes (blood pressure 130/80
mmHg) than in those without diabetes
(blood pressure 140/90 mmHg) (184).
Homebloodpressureself-monitoring
and 24-h ambulatory blood pressure
monitoring may provide additional evi-
dence of “white coat” and masked hyper-
tension and other discrepancies between
ofﬁce and “true” blood pressure, and
studies in nondiabetic populations show
that home measurements may correlate
better with CVD risk than ofﬁce measure-
ments (185,186). However, the prepon-
deranceoftheclearevidenceofbeneﬁtsof
treatment of hypertension in people with
diabetes is based on ofﬁce measurements.
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trials have demonstrated the beneﬁt (re-
duction of coronary heart disease [CHD]
events, stroke, and nephropathy) of low-
eringbloodpressureto140mmHgsys-
tolic and 80 mmHg diastolic in
individualswithdiabetes(184,187–189).
Epidemiologic analyses show that blood
pressure 115/75 mmHg is associated
with increased cardiovascular event rates
andmortalityinindividualswithdiabetes
(184,190,191). Therefore, a target blood
pressure goal of 130/80 mmHg is rea-
sonable if it can be achieved safely. The
ongoing ACCORD trial is designed to de-
termine whether blood pressure lowering
to systolic blood pressure 120 mmHg
provides greater cardiovascular protec-
tionthanasystolicbloodpressurelevelof
140 mmHg in patients with type 2 dia-
betes (192).
c. Treatment strategies. Although there
are no well-controlled studies of diet and
exercise in the treatment of hypertension
in individuals with diabetes, the Dietary
Approaches to Stop Hypertension
(DASH) study in nondiabetic individuals
has shown antihypertensive effects simi-
lar to those of pharmacologic mono-
therapy. Lifestyle therapy consists of
reducing sodium intake (to 1,500 mg/
day) and excess body weight; increasing
consumption of fruits, vegetables (8–10
servings/day), and low-fat dairy products
(2–3 servings/day); avoiding excessive al-
cohol consumption (no more than two
servingsperdayinmenandnomorethan
one serving per day in women); and in-
creasing activity levels (184,193). These
nonpharmacological strategies may also
positively affect glycemia and lipid con-
trol. Their effects on cardiovascular
eventshavenotbeenestablished.Anini-
tial trial of nonpharmacologic therapy
may be reasonable in diabetic individu-
als with mild hypertension (systolic
130–139 mmHg or diastolic 80–89
mmHg). If the blood pressure is 140
mmHg systolic and/or 90 mmHg dia-
stolic at the time of diagnosis, pharma-
cologic therapy should be initiated
along with nonpharmacologic therapy
(184).
Lowering of blood pressure with reg-
imens based on a variety of antihyperten-
sive drugs, including ACE inhibitors,
ARBs, -blockers, diuretics, and calcium
channel blockers, has been shown to be
effective in reducing cardiovascular
events. Several studies suggested that
ACE inhibitors may be superior to dihy-
dropyridine calcium channel blockers in
reducing cardiovascular events (194–
196). However, a variety of other studies
have shown no speciﬁc advantage to ACE
inhibitorsasinitialtreatmentofhyperten-
sion in the general hypertensive popula-
tion, but rather an advantage on
cardiovascularoutcomesofinitialtherapy
with low-dose thiazide diuretics
(184,197,198).
In people with diabetes, inhibitors of
the renin-angiotensin system (RAS) may
haveuniqueadvantagesforinitialorearly
therapy of hypertension. In a nonhyper-
tension trial of high-risk individuals in-
cluding a large subset with diabetes, an
ACE inhibitor reduced CVD outcomes
(199). In patients with congestive heart
failure (CHF), including diabetic sub-
groups, ARBs have been shown to reduce
major CVD outcomes (200–203), and in
type 2 patients with signiﬁcant nephrop-
athy, ARBs were superior to calcium
channel blockers for reducing heart fail-
ure (204–206). Though evidence for dis-
tinct advantages of RAS inhibitors on
CVD outcomes in diabetes remains con-
ﬂicting (187,207), the high CVD risks as-
sociated with diabetes, and the high
prevalenceofundiagnosedCVD,maystill
favor recommendations for their use as
ﬁrst-line hypertension therapy in people
with diabetes (184). Recently, the blood
pressure arm of the ADVANCE trial dem-
onstrated that routine administration of a
ﬁxed combination of the ACE inhibitor
perindopril and the diuretic indapamide
signiﬁcantly reduced combined micro-
vascular and macrovascular outcomes, as
well as CVD and total mortality. The im-
proved outcomes also could have been
due to lower achieved blood pressure in
the perindopril-indapamide arm (208).
Inaddition,theACCOMPLISH(Avoiding
Cardiovascular Events in Combination
Therapy in Patients Living with Systolic
Hypertension) trial showed a decrease in
morbidity and mortality in those receiv-
ing benazapril and amlodipine versus
benazapril and hydrochlorothiazide. The
compelling beneﬁts of RAS inhibitors in
diabetic patients with albuminuria or re-
nal insufﬁciency provide additional ratio-
nale for use of these agents (see below,
VI.B. Nephropathy screening and
treatment).
An important caveat is that most pa-
tients with hypertension require multi-
drug therapy to reach treatment goals,
especially diabetic patients whose targets
are lower. Many patients will require
three or more drugs to reach target goals
(184). If blood pressure is refractory to
optimal doses of at least three antihyper-
tensive agents of different classiﬁcations,
one of which should be a diuretic, clini-
cians should consider an evaluation for
secondary forms of hypertension.
During pregnancy in diabetic women
with chronic hypertension, target blood
pressure goals of 110–129 mmHg sys-
tolic and 65–79 mmHg diastolic are rea-
sonable, as they contribute to long-term
maternal health. Lower blood pressure
levels may be associated with impaired
fetal growth. During pregnancy, treat-
ment with ACE inhibitors and ARBs is
contraindicated,sincetheycancausefetal
damage. Antihypertensive drugs known
to be effective and safe in pregnancy in-
clude methyldopa, labetalol, diltiazem,
clonidine, and prazosin. Chronic diuretic
useduringpregnancyhasbeenassociated
with restricted maternal plasma volume,
whichmightreduceuteroplacentalperfu-
sion (209).
2. Dyslipidemia/lipid management
Recommendations
Screening
● In most adult patients, measure fasting
lipid proﬁle at least annually. In adults
with low-risk lipid values (LDL choles-
terol 100 mg/dl, HDL cholesterol
50 mg/dl, and triglycerides 150
mg/dl), lipid assessments may be re-
peated every 2 years. (E)
Treatmentrecommendationsandgoals
● Lifestyle modiﬁcation focusing on the
reduction of saturated fat, trans fat,
andcholesterolintake;increaseofn-3
fatty acids, viscous ﬁber, and plant
stanols/sterols; weight loss (if indi-
cated);andincreasedphysicalactivity
should be recommended to improve
the lipid proﬁle in patients with dia-
betes. (A)
● Statin therapy should be added to life-
style therapy, regardless of baseline
lipid levels, for diabetic patients:
● with overt CVD. (A)
● without CVD who are over the age of
40 years and have one or more other
CVD risk factors. (A)
● For patients at lower risk than de-
scribed above (e.g., without overt CVD
and under the age of 40 years), statin
therapy should be considered in addi-
tion to lifestyle therapy if LDL choles-
terol remains 100 mg/dl or in those
with multiple CVD risk factors. (E)
● In individuals without overt CVD, the
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100 mg/dl (2.6 mmol/l). (A)
● In individuals with overt CVD, a lower
LDLcholesterolgoalof70mg/dl(1.8
mmol/l),usingahighdoseofastatin,is
an option. (B)
● Ifdrug-treatedpatientsdonotreachthe
above targets on maximal tolerated sta-
tin therapy, a reduction in LDL choles-
terol of 30–40% from baseline is an
alternative therapeutic goal. (A)
● Triglycerides levels 150 mg/dl (1.7
mmol/l) and HDL cholesterol 40
mg/dl (1.0 mmol/l) in men and 50
mg/dl (1.3 mmol/l) in women, are de-
sirable. However, LDL cholesterol–
targeted statin therapy remains the
preferred strategy. (C)
● If targets are not reached on maximally
tolerated doses of statins, combination
therapy using statins and other lipid-
lowering agents may be considered to
achieve lipid targets but has not been
evaluated in outcome studies for either
CVD outcomes or safety. (E)
● Statin therapy is contraindicated in
pregnancy. (E)
a. Evidence for beneﬁts of lipid-lowering
therapy. Patients with type 2 diabetes
have an increased prevalence of lipid ab-
normalities, contributing to their high
risk of CVD. Over the past decade or
more,multipleclinicaltrialshavedemon-
strated signiﬁcant effects of pharmaco-
logic (primarily statin) therapy on CVD
outcomes in subjects with CHD and for
primary CVD prevention (210). Analyses
of diabetic subgroups of larger trials
(211–215) and trials speciﬁcally in sub-
jects with diabetes (216,217) showed sig-
niﬁcant primary and secondary
prevention of CVD events with and with-
out CHD deaths in diabetic populations.
AsshowninTable12,andsimilartoﬁnd-
ings in nondiabetic subjects, reduction in
“hard” CVD outcomes (CHD death and
nonfatal MI) can be more clearly seen in
diabetic subjects with high baseline CVD
risk (known CVD and/or very high LDL
cholesterollevels),butoverallthebeneﬁts
ofstatintherapyinpeoplewithdiabetesat
moderate or high risk for CVD are
convincing.
Low levels of HDL cholesterol, often
associated with elevated triglyceride lev-
els, are the most prevalent pattern of dys-
lipidemia in people with type 2 diabetes.
However,theevidencebasefordrugsthat
target these lipid fractions is signiﬁcantly
less robust than that for statin therapy
(217). Nicotinic acid has been shown to
reduce CVD outcomes (218), although
the study was done in a nondiabetic co-
hort.Gemﬁbrozilhasbeenshowntode-
crease rates of CVD events in subjects
without diabetes (219,220) and in a di-
abetic subgroup of a larger trial (219).
However, in a large trial speciﬁc to dia-
betic patients, fenoﬁbrate failed to re-
duce overall cardiovascular outcomes
(221).
b. Dyslipidemia treatment and target
lipid levels. For most patients with dia-
betes, the ﬁrst priority of dyslipidemia
therapy (unless severe hypertriglyceride-
mia is the immediate issue) is to lower
LDL cholesterol to a target goal of 100
mg/dl (2.60 mmol/l) (222). Lifestyle in-
tervention, including MNT, increased
physical activity, weight loss, and smok-
ing cessation, may allow some patients to
reach lipid goals. Nutrition intervention
should be tailored according to each pa-
tient’sage,typeofdiabetes,pharmacolog-
ical treatment, lipid levels, and other
medical conditions and should focus on
thereductionofsaturatedfat,cholesterol,
and trans unsaturated fat intake and in-
creases in n-3 fatty acids, viscous ﬁber
(such as in oats, legumes, citrus), and
plant stanols/sterols. Glycemic control
can also beneﬁcially modify plasma lipid
levels, particularly in patients with very
high triglycerides and poor glycemic
control.
In those with clinical CVD or who are
over age 40 years and have CVD risk fac-
tors, pharmacological treatment should
be added to lifestyle therapy regardless of
baseline lipid levels. Statins are the drugs
of choice for lowering LDL cholesterol.
Inpatientsotherthanthosedescribed
above, statin treatment should be consid-
ered if there is an inadequate LDL choles-
terol response to lifestyle modiﬁcations
and improved glucose control or if the
patient has increased cardiovascular risk
Table 12—Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or sub-studies of major trials,
in diabetic subjects (N  16,032)
Study (ref.)
CVD
prevention Statin dose and comparator Risk reduction
Relative risk
reduction
Absolute risk
reduction
LDL
cholesterol
reduction (%)
4S-DM (211) 2° Simvastatin 20–40 mg vs. placebo 85.7 to 43.2% 50% 42.5% 186 to 119 mg/dl (36%)
ASPEN 2° (216) 2° Atorvastatin 10 mg vs. placebo 39.5 to 24.5% 34% 12.7% 112 to 79 mg/dl (29%)
HPS-DM (212) 2° Simvastatin 40 mg vs. placebo 43.8 to 36.3% 17% 7.5% 123 to 84 mg/dl (31%)
CARE-DM (213) 2° Pravastatin 40 mg vs. placebo 40.8 to 35.4% 13% 5.4% 136 to 99 mg/dl (27%)
TNT-DM (214) 2° Atorvastatin 80 mg vs. 10 mg 26.3 to 21.6% 18% 4.7% 99 to 77 mg/dl (22%)
HPS-DM (212) 1° Simvastatin 40 mg vs. placebo 17.5 to 11.5% 34% 6.0% 124 to 86 mg/dl (31%)
CARDS (234) 1° Atorvastatin 10 mg vs. placebo 11.5 to 7.5% 35% 4.0% 118 to 71 mg/dl (40%)
ASPEN 1° (216) 1° Atorvastatin 10 mg vs. placebo 9.8 to 7.9% 19% 1.9% 114 to 80 mg/dl (30%)
ASCOT-DM (215) 1° Atorvastatin 10 mg vs. placebo 11.1 to 10.2% 8% 0.9% 125 to 82 mg/dl (34%)
Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation,
results of the statin on 10-year risk of major CVD endpoints (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD
riskofthecontrolgroupandtheabsoluteriskreductionwithstatintherapyishighlysigniﬁcant(P	0.0007).AnalysesprovidedbyCraigWilliams,PharmD,Oregon
Health & Science University, 2007.
Table 13—Summary of recommendations
forglycemic,bloodpressure,andlipidcontrol
for adults with diabetes
A1C 7.0%*
Blood pressure 130/80 mmHg
Lipids
LDL cholesterol 100 mg/dl (2.6
mmol/l)†
*Referenced to a nondiabetic range of 4.0–6.0%
using a DCCT-based assay. †In individuals with
overt CVD, a lower LDL cholesterol goal of 70
mg/dl (1.8 mmol/l), using a high dose of a statin, is
an option.
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or long duration of diabetes). Very little
clinical trial evidence exists for type 2 di-
abetic patients under the age of 40 years
andfortype1diabeticpatientsofanyage.
In the Heart Protection Study (lower age
limit 40 years), the subgroup of 600 pa-
tients with type 1 diabetes had a propor-
tionately similar reduction in risk as
patientswithtype2diabetesalthoughnot
statistically signiﬁcant (212). Although
the data are not deﬁnitive, consideration
should be given to lipid-lowering goals
for type 1 diabetic patients similar to
those for type 2 diabetic patients, partic-
ularly if other cardiovascular risk factors
are present.
c. Alternative LDL cholesterol goals.
Virtually all trials of statins and CVD out-
come have tested speciﬁc doses of statins
against placebo, other doses of statin, or
other statins, rather than aiming for spe-
ciﬁc LDL cholesterol goals (223). As can
be seen in Table 10, placebo-controlled
trials generally achieved LDL cholesterol
reductions of 30–40% from baseline.
Hence, LDL cholesterol lowering of this
magnitude is an acceptable outcome for
patients who cannot reach LDL choles-
terol goals due to severe baseline eleva-
tions in LDL cholesterol and/or
intolerance of maximal, or any, statin
doses. Additionally, for those with base-
lineLDLcholesterolminimally100mg/
dl, prescribing statin therapy to lower
LDL cholesterol to 30–40% from base-
line is probably more effective than pre-
scribing just enough to get LDL
cholesterol slightly 100 mg/dl.
Recent clinical trials in high-risk pa-
tients, such as those with acute coronary
syndromes or previous cardiovascular
events (224–226), have demonstrated
that more aggressive therapy with high
doses of statins to achieve an LDL choles-
terol of 70 mg/dl led to a signiﬁcant re-
duction in further events. Therefore, a
reduction in LDL cholesterol to a goal of
70 mg/dl is an option in very-high-risk
diabetic patients with overt CVD (227).
In individual patients, LDL choles-
terol lowering with statins is highly vari-
able, and this variable response is poorly
understood (228). Reduction of CVD
events with statins correlates very closely
with LDL cholesterol lowering (229).
When maximally tolerated doses of st-
atins fail to signiﬁcantly lower LDL cho-
lesterol (30% reduction from patients
baseline),theprimaryaimofcombination
therapy should be to achieve additional
LDL cholesterol lowering. Niacin, fenoﬁ-
brate, ezetimibe, and bile acid seques-
trants all offer additional LDL cholesterol
lowering. The evidence that combination
therapy provides a signiﬁcant increment
in CVD risk reduction over statin therapy
alone is still elusive.
d. Treatment of other lipoprotein frac-
tions or targets. Severe hypertriglyceri-
demia may warrant immediate therapy of
thisabnormalitywithlifestyleandusually
pharmacologic therapy (ﬁbric acid deriv-
ative or niacin) to reduce the risk of acute
pancreatitis. In the absence of severe hy-
pertriglyceridemia, therapy targeting
HDL cholesterol or triglycerides has intu-
itive appeal but lacks the evidence base of
statin therapy (186). If the HDL choles-
terol is 40 mg/dl and the LDL choles-
terol is 100–129 mg/dl, gemﬁbrozil or
niacin might be used, especially if a pa-
tient is intolerant to statins. Niacin is the
most effective drug for raising HDL cho-
lesterol.Itcansigniﬁcantlyincreaseblood
glucose at high doses, but recent studies
demonstrate that at modest doses (750–
2,000 mg/day), signiﬁcant improvements
in LDL cholesterol, HDL cholesterol, and
triglyceride levels are accompanied by
only modest changes in glucose that are
generally amenable to adjustment of dia-
betes therapy (230,231).
Combination therapy with a statin
and a ﬁbrate or a statin and niacin may be
efﬁcacious for treatment of all three lipid
fractions, but this combination is associ-
ated with an increased risk for abnormal
transaminase levels, myositis, or rhabdo-
myolysis. The risk of rhabdomyolysis is
higher with higher doses of statins and
with renal insufﬁciency and seems to be
lower when statins are combined with fe-
noﬁbrate than gemﬁbrozil (232). Several
ongoing trials may provide much-needed
evidence for the effects of combination
therapy on cardiovascular outcomes.
In 2008, a consensus panel convened
by ADA and the American College of Car-
diology (ACC) recommended a greater
focus on non-HDL cholesterol and apo
lipoprotein B (apo B) in patients who are
likely to have small LDL particles, such as
people with diabetes (233). The consen-
sus panel suggested that for statin-treated
patients in whom the LDL cholesterol
goalwouldbe70mg/dl(non-HDLcho-
lesterol 100 mg/dl), apo B should be
measured and treated to 80 mg/dl. For
patients on statins with an LDL choles-
terol goal of 100 mg/dl (non-HDL cho-
lesterol 130 mg/dl), apo B should be
measured and treated to 90 mg/dl.
For a summary of recommendations
for glycemic, blood pressure, and lipid
control for adults with diabetes, see Table
13.
3. Antiplatelet agents
Recommendations
● Consider aspirin therapy (75–162 mg/
day)asaprimarypreventionstrategyin
those with type 1 or type 2 diabetes at
increased cardiovascular risk (10-year
risk 10%). This includes most men
50 years of age or women 60 years
of age who have at least one additional
major risk factor (family history of
CVD, hypertension, smoking, dyslipi-
demia, or albuminuria). (C)
● There is not sufﬁcient evidence to rec-
ommend aspirin for primary preven-
tion in lower risk individuals, such as
men 50 years of age or women 60
years of age without other major risk
factors.Forpatientsintheseage-groups
withmultipleotherriskfactors,clinical
judgment is required. (C)
● Use aspirin therapy (75–162 mg/day)
as a secondary prevention strategy in
those with diabetes with a history of
CVD. (A)
● For patients with CVD and docu-
mented aspirin allergy, clopidogrel (75
mg/day) should be used. (B)
● Combination therapy with ASA (75–
162 mg/day) and clopidogrel (75 mg/
day) is reasonable for up to a year after
an acute coronary syndrome. (B)
ADA and the American Heart Association
(AHA) have, in the past, jointly recom-
mended that low-dose aspirin therapy be
used as a primary prevention strategy in
those with diabetes at increased cardio-
vascular risk, including those who are
over 40 years of age or those with addi-
tional risk factors (family history of CVD,
hypertension, smoking, dyslipidemia, or
albuminuria) (235). These recommenda-
tions were derived from several older tri-
als that included small numbers of
patients with diabetes.
Aspirin has been shown to be effec-
tive in reducing cardiovascular morbidity
and mortality in high-risk patients with
previous MI or stroke (secondary preven-
tion). Its net beneﬁt in primary preven-
tion among patients with no previous
cardiovascular events is more controver-
sial, both for patients with and without
a history of diabetes (236). The U.S.
Preventive Services Task Force recently
updateditsevidencebaseandrecommen-
dationsaboutaspirinuseforprimarypre-
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recommended encouraging aspirin use in
men 45–79 and women 55–79 years of
age and not encouraging aspirin use in
younger adults and did not differentiate
based on the presence or absence of
diabetes.
Two recent randomized controlled
trials of aspirin speciﬁcally in patients
with diabetes failed to show a signiﬁcant
reduction in CVD end points, raising fur-
ther questions about the efﬁcacy of aspi-
rin for primary prevention in people with
diabetes (239,240). In 2009, ADA AHA,
and ACC convened a group of experts to
review and synthesize the available evi-
dence and use this information to create
an updated recommendation. Their re-
port, including analyses in addition to
those described below, will be published
in early 2010.
The ATT (Anti-Thrombotic Trialists’)
collaborators recently published an indi-
vidual patient-level meta-analysis of the
six large trials of aspirin for primary pre-
vention in the general population (236).
These trials collectively enrolled over
95,000 participants, including almost
4,000 with diabetes. Overall, they found
that aspirin reduced the risk of vascular
events by 12% (RR 0.88 [95% CI 0.82–
0.94]).Thelargestreductionwasfornon-
fatal MI (0.77 [0.67–0.89]). Aspirin had
little effect on CHD death (0.95 [0.78–
1.15]) or total stroke (0.95 [0.85–1.06]).
The net effect on total stroke reﬂected a
relative reduction in risk of ischemic
stroke (14%) and a relative increased
risk of hemorrhagic stroke (
32%).
There was some evidence of a difference
in aspirin effect by sex. Aspirin reduced
CHD events in men (0.77 [0.67–0.89])
but not in women (0.95 [0.77–1.17]).
Conversely, aspirin had no effect on
stroke in men (1.01 [0.74–1.39]) but re-
duced stroke in women (0.77 [0.59–
0.99]). These potential differences in
effect by sex were of borderline statistical
signiﬁcance,wereaffectedstronglybythe
results of one trial, and cannot be consid-
ereddeﬁnitive.Notably,sexdifferencesin
aspirin’seffectshavenotbeenobservedin
studies of secondary prevention (236). In
the six trials examined by the ATT collab-
orators, the effect of aspirin on major vas-
cular events was similar for patients with
and without diabetes (0.88 [0.67–1.15]
and 0.87 [0.79–0.96], respectively). The
CI was wider for those with diabetes be-
cause of their smaller number.
Based on the currently available evi-
dence, aspirin appears to have a modest
effect on ischemic vascular events with
theabsolutedecreaseineventsdepending
on the underlying CVD risk. The main
adverse effects appear to be an increased
risk of gastrointestinal bleeding. The ex-
cess risk may be as high as 1–5 per 1,000
per year in real-world settings. In adults
with CVD risk greater than 1% per year,
the number of CVD events prevented will
besimilartoorgreaterthanthenumberof
episodes of bleeding induced, although
these complications do not have equal ef-
fects on long-term health (241).
Average daily dosages used in most
clinical trials involving patients with dia-
betes ranged from 50–650 mg but were
mostly in the range of 100–325 mg/day.
Thereislittleevidencetosupportanyspe-
ciﬁc dose, but using the lowest possible
dosage may help reduce side effects
(242). Although platelets from patients
with diabetes have altered function, it is
unclear what, if any, impact that ﬁnding
has on the required dose of aspirin for
cardioprotective effects in the patient
with diabetes. Many alternate pathways
for platelet activation exist that are inde-
pendent of thromboxane A2 and thus not
sensitive to the effects of aspirin (243).
Therefore, while “aspirin resistance” ap-
pears higher in diabetic patients when
measured by a variety of ex vivo and in
vitro methods (platelet aggrenometry,
measurement of thromboxane B2), these
observations alone are insufﬁcient to em-
pirically recommend at this time that
higher doses of aspirin be used in the di-
abetic patient (244–246).
Aspirin use for secondary prevention
continues to have a strong evidence base
and is recommended. Until further evi-
dence is available, low-dose (75–162 mg/
day) aspirin use for primary prevention is
reasonableforadultswithdiabetesandno
previous history of vascular disease who
are at increased CVD risk (10-year risk of
CVD events 10%) and who are not at
increasedriskforbleeding.Thisgenerally
includes most men over age 50 years and
women over age 60 years who also have
one or more of the following major risk
factors: smoking, hypertension, dyslipi-
demia, family history of premature CVD,
and albuminuria.
Aspirin should not be recommended
for those at low CVD risk (women under
age 60 years and men under age 50 years
with no major CVD risk factors; 10-year
CVD risk 5%), as the low beneﬁt is off-
set by the incidence of signiﬁcant bleed-
ing. Clinical judgment should be used for
those at intermediate risk (younger pa-
tients with one or risk factors or older pa-
tients with no risk factors; those with 10-
year CVD risk 5–10%) until further
research is available. Use of aspirin in pa-
tients under the age of 21 years is contra-
indicated due to the associated risk of
Reye’s syndrome.
Clopidogrel has been demonstrated
to reduce CVD events in diabetic individ-
uals (247). It is recommended as adjunc-
tive therapy in the 1st year after an acute
coronary syndrome or as alternative ther-
apy in aspirin-intolerant patients.
4. Smoking cessation
Recommendations
● Advise all patients not to smoke. (A)
● Include smoking cessation counseling
and other forms of treatment as a rou-
tine component of diabetes care. (B)
Issuesofsmokinganddiabetesarereviewed
in detail in the ADA technical review (248)
and position statement (249) on this topic.
Alargebodyofevidencefromepidemiolog-
ical, case-control, and cohort studies pro-
vides convincing documentation of the
causal link between cigarette smoking and
health risks. Cigarette smoking contributes
to one of every ﬁve deaths in the U.S. and is
themostimportantmodiﬁablecauseofpre-
mature death. Much of the prior work doc-
umenting the impact of smoking on health
didnotseparatelydiscussresultsonsubsets
ofindividualswithdiabetes,suggestingthat
the identiﬁed risks are at least equivalent to
those found in the general population.
Other studies of individuals with diabetes
consistently found a heightened risk of
CVDandprematuredeathamongsmokers.
Smokingisalsorelatedtotheprematurede-
velopment of microvascular complications
of diabetes and may have a role in the de-
velopment of type 2 diabetes.
A number of large randomized clini-
cal trials have demonstrated the efﬁcacy
and cost-effectiveness of smoking cessa-
tion counseling in changing smoking be-
havior and reducing tobacco use. The
routine and thorough assessment of to-
bacco use is important as a means of pre-
venting smoking or encouraging
cessation. Special considerations should
includeassessmentoflevelofnicotinede-
pendence, which is associated with difﬁ-
culty in quitting and relapse (250,251).
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and treatment
Recommendations
Screening
● In asymptomatic patients, evaluate risk
factors to stratify patients by 10-year
risk, and treat risk factors accordingly.
(B)
Treatment
● In patients with known CVD, ACE in-
hibitor (C), aspirin (A), and statin ther-
apy (A) (if not contraindicated) should
be used to reduce the risk of cardiovas-
cular events.
● In patients with a prior MI, -blockers
should be continued for at least 2 years
after the event. (B)
● Longer-term use of -blockers in the
absenceofhypertensionisreasonableif
well tolerated, but data are lacking. (E)
● Avoid thiazolidinedione (TZD) treat-
ment in patients with symptomatic
heart failure. (C)
● Metforminmaybeusedinpatientswith
stable CHF if renal function is normal.
Itshouldbeavoidedinunstableorhos-
pitalized patients with CHF. (C)
Screening for CAD is reviewed in a re-
centlyupdatedconsensusstatement(93).
To identify the presence of CAD in dia-
betic patients without clear or suggestive
symptoms, a risk factor–based approach
to the initial diagnostic evaluation and
subsequent follow-up has intuitive ap-
peal. However, recent studies concluded
that using this approach fails to identify
which patients will have silent ischemia
on screening tests (159,252).
Candidatesforcardiactestinginclude
those with 1) typical or atypical cardiac
symptoms and 2) an abnormal resting
electrocardiogram (ECG). The screening
ofasymptomaticpatientsremainscontro-
versial, especially since intensive medical
therapy, indicated in diabetic patients at
high risk for CVD, has an increasing evi-
dence base for providing equal outcomes
toinvasiverevascularization,includingin
diabetic patients (253,254). There is also
recent preliminary evidence that silent
myocardial ischemia may reverse over
time, adding to the controversy concern-
ing aggressive screening strategies (255).
Finally, a recent randomized observa-
tional trial demonstrated no clinical ben-
eﬁt to routine screening of asymptomatic
patients with type 2 diabetes and normal
ECGs (256). Despite abnormal myocar-
dial perfusion imaging in more than one
inﬁvepatients,cardiacoutcomeswerees-
sentially equal (and very low) in screened
versus unscreened patients. Accordingly,
the overall effectiveness, especially the
cost-effectiveness, of such an indiscrimi-
nate screening strategy is in question.
In all patients with diabetes, cardio-
vascular risk factors should be assessed at
least annually. These risk factors include
dyslipidemia, hypertension, smoking, a
positive family history of premature cor-
onary disease, and the presence of micro-
or macroalbuminuria. Abnormal risk
factors should be treated as described
elsewhere in these guidelines. Patients at
increasedCHDriskshouldreceiveaspirin
and a statin, and ACE inhibitor, or ARB
therapy if hypertensive, unless there are
contraindications to a particular drug
class. While clear beneﬁt exists for ACE
inhibitor and ARB therapy in patients
with nephropathy or hypertension, the
beneﬁts in patients with CVD in the ab-
sence of these conditions is less clear,
especially when LDL cholesterol is con-
comitantly controlled (257,258).
B. Nephropathy screening and
treatment
Recommendations
General recommendations
● To reduce the risk or slow the progres-
sion of nephropathy, optimize glucose
control. (A)
● To reduce the risk or slow the progres-
sion of nephropathy, optimize blood
pressure control. (A)
Screening
● Perform an annual test to assess urine
albuminexcretionintype1diabeticpa-
tients with diabetes duration of 5 years
and in all type 2 diabetic patients, start-
ing at diagnosis. (E)
● Measureserumcreatinineatleastannu-
ally in all adults with diabetes regard-
less of the degree of urine albumin
excretion. The serum creatinine should
be used to estimate GFR and stage the
level of chronic kidney disease (CKD),
if present. (E)
Treatment
● Inthetreatmentofthenonpregnantpa-
tientwithmicro-ormacroalbuminuria,
either ACE inhibitors or ARBs should
be used. (A)
● While there are no adequate head-to-
head comparisons of ACE inhibitors
and ARBs, there is clinical trial support
for each of the following statements:
● In patients with type 1 diabetes, hy-
pertension, and any degree of albu-
minuria, ACE inhibitors have been
showntodelaytheprogressionofne-
phropathy. (A)
● In patients with type 2 diabetes, hy-
pertension, and microalbuminuria,
both ACE inhibitors and ARBs have
been shown to delay the progression
to macroalbuminuria. (A)
● In patients with type 2 diabetes, hy-
pertension, macroalbuminuria, and
renal insufﬁciency (serum creatinine
1.5 mg/dl), ARBs have been shown
to delay the progression of nephrop-
athy. (A)
● If one class is not tolerated, the other
should be substituted. (E)
● Reduction of protein intake to 0.8–1.0
g   kg body wt
–1   day
–1 in individuals
with diabetes and the earlier stages of
CKD and to 0.8 g   kg body wt
–1   day
–1
in the later stages of CKD may improve
measures of renal function (urine albu-
min excretion rate and GFR) and is rec-
ommended. (B)
● When ACE inhibitors, ARBs, or diuret-
ics are used, monitor serum creatinine
and potassium levels for the develop-
ment of acute kidney disease and hy-
perkalemia. (E)
● Continued monitoring of urine albu-
min excretion to assess both response
to therapy and progression of disease is
recommended. (E)
● Consider referral to a physician experi-
enced in the care of kidney disease
when there is uncertainty about the eti-
ology of kidney disease (active urine
sediment, absence of retinopathy, or
rapiddeclineinGFR),difﬁcultmanage-
ment issues, or advanced kidney dis-
ease. (B)
Diabetic nephropathy occurs in 20–40%
of patients with diabetes and is the single
leading cause of end-stage renal disease
(ESRD). Persistent albuminuria in the
range of 30–299 mg/24 h (microalbu-
minuria)hasbeenshowntobetheearliest
stage of diabetic nephropathy in type 1
diabetes and a marker for development of
nephropathy in type 2 diabetes. Mi-
croalbuminuria is also a well-established
marker of increased CVD risk (259,260).
Patients with microalbuminuria who
progress to macroalbuminuria (300
mg/24 h) are likely to progress to ESRD
(261,262). However, a number of inter-
ventions have been demonstrated to re-
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renal disease.
Intensive diabetes management
with the goal of achieving near-
normoglycemiahasbeenshowninlarge
prospective randomized studies to de-
lay the onset of microalbuminuria and
the progression of micro- to macroalbu-
minuria in patients with type 1
(263,264) and type 2 (57,58) diabetes.
The UKPDS provided strong evidence
that control of blood pressure can re-
duce the development of nephropathy
(187). In addition, large prospective
randomized studies in patients with
type 1 diabetes have demonstrated that
achievement of lower levels of systolic
bloodpressure(140mmHg)resulting
from treatment using ACE inhibitors
provides a selective beneﬁt over other
antihypertensive drug classes in delay-
ing the progression from micro- to mac-
roalbuminuria and can slow the decline
in GFR in patients with macroalbumin-
uria (205,206,265). In type 2 diabetes
with hypertension and normoalbuminuria,
RAS inhibition has been demonstrated to
delay onset of microalbuminuria (266).
Inaddition,ACEinhibitorshavebeen
shown to reduce major CVD outcomes
(i.e., MI, stroke, and death) in patients
withdiabetes(199),thusfurthersupport-
ingtheuseoftheseagentsinpatientswith
microalbuminuria, a CVD risk factor.
ARBsdonotpreventmicroalbuminuriain
normotensivepatientswithtype1ortype
2 diabetes (267,268); however, ARBs
have been shown to reduce the rate of
progression from micro- to macroalbu-
minuria as well as ESRD in patients with
type 2 diabetes (269–271). Some evi-
dence suggests that ARBs have a smaller
magnitude of rise in potassium compared
with ACE inhibitors in people with ne-
phropathy (272,273). It is important to
note that both ACE inhibitors and ARBs
reduce loss of kidney function in people
withdiabeticnephropathy,aboveandbe-
yond any such effect attributable to a re-
duction in systemic blood pressure.
Combinationsofdrugsthatblocktheren-
nin-angiotensin-aldosterone system (e.g.,
an ACE inhibitor plus an ARB, a miner-
alocorticoid antagonist, or a direct renin
inhibitor)havebeenshowntoprovidead-
ditional lowering of albuminuria (274–
277). However, the long-term effects of
such combinations on renal or cardiovas-
cular outcomes have not yet been evalu-
ated in clinical trials.
Other drugs, such as diuretics, cal-
cium channel blockers, and -blockers,
should be used as additional therapy to
further lower blood pressure in patients
already treated with ACE inhibitors or
ARBs (204) or as alternate therapy in the
rare individual unable to tolerate ACE in-
hibitors or ARBs.
Studiesinpatientswithvaryingstages
of nephropathy have shown that protein
restriction helps slow the progression of
albuminuria, GFR decline, and occur-
rence of ESRD (278–281). Protein re-
striction should be considered
particularly in patients whose nephropa-
thy seems to be progressing despite opti-
mal glucose and blood pressure control
and use of ACE inhibitor and/or ARBs
(281).
Assessment of albuminuria status
and renal function
Screening for microalbuminuria can be
performed by measurement of the albu-
min-to-creatinine ratio in a random spot
collection (preferred method); 24-h or
timed collections are more burdensome
and add little to prediction or accuracy
(282,283). Measurement of a spot urine
for albumin only, whether by immunoas-
say or by using a dipstick test speciﬁc for
microalbumin, without simultaneously
measuring urine creatinine, is somewhat
less expensive but susceptible to false-
negativeand-positivedeterminationsasa
result of variation in urine concentration
due to hydration and other factors.
Abnormalities of albumin excretion
are deﬁned in Table 14. Because of vari-
ability in urinary albumin excretion, two
ofthreespecimenscollectedwithina3-to
6-month period should be abnormal be-
fore considering a patient to have crossed
one of these diagnostic thresholds. Exer-
cise within 24 h, infection, fever, CHF,
marked hyperglycemia, and marked hy-
pertension may elevate urinary albumin
excretion over baseline values.
Information on presence of abnormal
urine albumin excretion in addition to
level of GFR may be used to stage CKD.
The National Kidney Foundation classiﬁ-
cation (Table 15) is primarily based on
GFR levels and therefore differs from
other systems, in which staging is based
primarily on urinary albumin excretion
(284). Studies have found decreased GFR
in the absence of increased urine albumin
excretion in a substantial percentage of
adults with diabetes (285,286). Epidemi-
ologicevidencesuggeststhatasubstantial
fraction of those with CKD in the setting
of diabetes have little or no detectable al-
buminuria (285). Serum creatinine
should therefore be measured at least an-
nually in all adults with diabetes, regard-
less of the degree of urine albumin
excretion.
Serum creatinine should be used to
estimate GFR and to stage the level of
CKD,ifpresent.EstimatedGFR(eGFR)is
commonly co-reported by laboratories or
can be estimated using formulae such as
the Modiﬁcation of Diet in Renal Disease
(MDRD)studyequation(287).Recentre-
ports have indicated that the MDRD is
more accurate for the diagnosis and strat-
iﬁcation of CKD in patients with diabetes
than the Cockcroft-Gault formula (288).
GFR calculators are available at http://
www.nkdep.nih.gov.
The role of continued annual quanti-
tative assessment of albumin excretion af-
ter diagnosis of microalbuminuria and
institution of ACE inhibitor or ARB ther-
apyandbloodpressurecontrolisunclear.
Continued surveillance can assess both
response to therapy and progression of
disease. Some suggest that reducing ab-
normal albuminuria (30 mg/g) to the
normal or near-normal range may im-
proverenalandcardiovascularprognosis,
but this approach has not been formally
evaluated in prospective trials.
Complications of kidney disease cor-
relatewithlevelofkidneyfunction.When
theeGFRislessthan60ml min/1.73m
2,
screening for anemia, malnutrition, and
metabolic bone disease is indicated. Early
vaccination against Hepatitis B is indi-
catedinpatientslikelytoprogresstoend-
stage kidney disease.
Consider referral to a physician expe-
riencedinthecareofkidneydiseasewhen
there is uncertainty about the etiology of
kidneydisease(activeurinesediment,ab-
sence of retinopathy, or rapid decline in
GFR), difﬁcult management issues, or ad-
vanced kidney disease. The threshold for
referral may vary depending on the fre-
quencywithwhichaproviderencounters
diabetic patients with signiﬁcant kidney
disease. Consultation with a nephrologist
when stage 4 CKD develops has been
Table14—Deﬁnitionsofabnormalitiesinal-
bumin excretion
Category
Spot collection
(g/mg
creatinine)
Normal 30
Microalbuminuria 30–299
Macroalbuminuria (clinical) 300
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care, and keep people off dialysis longer
(289,290). However, nonrenal specialists
should not delay educating their patients
about the progressive nature of diabetic
kidney disease, the renal preservation
beneﬁts of aggressive treatment of blood
pressure, blood glucose, and hyperlipid-
emia, and the potential need for renal re-
placement therapy.
C. Retinopathy screening and
treatment
Recommendations
General recommendations
● To reduce the risk or slow the progres-
sion of retinopathy, optimize glycemic
control. (A)
● To reduce the risk or slow the progres-
sion of retinopathy, optimize blood
pressure control. (A)
Screening
● Adults and children aged 10 years or
older with type 1 diabetes should have
an initial dilated and comprehensive
eyeexaminationbyanophthalmologist
or optometrist within 5 years after the
onset of diabetes. (B)
● Patients with type 2 diabetes should
have an initial dilated and comprehen-
siveeyeexaminationbyanophthalmol-
ogist or optometrist shortly after the
diagnosis of diabetes. (B)
● Subsequent examinations for type 1
and type 2 diabetic patients should be
repeated annually by an ophthalmolo-
gistoroptometrist.Lessfrequentexams
(every 2–3 years) may be considered
following one or more normal eye ex-
ams. Examinations will be required
more frequently if retinopathy is pro-
gressing. (B)
● High-quality fundus photographs can
detect most clinically signiﬁcant dia-
betic retinopathy. Interpretation of the
images should be performed by a
trained eye care provider. While retinal
photography may serve as a screening
tool for retinopathy, it is not a substi-
tute for a comprehensive eye exam,
which should be performed at least ini-
tially and at intervals thereafter as rec-
ommendedbyaneyecareprofessional.
(E)
● Women with preexisting diabetes who
are planning pregnancy or who have
become pregnant should have a com-
prehensive eye examination and be
counseled on the risk of development
and/or progression of diabetic retinop-
athy. Eye examination should occur in
the ﬁrst trimester with close follow-up
throughout pregnancy and for 1 year
postpartum. (B)
Treatment
● Promptlyreferpatientswithanylevelof
macular edema, severe NPDR, or any
PDR to an ophthalmologist who is
knowledgeable and experienced in the
management and treatment of diabetic
retinopathy. (A)
● Laser photocoagulation therapy is indi-
cated to reduce the risk of vision loss in
patients with high-risk PDR, clinically
signiﬁcantmacularedema,andinsome
cases of severe NPDR. (A)
● The presence of retinopathy is not a
contraindication to aspirin therapy for
cardioprotection, as this therapy does
not increase the risk of retinal hemor-
rhage. (A)
Diabetic retinopathy is a highly speciﬁc
vascular complication of both type 1 and
type 2 diabetes, with prevalence strongly
related to duration of diabetes. Diabetic
retinopathy is the most frequent cause of
newcasesofblindnessamongadultsaged
20–74 years. Glaucoma, cataracts, and
other disorders of the eye occur earlier
and more frequently in people with
diabetes.
In addition to duration of diabetes,
other factors that increase the risk of, or
are associated with, retinopathy include
chronic hyperglycemia (291), the pres-
ence of nephropathy (292), and hyper-
tension (293). Intensive diabetes
management with the goal of achieving
near normoglycemia has been shown in
large prospective randomized studies to
prevent and/or delay the onset and pro-
gression of diabetic retinopathy
(53,57,58). Lowering blood pressure has
been shown to decrease the progression
of retinopathy (187). Several case series
and a controlled prospective study sug-
gest that pregnancy in type 1 diabetic pa-
tients may aggravate retinopathy
(294,295); laser photocoagulation sur-
gery can minimize this risk (295).
One of the main motivations for
screening for diabetic retinopathy is the
established efﬁcacy of laser photocoagu-
lation surgery in preventing vision loss.
Two large trials, the Diabetic Retinopathy
Study (DRS) and the Early Treatment Di-
abetic Retinopathy Study (ETDRS), pro-
vide the strongest support for the
therapeutic beneﬁts of photocoagulation
surgery.
The DRS (296) showed that panreti-
nalphotocoagulationsurgeryreducedthe
risk of severe vision loss from PDR from
15.9% in untreated eyes to 6.4% in
treated eyes. The beneﬁt was greatest
among patients whose baseline evalua-
tion revealed high-risk characteristics
(chieﬂy disc neovascularization or vitre-
oushemorrhage).Giventherisksofmod-
est loss of visual acuity and contraction of
the visual ﬁeld from panretinal laser sur-
gery, such therapy is primarily recom-
mended for eyes with PDR approaching
or having high-risk characteristics.
The ETDRS (297) established the
beneﬁt of focal laser photocoagulation
surgery in eyes with macular edema,
particularly those with clinically signif-
icant macular edema, with reduction of
doubling of the visual angle (e.g., 20/
50–20/100) from 20% in untreated
eyes to 8% in treated eyes. The ETDRS
also veriﬁed the beneﬁts of panretinal
photocoagulation for high-risk PDR,
but not for mild or moderate NPDR. In
older-onset patients with severe NPDR
or less-than-high-risk PDR, the risk of
severe vision loss or vitrectomy was re-
duced 50% by early laser photocoagu-
lation surgery at these stages.
Table 15—Stages of CKD
Stage Description
GFR (ml/min per
1.73 m
2 body
surface area)
1 Kidney damage* with normal or increased GFR 90
2 Kidney damage* with mildly decreased GFR 60–89
3 Moderately decreased GFR 30–59
4 Severely decreased GFR 15–29
5 Kidney failure 15 or dialysis
*Kidney damage deﬁned as abnormalities on pathologic, urine, blood, or imaging tests. Adapted from ref.
283.
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both trials was beneﬁcial in reducing the
risk of further vision loss, but generally
not beneﬁcial in reversing already dimin-
ished acuity. This preventive effect and
thefactthatpatientswithPDRormacular
edema may be asymptomatic provide
strongsupportforascreeningprogramto
detect diabetic retinopathy.
As retinopathy is estimated to take at
least 5 years to develop after the onset of
hyperglycemia(298),patientswithtype1
diabetesshouldhaveaninitialdilatedand
comprehensive eye examination within 5
years after the onset of diabetes. Patients
with type 2 diabetes who generally have
had years of undiagnosed diabetes (299)
and who have a signiﬁcant risk of preva-
lent diabetic retinopathy at the time of
diabetes diagnosis should have an initial
dilated and comprehensive eye examina-
tion soon after diagnosis. Examinations
should be performed by an ophthalmolo-
gist or optometrist who is knowledgeable
and experienced in diagnosing the pres-
ence of diabetic retinopathy and is aware
of its management. Subsequent examina-
tions for type 1 and type 2 diabetic pa-
tients are generally repeated annually.
Less frequent exams (every 2–3 years)
may be cost effective after one or more
normal eye exams (300–302), while ex-
aminations will be required more fre-
quently if retinopathy is progressing.
Examinations can also be done with
retinalphotographs(withorwithoutdi-
lation of the pupil) read by experienced
experts. In-person exams are still nec-
essary when the photos are unaccept-
able and for follow-up of abnormalities
detected. Photos are not a substitute for
a comprehensive eye exam, which
should be performed at least initially
and at intervals thereafter as recom-
mended by an eye care professional.
This technology has great potential in
areas where qualiﬁed eye care profes-
sionals are not available and may also
enhance efﬁciency and reduce costs
when the expertise of ophthalmologists
can be used for more complex examina-
tions and for therapy (303).
Results of eye examinations should
be documented and transmitted to the
referring health care professional. For a
detailed review of the evidence and fur-
ther discussion of diabetic retinopathy,
see the ADA technical review and
position statement on this subject
(304,305).
D. Neuropathy screening and
treatment (306)
Recommendations
● All patients should be screened for dis-
talsymmetricpolyneuropathy(DPN)at
diagnosis and at least annually thereaf-
ter using simple clinical tests. (B)
● Electrophysiological testing is rarely
needed, except in situations where the
clinical features are atypical. (E)
● Screening for signs and symptoms of
cardiovascular autonomic neuropathy
shouldbeinstitutedatdiagnosisoftype
2 diabetes and 5 years after the diagno-
sis of type 1 diabetes. Special testing is
rarely needed and may not affect man-
agement or outcomes. (E)
● Medications for the relief of speciﬁc
symptoms related to DPN and auto-
nomic neuropathy are recommended,
as they improve the quality of life of the
patient. (E)
The diabetic neuropathies are heteroge-
neous with diverse clinical manifesta-
tions. They may be focal or diffuse. Most
common among the neuropathies are
chronic sensorimotor DPN and auto-
nomic neuropathy. Although DPN is a
diagnosis of exclusion, complex investi-
gations to exclude other conditions are
rarely needed.
The early recognition and appropri-
ate management of neuropathy in the pa-
tient with diabetes is important for a
number of reasons: 1) nondiabetic neu-
ropathies may be present in patients with
diabetes and may be treatable; 2) a num-
ber of treatment options exist for symp-
tomatic diabetic neuropathy; 3)u pt o
50% of DPN may be asymptomatic, and
patients are at risk of insensate injury to
their feet; 4) autonomic neuropathy may
involve every system in the body; and 5)
cardiovascular autonomic neuropathy
causes substantial morbidity and mortal-
ity. Speciﬁc treatment for the underlying
nerve damage is not currently available,
other than improved glycemic control,
which may slow progression but not re-
verse neuronal loss. Effective symptom-
atic treatments are available for some
manifestations of DPN and autonomic
neuropathy.
1. Diagnosis of neuropathy
a. Distal symmetric polyneuropathy.
Patients with diabetes should be screened
annually for DPN using tests such as pin-
prick sensation, vibration perception (us-
ing a 128-Hz tuning fork), 10-g
monoﬁlament pressure sensation at the
distalplantaraspectofbothgreattoesand
metatarsal joints, and assessment of ankle
reﬂexes. Combinations of more than one
test have 87% sensitivity in detecting
DPN. Loss of 10-g monoﬁlament percep-
tion and reduced vibration perception
predict foot ulcers (306).
b.Diabeticautonomicneuropathy(307).
The symptoms and signs of autonomic
dysfunction should be elicited carefully
during the history and physical examina-
tion. Major clinical manifestations of dia-
betic autonomic neuropathy include
resting tachycardia, exercise intolerance,
orthostatic hypotension, constipation,
gastroparesis, erectile dysfunction, sudo-
motor dysfunction, impaired neurovas-
cular function, “brittle diabetes,” and
hypoglycemic autonomic failure.
Cardiovascular autonomic neuropa-
thy, a CVD risk factor (93), is the most
studied and clinically important form of
diabetic autonomic neuropathy. Cardio-
vascular autonomic neuropathy may be
indicated by resting tachycardia (100
bpm), orthostasis (a fall in systolic blood
pressure 20 mmHg upon standing
without an appropriate heart rate re-
sponse), or other disturbances in auto-
nomic nervous system function involving
the skin, pupils, or gastrointestinal and
genitourinary systems.
Gastrointestinal neuropathies (e.g.,
esophageal enteropathy, gastroparesis,
constipation, diarrhea, and fecal incon-
tinence) are common, and any section
of the gastrointestinal tract may be af-
fected. Gastroparesis should be sus-
pected in individuals with erratic
glucose control or with upper gastroin-
testinal symptoms without other identi-
ﬁed cause. Evaluation of solid-phase
gastric emptying using double-isotope
scintigraphy may be done if symptoms
aresuggestive,buttestresultsoftencor-
relate poorly with symptoms. Constipa-
tion is the most common lower-
gastrointestinal symptom but can
alternate with episodes of diarrhea.
Diabetic autonomic neuropathy is
also associated with genitourinary tract
disturbances.Inmen,diabeticautonomic
neuropathy may cause erectile dysfunc-
tion and/or retrograde ejaculation. Evalu-
ation of bladder dysfunction should be
performed for individuals with diabetes
who have recurrent urinary tract infec-
tions, pyelonephritis, incontinence, or a
palpable bladder.
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a. Distal symmetric polyneuropathy.
The ﬁrst step in management of patients
with DPN should be to aim for stable and
optimal glycemic control. Although con-
trolled trial evidence is lacking, several
observational studies suggest that neuro-
pathic symptoms improve not only with
optimization of control, but also with the
avoidance of extreme blood glucose ﬂuc-
tuations. Patients with painful DPN may
beneﬁt from pharmacological treatment
of their symptoms: many agents have ef-
ﬁcacy conﬁrmed in published random-
ized controlled trials, with several FDA-
approved for the management of painful
DPN. See Table 16 for examples of agents
to treat DPN pain.
b.Diabeticautonomicneuropathy. Gas-
troparesis symptoms may improve with
dietary changes and prokinetic agents
suchasmetoclopramideorerythromycin.
Treatments for erectile dysfunction may
include phosphodiesterase type 5 inhibi-
tors, intracorporeal or intraurethral pros-
taglandins, vacuum devices, or penile
prostheses. Interventions for other mani-
festations of autonomic neuropathy are
described in the ADA statement on neu-
ropathy (306). As with DPN treatments,
these interventions do not change the un-
derlying pathology and natural history of
the disease process but may have a posi-
tive impact on the quality of life of the
patient.
E. Foot care
Recommendations
● For all patients with diabetes, perform
an annual comprehensive foot exami-
nationtoidentifyriskfactorspredictive
of ulcers and amputations. The foot ex-
amination should include inspection,
assessment of foot pulses, and testing
for loss of protective sensation (LOPS)
(10-g monoﬁlament plus testing any
one of: vibration using 128-Hz tuning
fork,pinpricksensation,anklereﬂexes,
or vibration perception threshold). (B)
● Providegeneralfootself-careeducation
to all patients with diabetes. (B)
● A multidisciplinary approach is recom-
mendedforindividualswithfootulcers
andhigh-riskfeet,especiallythosewith
a history of prior ulcer or amputation.
(B)
● Refer patients who smoke, have LOPS
and structural abnormalities, or have
history of prior lower-extremity com-
plicationstofootcarespecialistsforon-
going preventive care and life-long
surveillance. (C)
● Initial screening for peripheral arterial
disease (PAD) should include a history
for claudication and an assessment of
thepedalpulses.Considerobtainingan
ankle-brachialindex(ABI),asmanypa-
tients with PAD are asymptomatic. (C)
● Referpatientswithsigniﬁcantclaudica-
tion or a positive ABI for further vascu-
lar assessment and consider exercise,
medications, and surgical options. (C)
Amputation and foot ulceration, conse-
quences of diabetic neuropathy and/or
PAD, are common and major causes of
morbidity and disability in people with
diabetes. Early recognition and manage-
ment of risk factors can prevent or delay
adverse outcomes.
The risk of ulcers or amputations is
increased in people who have the follow-
ing risk factors:
● previous amputation
● past foot ulcer history
● peripheral neuropathy
● foot deformity
● peripheral vascular disease
● visual impairment
● diabetic nephropathy (especially pa-
tients on dialysis)
● poor glycemic control
● cigarette smoking
Many studies have been published pro-
posing a range of tests that might usefully
identify patients at risk of foot ulceration,
creatingconfusionamongpractitionersas
to which screening tests should be
adopted in clinical practice. An ADA task
force was therefore assembled in 2008 to
concisely summarize recent literature in
this area and recommend what should be
included in the comprehensive foot exam
foradultpatientswithdiabetes.Theirrec-
ommendations are summarized below,
but clinicians should refer to the task
force report (308) for further details and
practical descriptions of how to perform
components of the comprehensive foot
examination.
At least annually, all adults with dia-
betes should undergo a comprehensive
foot examination to identify high-risk
conditions. Clinicians should ask about
history of previous foot ulceration or am-
putation, neuropathic or peripheral vas-
cularsymptoms,impairedvision,tobacco
use, and foot care practices. A general in-
spection of skin integrity and musculo-
skeletal deformities should be done in a
well-lit room. Vascular assessment would
include inspection and assessment of
pedal pulses.
The neurologic exam recommended
is designed to identify LOPS rather than
early neuropathy. The clinical examina-
tion to identify LOPS is simple and re-
quires no expensive equipment. Five
simple clinical tests (use of a 10-g mono-
ﬁlament,vibrationtestingusinga128-Hz
tuning fork, tests of pinprick sensation,
anklereﬂexassessment,andtestingvibra-
tionperceptionthresholdwithabiothesi-
ometer), each with evidence from well-
conducted prospective clinical cohort
studies, are considered useful in the diag-
nosis of LOPS in the diabetic foot. The
task force agrees that any of the ﬁve tests
listed could be used by clinicians to iden-
tify LOPS, although ideally two of these
should be regularly performed during the
screening exam—normally the 10-g
monoﬁlament and one other test. One or
more abnormal tests would suggest
LOPS,whileatleasttwonormaltests(and
no abnormal test) would rule out LOPS.
The last test listed, vibration assessment
using a biothesiometer or similar instru-
ment,iswidelyusedintheU.S.;however,
Table 16—Table of drugs to treat symptomatic DPN
Class Examples Typical doses*
Tricyclic drugs Amitriptyline 10–75 mg at bedtime
Nortriptyline 25–75 mg at bedtime
Imipramine 25–75 mg at bedtime
Anticonvulsants Gabapentin 300–1,200 mg t.i.d.
Carbamazepine 200–400 mg t.i.d.
Pregabalin† 100 mg t.i.d.
5-Hydroxytryptamine and
norepinephrine uptake
inhibitor
Duloxetine† 60–120 mg daily fs
Substance P inhibitor Capsaicin cream 0.025–0.075% applied t.i.d.-q.i.d.
*Dose response may vary; initial doses need to be low and titrated up. †Has FDA indication for treatment of
painful diabetic neuropathy.
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can easily be carried out without this or
other expensive equipment.
Initial screening for PAD should in-
clude a history for claudication and an
assessmentofthepedalpulses.Adiagnos-
tic ABI should be performed in any pa-
tient with symptoms of PAD. Due to the
high estimated prevalence of PAD in pa-
tients with diabetes and the fact that
many patients with PAD are asymptom-
atic, an ADA consensus statement on
PAD (309) suggested that a screening
of ABI be performed in patients over
50 years of age and considered in patients
under 50 years of age who have other
PADriskfactors(e.g.,smoking,hyperten-
sion, hyperlipidemia, or duration of dia-
betes 10 years). Refer patients with
signiﬁcant symptoms or a positive ABI
for further vascular assessment and con-
sider exercise, medications, and surgical
options (309).
Patients with diabetes and high-risk
foot conditions should be educated re-
garding their risk factors and appropriate
management. Patients at risk should un-
derstand the implications of the LOPS,
the importance of foot monitoring on a
daily basis, the proper care of the foot in-
cluding nail and skin care, and the selec-
tion of appropriate footwear. Patients
withLOPSshouldbeeducatedonwaysto
substitute other sensory modalities (hand
palpation, visual inspection) for surveil-
lance of early foot problems. Patients’ un-
derstanding of these issues and their
physical ability to conduct proper foot
surveillance and care should be assessed.
Patients with visual difﬁculties, physical
constraintspreventingmovement,orcog-
nitiveproblemsthatimpairtheirabilityto
assess the condition of the foot and to in-
stitute appropriate responses will need
other people, such as family members, to
assist in their care.
People with neuropathy or evidence
of increased plantar pressure (e.g., ery-
thema, warmth, callus, or measured pres-
sure) may be adequately managed with
well-ﬁtted walking shoes or athletic
shoes that cushion the feet and redis-
tribute pressure. Callus can be debrided
with a scalpel by a foot care specialist or
other health professional with experience
and training in foot care. People with
bony deformities (e.g., hammertoes,
prominent metatarsal heads, or bunions)
may need extra-wide or -depth shoes.
People with extreme bony deformities
(e.g.,Charcotfoot)whocannotbeaccom-
modated with commercial therapeutic
footwear may need custom-molded
shoes.
Foot ulcers and wound care may re-
quire care by a podiatrist, orthopedic
or vascular surgeon, or rehabilitation
specialist experienced in the manage-
ment of individuals with diabetes. For a
complete discussion, see the ADA con-
sensus statement on diabetic foot wound
care (310).
VII. DIABETES CARE IN
SPECIFIC POPULATIONS
A. Children and adolescents
1. Type 1 diabetes
Three-quarters of all cases of type 1 dia-
betes are diagnosed in individuals 18
yearsofage.Becausechildrenarenotsim-
ply“smalladults,”itisappropriatetocon-
sider the unique aspects of care and
management of children and adolescents
with type 1 diabetes. Children with dia-
betes differ from adults in many respects,
including changes in insulin sensitivity
related to sexual maturity and physical
growth,abilitytoprovideself-care,super-
vision in child care and school, and
unique neurologic vulnerability to hypo-
glycemia and DKA. Attention to such is-
sues as family dynamics, developmental
stages,andphysiologicdifferencesrelated
to sexual maturity are all essential in de-
veloping and implementing an optimal
diabetes regimen. Although recommen-
dations for children and adolescents are
less likely to be based on clinical trial ev-
idence, because of current and historical
restraints placed on conducting research
in children, expert opinion and a review
of available and relevant experimental
data are summarized in the ADA state-
ment on care of children and adolescents
with type 1 diabetes (311).
Ideally, the care of a child or adoles-
cent with type 1 diabetes should be pro-
vided by a multidisciplinary team of
specialists trained in the care of children
with pediatric diabetes. At the very least,
education of the child and family should
be provided by health care providers
trained and experienced in childhood di-
abetes and sensitive to the challenges
posed by diabetes in this age-group. At
the time of initial diagnosis, it is essential
that diabetes education be provided in a
timely fashion, with the expectation that
the balance between adult supervision
and self-care should be deﬁned by, and
will evolve according to, physical, psy-
chological,andemotionalmaturity.MNT
should be provided at diagnosis, and at
least annually thereafter, by an individual
experienced with the nutritional needs of
the growing child and the behavioral is-
sues that have an impact on adolescent
diets,includingriskfordisorderedeating.
a. Glycemic control
Recommendations
● Consider age when setting glycemic
goals in children and adolescents with
type1diabetes,withlessstringentgoals
for younger children. (E)
While current standards for diabetes
management reﬂect the need to maintain
glucosecontrolasneartonormalassafely
possible, special consideration must be
giventotheuniquerisksofhypoglycemia
inyoungchildren.Glycemicgoalsneedto
be modiﬁed to take into account the fact
that most children 6 or 7 years of age
have a form of “hypoglycemic unaware-
ness.” Their counterregulatory mecha-
nismsareimmatureandtheymaylackthe
cognitive capacity to recognize and re-
spond to hypoglycemic symptoms, plac-
ing them at greater risk for severe
hypoglycemia and its sequelae. In addi-
tion, and unlike the case in adults, young
children under the age of 5 years are at
risk for permanent cognitive impairment
after episodes of severe hypoglycemia
(312–314). Extensive evidence indicates
that near normalization of blood glucose
levelsisseldomattainableinchildrenand
adolescents after the honeymoon (remis-
sion) period. The A1C level achieved in
the “intensive” adolescent cohort of the
DCCT group was 1% higher than that
achieved by adult DCCT subjects and
above current ADA recommendations for
patients in general. However, the in-
creased frequency of use of basal bolus
regimens (including insulin pumps) in
youth from infancy through adolescence
has been associated with more children
reaching ADA blood glucose targets
(315,316) in those families in which both
parents and the child with diabetes are
motivated to perform the required diabe-
tes-related tasks.
In selecting glycemic goals, the bene-
ﬁts on long-term health outcomes of
achieving a lower A1C must be weighed
against the unique risks of hypoglycemia
and the difﬁculties achieving near-
normoglycemia in children and youth.
Age-speciﬁc glycemic and A1C goals are
presented in Table 17.
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chronic complications in children and
adolescents with type 1 diabetes
i. Nephropathy
Recommendations
● Annual screening for microalbumin-
uria, with a random spot urine sample
for microalbumin-to-creatinine ratio,
should be initiated once the child is 10
years of age and has had diabetes for 5
years. (E)
● Conﬁrmed, persistently elevated mi-
croalbumin levels on two additional
urine specimens should be treated with
anACEinhibitor,titratedtonormaliza-
tion of microalbumin excretion if pos-
sible. (E)
ii. Hypertension
Recommendations
● Treatment of high-normal blood pres-
sure (systolic or diastolic blood pres-
sure consistently above the 90th
percentile for age, sex, and height)
should include dietary intervention
and exercise aimed at weight control
and increased physical activity, if ap-
propriate.Iftargetbloodpressureisnot
reached with 3–6 months of lifestyle
intervention, pharmacologic treatment
should be initiated. (E)
● Pharmacologic treatment of hyperten-
sion (systolic or diastolic blood pres-
sure consistently above the 95th
percentile for age, sex, and height or
consistently 130/80 mmHg, if 95%
exceeds that value) should be initiated
as soon as the diagnosis is conﬁrmed.
(E)
● ACE inhibitors should be considered
for the initial treatment of hyperten-
sion. (E)
● The goal of treatment is a blood pres-
sureconsistently130/80orbelowthe
90thpercentileforage,sex,andheight,
whichever is lower. (E)
Hypertension in childhood is deﬁned as
anaveragesystolicordiastolicbloodpres-
sure 95th percentile for age, sex, and
height percentile measured on at least
three separate days. “High-normal” blood
pressure is deﬁned as an average systolic
or diastolic blood pressure 90th but
95th percentile for age, sex, and height
percentile measured on at least 3 separate
days. Normal blood pressure levels for
age, sex, and height and appropriate
methods for determinations are available
online at www.nhlbi.nih.gov/health/
prof/heart/hbp/hbp_ped.pdf.
iii. Dyslipidemia
Recommendations
Screening
● If there is a family history of hypercho-
lesterolemia (total cholesterol 240
mg/dl) or a cardiovascular event before
age 55 years, or if family history is un-
known, then a fasting lipid proﬁle
should be performed on children 2
years of age soon after diagnosis (after
glucose control has been established).
If family history is not of concern, then
the ﬁrst lipid screening should be per-
formedatpuberty(10years).Allchil-
dren diagnosed with diabetes at or after
puberty should have a fasting lipid
proﬁle performed soon after diagnosis
(after glucose control has been estab-
lished). (E)
● Forbothage-groups,iflipidsareabnor-
mal, annual monitoring is recom-
mended. If LDL cholesterol values are
within the accepted risk levels (100
mg/dl [2.6 mmol/l]), a lipid proﬁle
should be repeated every 5 years. (E)
Treatment
● Initialtherapyshouldconsistofoptimi-
zation of glucose control and MNT us-
ing a Step II AHA diet aimed at a
decrease in the amount of saturated fat
in the diet. (E)
● Aftertheageof10years,theadditionof
a statin is recommended in patients
who, after MNT and lifestyle changes,
have LDL cholesterol 160 mg/dl (4.1
mmol/l) or LDL cholesterol 130
mg/dl (3.4 mmol/l) and one or more
CVD risk factors. (E)
● The goal of therapy is an LDL choles-
terol value 100 mg/dl (2.6 mmol/l).
(E)
People diagnosed with type 1 diabetes in
childhood have a high risk of early sub-
clinical (317–319) and clinical (320)
CVD. Although intervention data are
lacking, the AHA categorizes type 1 dia-
betic children in the highest tier for car-
diovascular risk and recommends both
lifestyle and pharmacologic treatment for
thosewithelevatedLDLcholesterollevels
(321,322). Initial therapy should be with
a Step II AHA diet, which restricts satu-
rated fat to 7% of total calories and re-
stricts dietary cholesterol to 200 mg per
day. Data from randomized clinical trials
Table 17—Plasma blood glucose and A1C goals for type 1 diabetes by age-group
Values by age (years)
Plasma blood glucose goal
range (mg/dl)
A1C Rationale Before meals
Bedtime/
overnight
Toddlers and preschoolers (0–6) 100–180 110–200 8.5% (but 7.5%) High risk and vulnerability to hypoglycemia
School age (6–12) 90–180 100–180 8% Risks of hypoglycemia and relatively low risk of
complications prior to puberty
Adolescents and young adults (13–19) 90–130 90–150 7.5% Risk of severe hypoglycemia
Developmental and psychological issues
A lower goal (7.0%) is reasonable if it can be
achieved without excessive hypoglycemia
Key concepts in setting glycemic goals:
● Goals should be individualized and lower goals may be reasonable based on beneﬁt-risk assessment.
● Blood glucose goals should be higher than those listed above in children with frequent hypoglycemia or hypoglycemia unawareness.
● Postprandial blood glucose values should be measured when there is a discrepancy between pre-prandial blood glucose values and A1C
levels and to help assess glycemia in those on basal/bolus regimens.
Standards of Medical Care
S40 DIABETES CARE, VOLUME 33, SUPPLEMENT 1, JANUARY 2010 care.diabetesjournals.orgin children as young as 7 months of age
indicate that this diet is safe and does not
interfere with normal growth and devel-
opment (323,324).
For children over the age of 10 years
with persistent elevation of LDL choles-
terol despite lifestyle therapy, statins
should be considered. Neither long-term
safety nor cardiovascular outcome efﬁ-
cacy has been established for children.
However, recent studies have shown
short-term safety equivalent to that seen
in adults and efﬁcacy in lowering LDL
cholesterol levels, improving endothelial
function, and causing regression of ca-
rotid intimal thickening (325–327). No
statin is approved for use under the age of
10years,andstatintreatmentshouldgen-
erally not be used in type 1 diabetic chil-
dren prior to this age.
iv. Retinopathy
Recommendations
● The ﬁrst ophthalmologic examination
should be obtained once the child is 10
years of age and has had diabetes for
3–5 years. (E)
● After the initial examination, annual
routine follow-up is generally recom-
mended. Less frequent examinations
may be acceptable on the advice of an
eye care professional. (E)
Although retinopathy most commonly
occurs after the onset of puberty and after
5–10 years of diabetes duration, it has
been reported in prepubertal children
and with diabetes duration of only 1–2
years. Referrals should be made to eye
care professionals with expertise in dia-
betic retinopathy, an understanding of
the risk for retinopathy in the pediatric
population, and experience in counseling
the pediatric patient and family on the
importance of early prevention/inter-
vention.
v. Celiac disease
Recommendations
● Children with type 1 diabetes should be
screened for celiac disease by measuring
tissue transglutaminase or anti-
endomysial antibodies, with documenta-
tion of normal serum IgA levels, soon
after the diagnosis of diabetes. (E)
● Testing should be repeated if growth
failure, failure to gain weight, weight
loss,orgastroenterologicsymptomsoc-
cur. (E)
● Consideration should be given to peri-
odic rescreening of asymptomatic indi-
viduals. (E)
● Children with positive antibodies
should be referred to a gastroenterolo-
gist for evaluation. (E)
● Children with conﬁrmed celiac disease
should have consultation with a dieti-
tianandbeplacedonagluten-freediet.
(E)
Celiac disease is an immune-mediated
disorder that occurs with increased fre-
quency in patients with type 1 diabetes
(1–16% of individuals compared with
0.3–1% in the general population)
(328,329).Symptomsofceliacdiseasein-
cludediarrhea,weightlossorpoorweight
gain, growth failure, abdominal pain,
chronic fatigue, malnutrition due to mal-
absorption, other gastrointestinal prob-
lems, and unexplained hypoglycemia or
erratic blood glucose concentrations.
vi. Hypothyroidism
Recommendations
● Childrenwithtype1diabetesshouldbe
screened for thyroid peroxidase and
thyroglobulin antibodies at diagnosis.
(E)
● Thyroid-stimulating hormone (TSH)
concentrations should be measured af-
ter metabolic control has been estab-
lished. If normal, they should be
rechecked every 1–2 years or if the pa-
tient develops symptoms of thyroid
dysfunction,thyromegaly,oranabnor-
mal growth rate. Free T4 should be
measured if TSH is abnormal. (E)
Autoimmune thyroid disease is the most
common autoimmune disorder associ-
ated with diabetes, occurring in 17–30%
ofpatientswithtype1diabetes(330).The
presence of thyroid auto-antibodies is
predictive of thyroid dysfunction, gener-
ally hypothyroidism and less commonly
hyperthyroidism (331). Subclinical hy-
pothyroidism may be associated with in-
creased risk of symptomatic
hypoglycemia (332) and with reduced
linear growth (333). Hyperthyroidism al-
ters glucose metabolism, potentially re-
sulting in deterioration of metabolic
control.
c. Self-management. No matter how
soundthemedicalregimen,itcanonlybe
as good as the ability of the family and/or
individual to implement it. Family in-
volvement in diabetes remains an impor-
tant component of optimal diabetes
management throughout childhood and
into adolescence. Health care providers
who care for children and adolescents
therefore must be capable of evaluating
the behavioral, emotional, and psychoso-
cial factors that interfere with implemen-
tation and then must work with the
individualandfamilytoresolveproblems
that occur and/or to modify goals as
appropriate.
d. School and day care. Since a sizable
portion of a child’s day is spent in school,
close communication with school or day
care personnel is essential for optimal di-
abetes management, safety, and maximal
academic opportunities. See VIII.B. Dia-
betes Care in the School and Day Care
Setting, for further discussion.
2. Type 2 diabetes
The incidence of type 2 diabetes in ado-
lescents is increasing, especially in ethnic
minority populations (21). Distinction
between type 1 and type 2 diabetes in
children can be difﬁcult, since the preva-
lence of overweight in children continues
to rise and since autoantigens and ketosis
maybepresentinasubstantialnumberof
patients with features of type 2 diabetes
(including obesity and acanthosis nigri-
cans). Such a distinction at the time of
diagnosis is critical because treatment
regimens, educational approaches, and
dietary counsel will differ markedly be-
tween the two diagnoses.
Type 2 diabetes has a signiﬁcant in-
cidence of comorbidities already
present at the time of diagnosis (334). It
is recommended that blood pressure
measurement, a fasting lipid proﬁle,
microalbuminuria assessment, and di-
lated eye examination be performed at
the time of diagnosis. Thereafter,
screening guidelines and treatment rec-
ommendations for hypertension, dys-
lipidemia, microalbuminuria, and
retinopathy in youth with type 2 diabe-
tes are similar to those for youth with
type 1 diabetes. Additional problems
that may need to be addressed include
polycystic ovary disease and the various
comorbidities associated with pediatric
obesity such as sleep apnea, hepatic ste-
atosis, orthopedic complications, and
psychosocial concerns. The ADA con-
sensus statement on this subject (23)
provides guidance on the prevention,
screening, and treatment of type 2 dia-
betes and its comorbidities in young
people.
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Recommendations
● A1C levels should be as close to normal
as possible (7%) in an individual pa-
tient before conception is attempted.
(B)
● Starting at puberty, preconception
counseling should be incorporated in
the routine diabetes clinic visit for all
women of child-bearing potential. (C)
● Womenwithdiabeteswhoarecontem-
plating pregnancy should be evaluated
and, if indicated, treated for diabetic
retinopathy,nephropathy,neuropathy,
and CVD. (E)
● Medications used by such women
should be evaluated prior to concep-
tion because drugs commonly used to
treat diabetes and its complications
may be contraindicated or not recom-
mended in pregnancy, including st-
atins, ACE inhibitors, ARBs, and most
noninsulin therapies. (E)
Major congenital malformations remain
the leading cause of mortality and serious
morbidity in infants of mothers with type
1 or type 2 diabetes. Observational stud-
ies indicate that the risk of malformations
increases continuously with increasing
maternal glycemia during the ﬁrst 6–8
weeks of gestation, as deﬁned by ﬁrst-
trimesterA1Cconcentrations.Thereisno
threshold for A1C values below which
risk disappears entirely. However, mal-
formation rates above the 1–2% back-
ground rate of nondiabetic pregnancies
appear to be limited to pregnancies in
which ﬁrst-trimester A1C concentrations
are 1% above the normal range for a
nondiabetic pregnant woman.
Preconception care of diabetes ap-
pearstoreducetheriskofcongenitalmal-
formations. Five nonrandomized studies
comparedratesofmajormalformationsin
infants between women who participated
in preconception diabetes care programs
andwomenwhoinitiatedintensivediabe-
tes management after they were already
pregnant. The preconception care pro-
grams were multidisciplinary and de-
signed to train patients in diabetes self-
managementwithdiet,intensiﬁedinsulin
therapy, and SMBG. Goals were set to
achieve normal blood glucose concentra-
tions, and 80% of subjects achieved
normal A1C concentrations before they
became pregnant (335–339). In all ﬁve
studies, the incidence of major congenital
malformations in women who partici-
pated in preconception care (range 1.0–
1.7% of infants) was much lower than the
incidence in women who did not partici-
pate (range 1.4–10.9% of infants). One
limitation of these studies is that partici-
pation in preconception care was self-
selected rather than randomized. Thus, it
is impossible to be certain that the lower
malformation rates resulted fully from
improved diabetes care. Nonetheless, the
evidence supports the concept that mal-
formations can be reduced or prevented
by careful management of diabetes before
pregnancy.
Planned pregnancies greatly facilitate
preconception diabetes care. Unfortu-
nately, nearly two-thirds of pregnancies
in women with diabetes are unplanned,
leading to a persistent excess of malfor-
mationsininfantsofdiabeticmothers.To
minimize the occurrence of these devas-
tatingmalformations,standardcareforall
women with diabetes who have child-
bearing potential, beginning at the onset
of puberty or at diagnosis, should include
1) education about the risk of malforma-
tionsassociatedwithunplannedpregnan-
cies and poor metabolic control; and 2)
use of effective contraception at all times,
unless the patient has good metabolic
control and is actively trying to conceive.
Women contemplating pregnancy
need to be seen frequently by a multidis-
ciplinary team experienced in the man-
agement of diabetes before and during
pregnancy. The goals of preconception
care are to 1) involve and empower the
patient in the management of her diabe-
tes, 2) achieve the lowest A1C test results
possiblewithoutexcessivehypoglycemia,
3) assure effective contraception until sta-
ble and acceptable glycemia is achieved,
and 4) identify, evaluate, and treat long-
term diabetes complications such as reti-
nopathy, nephropathy, neuropathy,
hypertension, and CHD (76).
Among the drugs commonly used in
the treatment of patients with diabetes, a
number may be relatively or absolutely
contraindicated during pregnancy. St-
atins are category X (contraindicated for
use in pregnancy) and should be discon-
tinued before conception, as should ACE
inhibitors (340). ARBs are category C
(risk cannot be ruled out) in the ﬁrst tri-
mester but category D (positive evidence
of risk) in later pregnancy and should
generally be discontinued before preg-
nancy. Among the oral antidiabetic
agents, metformin and acarbose are clas-
siﬁed as category B (no evidence of risk in
humans) and all others as category C. Po-
tential risks and beneﬁts of oral antidia-
betic agents in the preconception period
must be carefully weighed, recognizing
that data are insufﬁcient to establish the
safety of these agents in pregnancy.
For further discussion of preconcep-
tion care, see the related ADA consensus
statement (76) and position statement
(341) on preexisting diabetes and
pregnancy.
C. Older adults
Recommendations
● Older adults who are functional, are
cognitively intact, and have signiﬁcant
life expectancy should receive diabetes
care using goals developed for younger
adults. (E)
● Glycemic goals for older adults not
meeting the above criteria may be re-
laxed using individual criteria, but hy-
perglycemia leading to symptoms or
risk of acute hyperglycemic complica-
tions should be avoided in all patients.
(E)
● Other cardiovascular risk factors
should be treated in older adults with
consideration of the time frame of ben-
eﬁt and the individual patient. Treat-
ment of hypertension is indicated in
virtually all older adults, and lipid and
aspirin therapy may beneﬁt those with
lifeexpectancyatleastequaltothetime
frame of primary or secondary preven-
tion trials. (E)
● Screening for diabetes complications
should be individualized in older
adults, but particular attention should
be paid to complications that would
lead to functional impairment. (E)
Diabetes is an important health condition
for the aging population; at least 20% of
patients over the age of 65 years have di-
abetes, and this number can be expected
to grow rapidly in the coming decades.
Older individuals with diabetes have
higher rates of premature death, func-
tional disability, and coexisting illnesses
such as hypertension, CHD, and stroke
than those without diabetes. Older adults
with diabetes are also at greater risk than
otherolderadultsforseveralcommonge-
riatricsyndromes,suchaspolypharmacy,
depression, cognitive impairment, uri-
nary incontinence, injurious falls, and
persistent pain.
The American Geriatric Society’s
guidelines for improving the care of the
older person with diabetes (342) have in-
ﬂuenced the following discussion and
recommendations. The care of older
Standards of Medical Care
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their clinical and functional heterogene-
ity. Some older individuals developed di-
abetes years earlier and may have
signiﬁcant complications; others who are
newly diagnosed may have had years of
undiagnoseddiabeteswithresultantcom-
plications or may have few complications
from the disease. Some older adults with
diabetes are frail and have other underly-
ing chronic conditions, substantial diabe-
tes-related comorbidity, or limited
physical or cognitive functioning. Other
older individuals with diabetes have little
comorbidityandareactive.Lifeexpectan-
ciesarehighlyvariableforthispopulation
but often longer than clinicians realize.
Providers caring for older adults with di-
abetes must take this heterogeneity into
consideration when setting and prioritiz-
ing treatment goals.
There are few long-term studies in
older adults that demonstrate the beneﬁts
ofintensiveglycemic,bloodpressure,and
lipid control. Patients who can be ex-
pected to live long enough to reap the
beneﬁts of long-term intensive diabetes
management and who are active, have
good cognitive function, and are willing
should be provided with the needed edu-
cation and skills to do so and be treated
using the goals for younger adults with
diabetes.
For patients with advanced diabetes
complications, life-limiting comorbid ill-
ness, or substantial cognitive or func-
tional impairment, it is reasonable to set
less-intensiveglycemictargetgoals.These
patients are less likely to beneﬁt from re-
ducing the risk of microvascular compli-
cations and more likely to suffer serious
adverse effects from hypoglycemia. How-
ever, patients with poorly controlled
diabetes may be subject to acute compli-
cations of diabetes, including dehydra-
tion, poor wound healing, and
hyperglycemic hyperosmolar coma. Gly-
cemic goals at a minimum should avoid
these consequences.
Although control of hyperglycemia
may be important in older individuals
with diabetes, greater reductions in mor-
bidity and mortality may result from con-
trol of other cardiovascular risk factors
rather than from tight glycemic control
alone. There is strong evidence from clin-
ical trials of the value of treating hyper-
tension in the elderly (343,344). There is
less evidence for lipid-lowering and aspi-
rin therapy, although the beneﬁts of these
interventions for primary and secondary
prevention are likely to apply to older
adults whose life expectancies equal or
exceed the time frames seen in clinical
trials.
Special care is required in prescribing
andmonitoringpharmacologictherapyin
older adults. Metformin is often contrain-
dicated because of renal insufﬁciency or
signiﬁcant heart failure. TZDs can cause
ﬂuid retention, which may exacerbate or
lead to heart failure. They are contraindi-
cated in patients with CHF (New York
Heart Association class III and IV), and if
used at all should be used very cautiously
inthosewith,oratriskfor,milderdegrees
of CHF. Sulfonylureas, other insulin
secretagogues, and insulin can cause hy-
poglycemia. Insulin use requires that pa-
tients or caregivers have good visual and
motor skills and cognitive ability. Drugs
should be started at the lowest dose and
titrated up gradually until targets are
reached or side effects develop.
Screening for diabetes complications
in older adults also should be individual-
ized. Particular attention should be paid
to complications that can develop over
short periods of time and/or that would
signiﬁcantly impair functional status,
such as vision and lower-extremity
complications.
D. Cystic ﬁbrosis–related diabetes
Cystic ﬁbrosis-related diabetes (CFRD) is
the most common comorbidity in people
withcysticﬁbrosis,occurringin20%of
adolescents and 40–50% of adults. The
additional diagnosis of diabetes in this
populationisassociatedwithworsenutri-
tional status, more severe inﬂammatory
lung disease, and greater mortality from
respiratory failure. For reasons that are
not well understood, women with CFRD
are particularly vulnerable to excess mor-
bidityandmortality.Insulininsufﬁciency
related to partial ﬁbrotic destruction of
the islet mass is the primary defect in
CFRD. Genetically determined function
of the remaining -cells and insulin resis-
tance associated with infection and in-
ﬂammation may also play a role.
Encouraging new data suggest that early
detection and aggressive insulin therapy
have narrowed the gap in mortality be-
tween cystic ﬁbrosis patients with and
without diabetes and have eliminated the
sex difference in mortality.
A consensus conference on CFRD
was cosponsored in 2009 by ADA, the
Cystic Fibrosis Foundation, and the Law-
son Wilkins Pediatric Endocrine Society.
Recommendations for the clinical man-
agement of CFRD will be found in the
consensusreporttobepublishedin2010.
VIII. DIABETES CARE IN
SPECIFIC SETTINGS
Diabetes care in the hospital
Recommendations
● All patients with diabetes admitted to
the hospital should have their diabetes
clearly identiﬁed in the medical record.
(E)
● All patients with diabetes should have
an order for blood glucose monitoring,
with results available to all members of
the health care team. (E)
● Goals for blood glucose levels
● Critically ill patients: Insulin therapy
should be initiated for treatment of
persistenthyperglycemiastartingata
threshold of 180 mg/dl (10 mmol/
l). Once insulin therapy is started, a
glucose range of 140–180 mg/dl
(7.8–10 mmol/l) is recommended
for the majority of critically ill pa-
tients. (A) These patients require an
intravenous insulin protocol that has
demonstrated efﬁcacy and safety in
achieving the desired glucose range
without increasing risk for severe hy-
poglycemia. (E)
● Non–critically ill patients: There is
no clear evidence for speciﬁc blood
glucose goals. If treated with insulin,
the premeal blood glucose target
should generally be 140 mg/dl (7.8
mmol/l) with random blood glucose
180mg/dl(10.0mmol/l),provided
these targets can be safely achieved.
More stringent targets may be appro-
priateinstablepatientswithprevious
tight glycemic control. Less stringent
targets may be appropriate in those
with severe comorbidites. (E)
● Scheduled subcutaneous insulin with
basal, nutritional, and correction com-
ponents is the preferred method for
achieving and maintaining glucose
control in noncritically ill patients. (C)
Using correction dose or “supplemen-
tal” insulin to correct premeal hyper-
glycemia in addition to scheduled
prandial and basal insulin is recom-
mended. (E)
● Glucose monitoring should be initiated
in any patient not known to be diabetic
who receives therapy associated with
high risk for hyperglycemia, including
high-doseglucocorticoidtherapy,initi-
ation of enteral or parenteral nutrition,
or other medications such as octreotide
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(B) If hyperglycemia is documented
and persistent, treatment is necessary.
Such patients should be treated to the
same glycemic goals as patients with
known diabetes. (E)
● A plan for treating hypoglycemia
should be established for each patient.
Episodes of hypoglycemia in the hospi-
tal should be tracked. (E)
● All patients with diabetes admitted to
the hospital should have an A1C ob-
tained if the result of testing in the pre-
vious 2–3 months is not available. (E)
● Patientswithhyperglycemiainthehos-
pital who do not have a diagnosis of
diabetes should have appropriate plans
for follow-up testing and care docu-
mented at discharge. (E)
The subject of diabetes in the hospital is
extensively reviewed in an ADA technical
review(345).Arecentupdatedconsensus
statement by the American Association of
ClinicalEndocrinologists(AACE)andthe
ADA (346) form the basis for the discus-
sion and guidelines in this section.
The literature on hospitalized pa-
tients with hyperglycemia typically de-
scribes three categories:
● Medical history of diabetes: diabetes pre-
viously diagnosed and acknowledged by
the patient’s treating physician.
● Unrecognized diabetes: hyperglycemia
(fasting blood glucose 126 mg/dl or
random blood glucose 200 mg/dl)
occurring during hospitalization and
conﬁrmed as diabetes after hospitaliza-
tion by standard diagnostic criteria but
unrecognized as diabetes by the treat-
ing physician during hospitalization.
● Hospital-relatedhyperglycemia:hyper-
glycemia (fasting blood glucose 126
mg/dl or random blood glucose 200
mg/dl) occurring during the hospital-
ization that reverts to normal after hos-
pital discharge.
The management of hyperglycemia in the
hospital has logically been considered
secondary in importance to the condition
that prompted admission (345). How-
ever, a body of literature now supports
targeted glucose control in the hospital
setting for potential improved clinical
outcomes. Hyperglycemia in the hospital
may result from stress; decompensation
of type 1, type 2, or other forms of dia-
betes; and/or may be iatrogenic due to
withholding of antihyperglycemic
medications or administration of hyper-
glycemia-provoking agents such as glu-
cocorticoids or vasopressors.
People with diabetes are more likely
to be hospitalized and to have longer
lengths of stay than those without diabe-
tes.Arecentsurveyestimatedthat22%of
all hospital inpatient days were incurred
by people with diabetes and that hospital
inpatient care accounted for one-half of
the$174billiontotalU.S.medicalexpen-
ditures for this disease (347). This is due,
in part, to the continued expansion of the
worldwideepidemicoftype2diabetes.In
theU.S.alone,thereare1.6millionnew
cases of diabetes each year with an overall
prevalence of 23.6 million people (7.8%
of the population, with one-quarter of
cases remaining undiagnosed). An addi-
tional 57 million American adults are at
high risk for type 2 diabetes (348). While
thecostsofillness-relatedstresshypergly-
cemia are not known, they are likely to be
signiﬁcant given the poor prognosis of
such patients (349–352).
There is substantial observational ev-
idence linking hyperglycemia in hospital-
izedpatients(withorwithoutdiabetes)to
poor outcomes. Cohort studies as well as
a few early randomized controlled trials
(RCTs)suggestedthatintensivetreatment
of hyperglycemia improved hospital out-
comes (345,351,352). Interventions to
normalize glycemia, however, have had
inconsistent results. Indeed, recent trials
incriticallyillpatientshavefailedtoshow
a signiﬁcant improvement in mortality
with intensive glycemic control
(353,354) or have even shown increased
mortality risk (355). Moreover, these re-
cent RCTs have highlighted the risk of se-
vere hypoglycemia resulting from such
efforts (353–358).
The largest study to date, NICE-
SUGAR, a multicenter, multinational
RCT, tested the effect of tight glycemic
control (target 81–108 mg/dl) on out-
comes among 6,104 critically ill partici-
pants, the majority of whom (95%)
required mechanical ventilation (355).
Ninety-day mortality was signiﬁcantly
higher in the intensive versus the conven-
tional group (target 144–180 mg/dl) (78
moredeaths;27.5vs.24.9%,P	0.02)in
both surgical and medical patients. Mor-
tality from cardiovascular causes was
more common in the intensive group (76
more deaths; 41.6 vs. 35.8%; P 	 0.02).
Severe hypoglycemia was also more com-
mon in the intensively treated group (6.8
vs. 0.5%; P  0.001). The precise reason
for the increased mortality in the tightly
controlled group is unknown. The results
of this study lie in stark contrast to a fa-
mous 2001 single-center study that re-
ported a 42% relative reduction in
intensivecareunit(ICU)mortalityincrit-
ically ill surgical patients treated to a tar-
get blood glucose of 80–110 mg/dl.
Importantly, the control group in NICE-
SUGAR had reasonably good blood glu-
cose management, maintained at a mean
glucose of 144 mg/dl, only 29 mg/dl
above the intensively managed patients.
Accordingly, this study’s ﬁndings do not
disprove the notion that glycemic control
intheICUisimportant.However,theydo
strongly suggest that it is not necessary to
target blood glucose values 140 mg/dl
and that a highly stringent target of 110
mg/dl actually may be dangerous.
In a recent meta-analysis of 26 trials
(N 	 13,567), which included the NICE-
SUGARdata,thepooledrelativerisk(RR)
of death with intensive insulin therapy
was 0.93 as compared with conventional
therapy (95% CI 0.83–1.04) (358). Ap-
proximately half of these trials reported
hypoglycemia, with a pooled RR of inten-
sivetherapyof6.0(95%CI4.5–8.0).The
speciﬁc ICU setting inﬂuenced the ﬁnd-
ings, with patients in surgical ICUs ap-
pearing to beneﬁt from intensive insulin
therapy (RR 0.63 [95% CI 0.44–0.91]),
while those in other critical care settings
did not (medical ICU: 1.0 [0.78–1.28];
“mixed” ICU: 0.99 [0.86–1.12]). It was
concluded that overall, intensive insulin
therapy increased the risk of hypoglyce-
mia but provided no overall beneﬁt on
mortality in the critically ill, although a
beneﬁttopatientsadmittedtothesurgical
ICU was suggested.
Itisveryclearthatthemanagementof
hyperglycemia in the hospital presents
unique challenges that stem from varia-
tions in a patient’s nutritional status and
level of consciousness, the practical limi-
tations of intermittent glycemic monitor-
ing, and the ultimate importance of
patient safety. Accordingly, reasonable
glucose targets in the hospital setting are
modestly higher than may be routinely
advised in patients with diabetes in the
outpatient setting. The following recom-
mendations represent a synthesis of the
evidence base over the past decade and
are somewhat less stringent than prior
recommendations of the ADA Standards
of Medical Care in Diabetes. For a com-
prehensive review of these data, the
reader is referred to the latest consensus
statement from AACE and ADA on inpa-
tient management of hyperglycemia
(346).
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a. Deﬁnition of glucose abnormalities in
the hospital setting. Hyperglycemia has
been deﬁned as any blood glucose 140
mg/dl (7.8 mmol/l). Levels that are signif-
icantlyandpersistentlyabovethismayre-
quire treatment in hospitalized patients.
In patients without a previous diagnosis
of diabetes, elevated blood glucose may
bedueto“stresshyperglycemia,”acondi-
tion that can be established by a review of
prior records or measurement of an A1C.
A1C values 6.5% suggest that diabetes
preceded hospitalization (359). Hypogly-
cemia has been deﬁned as any blood glu-
cose 70 mg/dl (3.9 mmol/l). This is the
standard deﬁnition in outpatients and
correlateswiththeinitialthresholdforthe
release of counterregulatory hormones
(177). Severe hypoglycemia in hospital-
ized patients has been deﬁned by many
as 40 mg/dl (2.2 mmol/l), although
this is lower than the 50 mg/dl (2.8
mmol/l)levelatwhichcognitiveimpair-
ment begins in normal individuals
(177,360,361). As with hyperglycemia,
hypoglycemiaamonginpatientsisalsoas-
sociated with adverse short- and long-
term outcomes. Early recognition and
treatmentofmildtomoderatehypoglyce-
mia (40 and 69 mg/dl [2.2 and 3.8 mmol/
l]) can prevent deterioration to a more
severe episode with potential adverse se-
quelae (361,362).
i. Critically ill patients. Based on the
weight of the available evidence, for the
majorityofcriticallyillpatientsintheICU
setting,insulininfusionshouldbeusedto
control hyperglycemia, with a starting
threshold of 180 mg/dl (10.0 mmol/l).
Once intravenous insulin is started, the
glucose level should be maintained be-
tween 140 and 180 mg/dl (7.8 and 10.0
mmol/l). Greater beneﬁt may be realized
at the lower end of this range. Although
strong evidence is lacking, somewhat
lower glucose targets may be appropriate
in selected patients. However, targets
110 mg/dl (6.1 mmol/l) are not recom-
mended.Useofinsulininfusionprotocols
withdemonstratedsafetyandefﬁcacy,re-
sulting in low rates of hypoglycemia, are
highly recommended.
ii. Noncritically ill patients. With no pro-
spective, RCT data to inform speciﬁc gly-
cemic targets in noncritically ill patients,
recommendations are based on clinical
experience and judgment. For the major-
ityofnoncriticallyillpatientstreatedwith
insulin, premeal glucose targets should
generally be 140 mg/dl (7.8 mmol/l)
with random blood glucose 180 mg/dl
(10.0mmol/l),aslongasthesetargetscan
be safely achieved. To avoid hypoglyce-
mia, consideration should be given to re-
assessing the insulin regimen if blood
glucose levels fall below 100 mg/dl (5.6
mmol/l). Modiﬁcation of the regimen is
required when blood glucose values are
70mg/dl(3.9mmol/l),unlesstheevent
is easily explained by other factors (such
as a missed meal, etc.).
Occasional patients with a prior his-
toryofsuccessfultightglycemiccontrolin
the outpatient setting who are clinically
stable may be maintained with a glucose
range below the above cut points. Con-
versely, higher glucose ranges may be ac-
ceptable in terminally ill patients or in
patients with severe comorbidities, as
well as in those in patient-care settings
where frequent glucose monitoring or
close nursing supervision is not feasible.
Clinical judgment, combined with
ongoing assessment of the patient’s clini-
calstatus,includingchangesinthetrajec-
tory of glucose measures, severity of
illness, nutritional status, or concurrent
use of medications that might affect glu-
cose levels (e.g., steroids, octreotide)
must be incorporated into the day-to-day
decisions regarding insulin dosing (363).
2. Treatment options in hospitalized
patients
In the hospital setting, insulin therapy is
the preferred method of glycemic control
in majority of clinical situations (346). In
the ICU, intravenous infusion is the pre-
ferred route of insulin administration.
Outside of critical care units, subcutane-
ousinsulinisusedmuchmorefrequently.
Oral agents have a limited role in the in-
patient setting.
a. Intravenous insulin infusions. In the
critical care setting, continuous intrave-
nous insulin infusion has been shown to
be the most effective method for achiev-
ing speciﬁc glycemic targets (346). Be-
cause of the very short half-life of
circulating insulin, intravenous delivery
allows rapid dosing adjustments to ad-
dress alterations in patients’ status.
Intravenous insulin is ideally admin-
istered via validated written or computer-
ized protocols that allow for predeﬁned
adjustments to the insulin infusion rate
accordingtoglycemicﬂuctuationsandin-
sulin dose. An extensive review of the
merits and deﬁciencies of published pro-
tocols is beyond the intent of this state-
ment, and the reader is referred to several
available reports and reviews (364–366).
Continued education of staff with peri-
odic ongoing review of patient data are
critical for successful implementation of
any insulin protocol (364–366).
Patients who receive intravenous in-
sulin infusion will usually require transi-
tion to subcutaneous insulin when they
begin eating regular meals or are trans-
ferred to lower intensity care. Typically, a
percentage (usually 75–80%) of the total
dailyintravenousinfusiondoseispropor-
tionately divided into basal and prandial
components (see below). Importantly,
subcutaneous insulin must be given 1–4
h prior to discontinuation of intravenous
insulin to prevent hyperglycemia (367).
b. Subcutaneous insulin. Scheduled
subcutaneous insulin is the preferred
method for achieving and maintaining
glucose control in non-ICU patients with
diabetesorstresshyperglycemia.Therec-
ommended components of inpatient sub-
cutaneous insulin regimens include a
basal,nutritional,andsupplemental(cor-
rection) component (345,346,368). Each
component can be met by one of several
available insulin products, depending on
the particular hospital situation. The
reader is referred to several recent publi-
cations and reviews that describe cur-
rently available insulin preparations and
protocols (366–370).
A topic that deserves particular atten-
tion is the persistent overuse of what has
beenbrandedasslidingscaleinsulin(SSI)
for management of hyperglycemia. The
term “correction insulin,” which refers to
the use of additional short or rapid-acting
insulin with scheduled insulin doses to
treat blood glucose above desired targets,
is preferred (345). Prolonged therapy
with SSI as the sole regimen is ineffective
inthemajorityofpatients(andpotentially
dangerousintype1diabetes)(370–375).
c. Noninsulin agents. These agents are
inappropriate in the majority of hospital-
ized patients because they are less titrat-
able than insulin in the short tem and are
meant to be used in patients eating on a
regular meal schedule. Continuation of
these agents may be appropriate in se-
lected stable patients who are expected to
consume meals at regular intervals. Spe-
ciﬁc caution is required with metformin,
due to the possibility that a contraindica-
tion may develop during the hospitaliza-
tion, such as renal insufﬁciency, unstable
hemodynamic status, or need for an im-
aging study that requires a radio-contrast
dye (345,376). Injectable noninsulin
therapies such as exenatide and pramlint-
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oral agents in the hospital setting.
d. Speciﬁc clinical situations
i. Insulin pumps. Patients who use CSII
pump therapy in the outpatient setting
can be candidates for diabetes self-
management in the hospital, provided
that they have the mental and physical
capacity to do so (346,368). It is impor-
tant that nursing personnel document
basal rates and bolus doses on a regular
basis (at least daily). The availability of
hospital personnel with expertise in CSII
therapy is essential.
ii. Enteral nutrition. Hyperglycemia is a
common side effect of inpatient enteral
nutrition therapy (377). A recent report
using a combination of basal insulin with
correction insulin achieved a mean glu-
cose value of 160 mg/dl (8.9 mmol/l).
Similarresultswereachievedinthegroup
randomized to receive SSI alone; how-
ever, 48% of patients required the addi-
tion of intermediate-acting insulin to
achieve glycemic targets (373).
iii. Parenteral nutrition. The high glu-
cose load in standard parenteral nutrition
frequently results in hyperglycemia,
which is associated with a higher inci-
dence of complications and mortality in
critically ill ICU patients (378). Insulin
therapyishighlyrecommended,withglu-
cose targets as deﬁned previously by se-
verity of illness.
iv. Glucocorticoid therapy. Hyperglyce-
mia is a common complication of cortico-
steroidtherapy(363).Severalapproaches
have been proposed for treatment of this
condition, but there are no published
protocols or studies that investigate the
efﬁcacyoftheseapproaches.Areasonable
approach is to institute glucose monitor-
ing for at least 48 h in all patients receiv-
ing high dose glucocorticoid therapy and
initiate insulin as appropriate. In patients
who are already being treated for hyper-
glycemia, early adjustment of insulin
dosesisrecommended.Importantly,dur-
ing steroid tapers, insulin dosing should
be proactively adjusted to avoid
hypoglycemia.
v. Hypoglycemia prevention. Hypogly-
cemia, especially in insulin-treated pa-
tients, is the leading limiting factor in the
glycemic management of type 1 and type
2 diabetes (174). In the hospital, multiple
additional risk factors for hypoglycemia
are present, even among patients who are
neither“brittle”nortightlycontrolled.Pa-
tients with or without diabetes may expe-
rience hypoglycemia in the hospital in
association with altered nutritional state,
heart failure, renal or liver disease, malig-
nancy,infection,orsepsis(379,379,380).
Additional triggering events leading to
iatrogenic hypoglycemia include sudden
reduction of corticosteroid dose, altered
ability of the patient to self-report symp-
toms, reduction of oral intake, emesis,
new NPO status, inappropriate timing of
short- or rapid-acting insulin in relation
to meals, reduction of rate of administra-
tion of intravenous dextrose, and unex-
pected interruption of enteral feedings or
parenteral nutrition.
Despite the preventable nature of
many inpatient episodes of hypoglyce-
mia, institutions are more likely to have
nursing protocols for the treatment of hy-
poglycemia than for its prevention.
Tracking such episodes and analyzing
their causes are important quality im-
provement activities.
3. Diabetes care providers in the
hospital
Inpatient diabetes management may be
effectively provided by primary care phy-
sicians, endocrinologists, or hospitalists.
Involvementofappropriatelytrainedspe-
cialists or specialty teams may reduce
length of stay, improve glycemic control,
and improve outcomes (381–384). In the
care of diabetes, implementation of stan-
dardizedordersetsforscheduledandcor-
rection-dose insulin may reduce reliance
on sliding-scale management. A team ap-
proach is needed to establish hospital
pathways. To achieve glycemic targets
associated with improved hospital out-
comes, hospitals will need multidisci-
plinary support to develop protocols for
subcutaneous insulin therapy that effec-
tively and safely achieve glycemic targets
(385).
4. Self-management in the hospital
Self-management of diabetes in the hos-
pital may be appropriate for competent
adult patients who have a stable level of
consciousness, have reasonably stable
daily insulin requirements, successfully
conduct self-management of diabetes at
home, have physical skills needed to suc-
cessfully self-administer insulin and per-
form SMBG, have adequate oral intake,
and are proﬁcient in carbohydrate count-
ing, use of multiple daily insulin injec-
tions, or insulin pump therapy and sick-
day management. The patient and
physician, in consultation with nursing
staff, must agree that patient self-
management is appropriate under the
conditionsofhospitalization.Forpatients
conducting self-management in the hos-
pital, it is imperative that basal, prandial,
andcorrectiondosesofinsulinandresults
of bedside glucose monitoring be re-
corded as part of the patient’s hospital
medical record. While many institutions
allow patients on insulin pumps to con-
tinue these devices in the hospital, others
express concern regarding use of a device
unfamiliar to staff, particularly in patients
who are not able to manage their own
pump therapy. If a patient is too ill to
self-manage either multiple daily injec-
tions or CSII, then appropriate subcuta-
neousdosescanbecalculatedonthebasis
oftheirbasalandbolusinsulinneedsdur-
ing hospitalization, with adjustments for
changesinnutritionalormetabolicstatus.
5. DSME in the hospital
Teaching diabetes self-management to
patients in hospitals is a challenging task.
Patients are ill, under increased stress re-
lated to their hospitalization and diagno-
sis, and in an environment not conducive
to learning. Ideally, people with diabetes
should be taught at a time and place con-
ducive to learning—as an outpatient in
a recognized program of diabetes
education.
For the hospitalized patient, diabetes
“survival skills” education is generally a
feasible approach. Patients and/or family
members receive sufﬁcient information
and training to enable safe care at home.
Those newly diagnosed with diabetes or
who are new to insulin and/or blood glu-
cose monitoring need to be instructed
beforedischarge.Thosepatientshospital-
ized because of a crisis related to diabetes
management or poor care at home need
educationtopreventsubsequentepisodes
of hospitalization. An assessment of the
need for a home health referral or referral
to an outpatient diabetes education pro-
gram should be part of discharge plan-
ning for all patients.
6. MNT in the hospital
Hospital diets continue to be ordered by
calorie levels based on the “ADA diet.”
However,since1994theADAhasnoten-
dorsed any single meal plan or speciﬁed
percentages of macronutrients, and the
term “ADA diet” should no longer be
used. Current nutrition recommenda-
tions advise individualization based on
treatment goals, physiologic parameters,
and medication usage. Because of the
complexity of nutrition issues in the hos-
pital, a registered dietitian, knowledge-
able and skilled in MNT, should serve as
Standards of Medical Care
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is responsible for integrating information
about the patient’s clinical condition, eat-
ing, and lifestyle habits and for establish-
ing treatment goals in order to determine
a realistic plan for nutrition therapy
(386,387).
7. Bedside blood glucose monitoring
Bedside blood glucose monitoring using
point-of-careglucosemetersisperformed
before meals and bedtime in the majority
of inpatients who are eating usual meals.
In patients who are receiving continuous
enteral or parenteral nutrition, glucose
monitoring is optimally performed every
4–6 h. In patients who are receiving cy-
cled enteral or parenteral nutrition, the
schedule for glucose monitoring can be
individualized but should be frequent
enough to detect hyperglycemia during
feedings and risk of hypoglycemia when
feedings are interrupted (374,376). More
frequentbloodglucosetestingrangingfrom
every 30 min to every2hi srequired for
patients on intravenous insulin infusions.
Safe and rational glycemic manage-
ment relies on the accuracy of blood glu-
cose measurements using point-of-care
blood glucose meters, which have several
important limitations. Although the FDA
allows a 
20% error for glucose meters,
questions about the appropriateness of
thiscriterionhavebeenraised(388).Glu-
cosemeasuresdiffersigniﬁcantlybetween
plasmaandwholeblood,termswhichare
often used interchangeably and can lead
to misinterpretation. Most commercially
available capillary glucose meters intro-
duce a correction factor of 1.12 to re-
port a “plasma-adjusted” value (389).
Signiﬁcant discrepancies between
capillary, venous, and arterial plasma
samples have been observed in patients
with low or high hemoglobin concentra-
tions, hypoperfusion, and the presence of
interfering substances (389,390). Analyt-
ical variability has been described with
several point-of-care meters (391). Any
glucose result that does not correlate with
the patient’s status should be conﬁrmed
through conventional laboratory sam-
pling of PG.
While laboratory measurement of PG
has less variability and interference, mul-
tiple daily phlebotomies are not practical.
The use of indwelling lines as the sam-
pling source also poses risks for infection.
Studies performed using continuous in-
terstitial glucose monitoring systems in
thecriticalcaresetting(392)currentlyare
limited by the lack of reliability in the hy-
poglycemic range as well as by cost.
8. Discharge planning
It is important to anticipate the postdis-
chargeantihyperglycemicregimeninall
patients with diabetes or newly discov-
ered hyperglycemia. The optimal pro-
gram will need to consider the type and
severity of diabetes, the effects of the
patient’s illness on blood glucose levels,
and the capacities and desires of the pa-
tient. Smooth transition to outpatient
care should be ensured, especially in
those new to insulin therapy or in
whom the diabetes regimen has been
substantially altered during the hospi-
talization. All patients in whom the di-
agnosis of diabetes is new should have,
at minimum, “survival skills” training
prior to discharge.
It is recommended that the following
areas be reviewed and addressed prior to
hospital discharge:
● levelofunderstandingrelatedtothedi-
agnosis of diabetes
● SMBG and explanation of home blood
glucose goals
● deﬁnition, recognition, treatment, and
prevention of hyperglycemia and
hypoglycemia
● identiﬁcation of health care provider
who will provide diabetes care after
discharge
● information on consistent eating
patterns
● when and how to take blood glucose–
lowering medications including insulin
administration (if going home on
insulin)
● sick-day management
● proper use and disposal of needles and
syringes
More expanded diabetes education can
be arranged in the community. An out-
patient follow-up visit with the primary
care provider, endocrinologist, or diabe-
tes educator within 1 month of discharge
isadvisedforallpatientshavinghypergly-
cemia in the hospital. Clear communica-
tion with outpatient providers either
directly or via hospital discharge summa-
ries facilitates safe transitions to outpa-
tient care. Providing information
regarding the cause or the plan for deter-
mining the cause of hyperglycemia, re-
lated complications and comorbidities,
and recommended treatments can assist
outpatient providers as they assume on-
going care.
IX. STRATEGIES FOR
IMPROVING DIABETES
CARE— The implementation of the
standards of care for diabetes has been
suboptimal in most clinical settings. A re-
cent report (393) indicated that only
57.1% of adults with diagnosed diabetes
achieved an A1C of 7%, only 45.5%
had a blood pressure 130/80 mmHg,
and just 46.5% had a total cholesterol
200 mg/dl. Most distressing was that
only 12.2% of people with diabetes
achieved all three treatment goals.
While numerous interventions to im-
prove adherence to the recommended
standards have been implemented, the
challengeofprovidinguniformlyeffective
diabetes care has thus far deﬁed a simple
solution. A major contributor to subopti-
malcareisadeliverysystemthattoooften
is fragmented, lacks clinical information
capabilities,oftenduplicatesservices,and
is poorly designed for the delivery of
chronic care. The chronic care model
(CCM) includes ﬁve core elements for the
provision of optimal care of patients with
chronic disease: delivery system design,
self-management support, decision sup-
port, clinical information systems, and
communityresourcesandpolicies.Redef-
inition of the roles of the clinic staff and
promoting self-management on the part
of the patient are fundamental to the suc-
cessful implementation of the CCM
(394). Collaborative, multidisciplinary
teams are best suited to provide such care
for people with chronic conditions like
diabetesandtoempowerpatients’perfor-
mance of appropriate self-management.
Alterations in reimbursement that reward
theprovisionofqualitycare,asdeﬁnedby
the attainment of quality measures devel-
oped by such programs as the ADA/
National Committee for Quality
Assurance Diabetes Provider Recognition
Program, will also be required to achieve
desired outcome goals.
In recent years, numerous health care
organizations, ranging from large health
care systems such as the U.S. Veteran’s
Administration to small private practices,
have implemented strategies to improve
diabetes care. Successful programs have
published results showing improvement
inprocessmeasuressuchasmeasurement
ofA1C,lipids,andbloodpressure.Effects
on in important intermediate outcomes,
such as mean A1C for populations, have
been more difﬁcult to demonstrate (395–
397), although examples do exist (398–
402), often taking more than 1 year to
manifest (394). Features of successful
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include
● Delivery of DSME: increases adherence
to standard of care and educating pa-
tientsonglycemictargetsandimproves
the percentage of patients who reach
goal A1C (142,403)
● Adoption of practice guidelines, with
participation of health care profession-
als in the process of development:
Guidelines should be readily accessible
at the point of service, preferably as
computerized reminders at the point of
care. Guidelines should begin with a
summary of their major recommenda-
tions instructing health care profes-
sionals what to do and how to do it.
● Useofcheckliststhatmirrorguidelines:
successful at improving adherence to
standards of care
● Systems changes: such as provision of
automated reminders to health care
professionals and patients and audit
and feedback of process and outcome
data to providers
● Quality improvement programs com-
bining continuous quality improve-
ment or other cycles of analysis and
intervention with provider perfor-
mance data
● Practice changes: such as availability of
pointofcaretestingofA1C,scheduling
planned diabetes visits, clustering of
dedicated diabetes visits into speciﬁc
times within a primary care practice
schedule, or group visits and/or visits
with multiple health care professionals
on a single day
● Tracking systems with either an elec-
tronic medical record or patient regis-
try: helpful at increasing adherence to
standardsofcarebyprospectivelyiden-
tifying those requiring assessments
and/or treatment modiﬁcations. They
likely could have greater efﬁcacy if they
suggestedspeciﬁctherapeuticinterven-
tions to be considered for a particular
patient at a particular point in time
(404).
● Availability of case or (preferably) care
management services (405): Nurses,
pharmacists, and other nonphysician
health care professionals using detailed
algorithms working under the supervi-
sion of physicians have demonstrated
the greatest reduction in A1C and
blood pressure (406,407).
Evidence suggests that these individual
initiatives work best when provided as
components of a multifactorial interven-
tion.Whenpracticesarecompared,those
that address more of the CCM elements
demonstrate lower A1C levels and lower
cardiovascular risk scores (408). The
most successful practices have an institu-
tional priority for quality of care, involve
all of the staff in their initiatives, redesign
their delivery system, activate and edu-
cate their patients, and use electronic
health record tools (409,410).
NDEP maintains an online resource
(www.betterdiabetescare.nih.gov)tohelp
health care professionals design and im-
plement more effective health care deliv-
ery systems for those with diabetes.
It is clear that optimal diabetes man-
agement requires an organized, system-
atic approach and involvement of a
coordinatedteamofdedicatedhealthcare
professionals working in an environment
where quality care is a priority.
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